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Introduction 
 
 
Since the development of the cowpox (Vaccinia) vaccine by Jenner in 1796, 
vaccination has been able to protect both humans and animals against several diseases 
and even to eliminate some pathogens. The majority of the vaccines in use today are 
against systemic pathogens or toxins, despite the fact that intestinal infections are still 
a major cause of disease in both humans and animals. Protection against intestinal 
pathogens is obtained by the induction of pathogen-specific secretory IgA (sIgA) in 
the mucosae. While the parenteral route of vaccination is effective in the development 
of systemic immunity, it generally does not extend to the mucosal surfaces. In 
addition, the secretion of antigen-specific sIgA in the mucosae is maximal near the 
induction site. Therefore, the development of systems for vaccination via the oral 
route is an essential prerequisite for the stimulation of protective immunity against the 
majority of enteric pathogens of both man and animals.  
Despite the need for oral vaccine technology, progress in this area has been 
rather slow. Indeed, inactivated vaccines are in some cases not effective, attenuated 
live vaccines could potentially be dangerous and oral delivery of non-replicating 
antigens deals with physiological and immunological obstacles. Indeed, most antigens 
that are taken up orally are digested due to the low gastric pH and the presence of 
proteases. As a consequence, effective oral immunization usually requires the 
repeated administration of very large quantities of antigen. Oral administration of 
large doses of non-replicating antigens can sometimes induce a short-lived mucosal 
IgA immune response, but often develops a systemic state of immunological 
hyporesponsiveness, called oral tolerance. On the other hand, receptor-mediated 
uptake of orally administered antigens mostly induces an antigen-specific mucosal 
immune response. Therefore, these mucosa-binding antigens can serve as mucosal 
carriers, inducing a mucosal immune response against coupled heterologous antigens 
following oral administration of antigen-carrier complexes. 
It has been demonstrated that oral administration of newly weaned piglets with 
purified F4 fimbriae induced a receptor-mediated F4-specific antibody response, 
protecting these piglets against a subsequent F4+ ETEC challenge. However, F4 
fimbriae have no mucosal adjuvant effect to co-administered antigens, in contrast to 
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Escherichia coli produced heat-labile enterotoxine (LT) and Vibrio cholerae produced 
cholera toxin (CT).  
It is interesting to analyse the potential of both virulence factors of F4+ ETEC, 
F4 fimbriae and LT enterotoxin (or the related CT), in the simultaneous induction of 
an immune response against coupled or co-administered heterologous antigens and 
against F4+ ETEC infections in pigs. To determine the potential of F4 fimbriae or 
recombinant produced F4 fimbrial adhesin FaeG as mucosal carrier to coupled 
heterologous antigens, knowledge on the F4 fimbrial biogenesis and the use of 
fimbriae as carrier is needed. In addition, to study if CT can act synergistically with 
F4 or FaeG as mucosal carrier to induce an immune response against the coupled 
antigen following oral administration, knowledge on the uptake and 
immunomodulating effects of CT is necessary. Therefore, Part I of this thesis 
represents the present knowledge on the use of fimbriae as carrier (Chapter 1), the F4 
fimbrial biosynthesis (Chapter 2), and the toxic and immunomodulatory effects of LT 
and CT (Chapter 3).  
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1.1. Introduction
The role of Escherichia coli as a pathogen has been well known for many
years and many strains of E. coli have an inherent capacity to cause disease (Table 1).
The most frequent infection caused in humans by E. coli is that of the urinary tract
(Wullt, 2003). Enteropathogenic and enterotoxigenic strains of E. coli cause
gastroenteritis, especially in developing countries (Presterl et al., 2003;
Ratchtrachenchai et al., 2004), and are responsible for many cases of traveler’s
diarrhoea (Clarke, 2001). In animals, enterotoxigenic and verotoxigenic E. coli are
known to cause severe diarrhoea and oedema disease in young animals.
The ability of many pathogenic bacteria to adhere to specific host tissues is a
factor of primary importance in causing disease. Specific adherence allows bacteria to
resist and circumvent the flushing and cleaning mechanisms that protect many
epithelial surfaces in humans and animals. In addition, adhesion determines the site of
microbial infection. However, the pathogenic potential of an E. coli strain also
depends on other determinants such as its ability to produce toxins.
Fimbriae and pili are long proteinaceous surface appendages that allow
adhesion of pathogenic bacteria to their specific receptor. Pili (e.g. P, type 1, F6) are
more rigid structures with a diameter of about 7-8 nm and have an axial hole, whereas
fimbriae (e.g. F4, F5, F18) are thin and flexible structures with a diameter of about 2-
4 nm without axial hole (Fig. 1) (De Graaf and Mooi, 1986). They are composed of
repeating major subunits and some additional minor subunits. In most fimbriae (e.g.
F17, F18) and pili (e.g. P, type 1), a minor subunit, mostly located at the tip, mediates
adhesion (Lund et al., 1987; Krogfelt et al., 1990; Smeds et al., 2001; Buts et al.,
2003a). However, in F4 and F5 fimbriae, the major subunit functions as the adhesin
(De Graaf et al., 1980; Bakker et al., 1992a).
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Infection with fimbriae-expressing ETEC induces fimbriae-specific antibodies 
(Evans et al., 1978; Verdonck et al., 2002). Moreover, these antibodies were shown to 
provide protection against a subsequent homologous ETEC infection by inhibiting 
attachment of the bacteria to the host cells (Nagy et al., 1978; Levine et al., 1984; 
Cravioto et al., 1990). Therefore, the ability of purified fimbriae to induce protective 
fimbriae-specific antibodies is of significant importance for the development of 
vaccines. 
 
1.2. Parenteral immunization with fimbriae  
Parenteral immunization of mice with purified P pili induces pili-specific 
antibodies in the urinary tract, which provide protection against a homologous 
challenge infection (O’Hanley, 1990; Roberts et al., 1994). However, the sequence 
variability in the major subunit of both P and type 1 pili leads to variation in 
antigenicity among clinical isolates (Abraham et al., 1988; Vandemaele et al., 2003a 
and 2003b). In addition, the predominant immune response is directed against the 
major subunit that composes more than 99% of the total protein mass of the pilus 
structure (Lund et al., 1988; Langermann et al., 1997). The low level of antibodies 
against the minor subunit and adhesin cannot protect against a subsequent 
P Type 1 F4 F5 
Figure 1 : Schematic representation of type 1 pili, P pili, F4 fimbriae 
and F5 fimbriae. Major subunit (white), minor subunit (shaded) 
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7  
heterologous challenge infection (Lund et al., 1988; Langermann et al., 1997). In 
contrast, immunization with recombinant type 1 adhesin subunit FimH (Langermann 
et al., 1997, 2000 and  2001; Palaszynski et al., 1998), the recombinant FimH 
receptor-binding domain (Thankavel et al., 1997) or complexes of FimH with its 
chaperone FimC (Meiland et al., 2004) induce a protective antibody response in mice 
and monkeys. However, the role of type 1 fimbriae in E. coli-induced pathogenesis 
seems to differ between animal species. Recent studies with denatured recombinant 
FimH and the bioactive FimH156 lectin domain reported the induction of FimH-
specific antibodies following vaccination of chickens, but they could not protect the 
chickens against a homologous E. coli infection (Kariyawasam et al., 2004; 
Vandemaele F., unpublished data). This is consistent with the observation that a fimH 
deletion mutant of an avian pathogenic E. coli colonized the chicken trachea better 
than did the wild type strain (Arné et al., 2000), suggesting that type 1 pili are not 
necessary for APEC-induced pathogenesis. On the other hand, recombinant PapG-
induced antibodies provided protection to chickens against subsequent homologous 
and heterologous APEC challenge (Kariyawasam et al., 2004). Moreover, the 
conservation of the adhesin among P pili of different clinical isolates supports its 
application as subunit vaccine against P pilus expressing E. coli (Vandemaele et al., 
2003b).  
In agreement, parenteral immunization of pigs with F4 fimbriae induces a 
fimbriae-specific systemic antibody response, which is mainly directed against the 
adhesin since the major F4 fimbrial subunit FaeG also constitutes the adhesin 
(Bianchi et al., 1996; Van der Stede et al., 2002b). Moreover, the induced antibodies 
block the fimbriae-receptor interaction (Yokoyama et al., 1992; Van den Broeck et al., 
1999c; Sun et al., 2000). As a consequence, vaccination of dams with F4 fimbriae 
produces fimbriae-specific antibodies in colostrum and milk which subsequently 
protects their suckling piglets from F4+ ETEC-induced neonatal diarrhoea (Rutter and 
Jones 1973; Rutter et al., 1976; Logan and Meneely, 1981; Nagy et al., 1985; Moon 
and Bunn, 1993; Osek et al., 1995; Barman and Sarma, 1999). Identical results are 
obtained with F5 fimbriae, as their major subunit FanC also constitutes the fimbrial 
adhesin (Morgan et al., 1978; Nagy et al., 1978 and 1980; Acres et al., 1979; Jacobs et 
al., 1987). Alternatively, fimbriae-specific antibodies produced by intramuscular 
immunization of chickens, extracted from egg yolk and then used to passively 
immunize pigs were shown to result in protection against a subsequent challenge 
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infection with pathogenic E. coli expressing homologous fimbriae (Yokoyama et al., 
1992; Imberechts et al., 1997b; Zuniga et al., 1997; Jin et al., 1998; Marquardt et al., 
1999; Hennig-Pauka et al., 2003; Kariyawasam et al., 2004).  
Despite the induction of systemic F4-specific antibody responses following 
parenteral immunization, no fimbriae-specific antibody secreting cells appear in the 
mucosa (Bianchi et al., 1996; Van der Stede et al., 2003). Bianchi et al. (1996) even 
observed that parenteral immunization of pigs with F4 fimbriae induced F4-specific 
suppression. However, parenteral immunization of pigs with purified F4 in the 
presence of adjuvants that modulate a systemically induced immune response towards 
a mucosal immune response, reduces the faecal F4+ E. coli excretion following 
challenge (Van der Stede et al, 2002b and 2003). This suggests that parenteral 
immunization under the right circumstances may have applications for the induction 
of a mucosal immune response. 
 
1.3. Mucosal immunization with fimbriae 
Protection against a mucosal infection can be achieved by the induction of a 
mucosal antigen-specific IgA response. The importance of IgA in mucosal secretions 
consists of its ability to agglutinate bacteria and neutralize antigens (Kilian et al., 
1988; Wold et al., 1990). The ability of IgA to block the adherence of bacteria to host 
mucosal epithelial cells has been demonstrated (Wold et al., 1990; McGhee et al., 
1992). In addition, IgA antibodies are more effective in inhibiting bacterial adherence 
than IgG of the same affinity as a result of its charge, extensive glycosylation and 
resistance to proteolysis (Magnusson et al., 1982; McGhee et al., 1992). 
Migration of B cells induced in nasal-associated lymphoid tissue and 
bronchus-associated lymphoid tissue to the gut lamina propria is negligible and results 
in a negligible level of intestinal IgA antibodies. This is in contrast with B cells 
induced in the gut-associated lymphoid tissue (Brandtzaeg et al., 1999; Ogra et al., 
2001). Thus, to induce mucosal fimbriae-specific antibodies preventing ETEC-
adhesion in the small intestine, oral immunizations are supposed to be most 
successful. However, it is known that oral immunization may alter the 
immunogenicity of antigens by effects of the acid environment of the stomach, 
presence of proteases and the flushing action of the intestines. Furthermore, the 
intestinal mucosal immune system only induces an immune response against 
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pathogenic antigens, whereas harmless antigens tend to induce oral tolerance (Stokes 
and Bailey, 2000; Garside and Mowat, 2001). 
Oral immunizations with intact or encapsulated CFA fimbriae induce poor 
mucosal IgA antibody responses. This has been suggested to be in part due to the 
alteration of CFA fimbrial antigens upon exposure to low pH in the gastro-intestinal 
tract (Evans et al., 1984; Schmidt et al., 1985; Edelman et al., 1993; Guillobel et al., 
2000; Byrd and Cassels, 2003). In contrast, F4 and F5 fimbriae are stable in the 
presence of proteolytic enzymes and although F5 dissociates at pH 2.5, the subunits 
are still able to bind their receptor (Gabor et al., 1997; Snoeck et al., 2004a). In 
agreement, oral immunization of F4R+ piglets with purified F4 fimbriae induces 
mucosal F4-specific antibodies, able to protect against a subsequent F4+ ETEC 
challenge (Van den Broeck et al., 1999a and 1999b). The presence of the F4 receptor 
is necessary since oral F4 immunization of F4R- piglets does not result in the 
induction of an F4-specific mucosal immune response (Van den Broeck et al, 1999b). 
Nevertheless, a secondary systemic F4-specific antibody response appears in F4R- 
piglets following oral and subsequent intramuscular immunization with purified F4 
(Van den Broeck et al., 2002). Van den Broeck et al. (2002) suggest that purified F4 
fimbriae act as normal food antigen in the absence of the F4R since identical 
immunization with a same low dose of OVA induces a similar secondary antigen-
specific antibody profile. However, the F4-specific antibody-response appears earlier 
than the OVA-specific response, which is likely due to a better intrinsic 
immunogenicity of the polymeric F4 antigen compared to monomer OVA. Oral co-
administration of OVA and F4 did not enhance an OVA-specific antibody response, 
suggesting that F4 has no adjuvant function (Van den Broeck, unpublished data). 
In contrast to F4 fimbriae, oral immunization of piglets with purified F18 
fimbriae does not induce a protective antibody response, even when using a 30-times 
higher dose of F18 fimbriae (Verdonck et al., unpublished data) or following 
incorporation of F18 fimbriae in microparticles (Felder et al., 2000). The fact that the 
minor subunit FedF functions as the adhesin of F18 fimbriae (Smeds et al., 2001 and 
2003) may at least partly explain the observed difference with F4 immunizations. 
1.4. Use of fimbriae as carrier molecules 
Fimbriae are attractive structures to use as carriers in vaccine design due to 
their polymeric character, their ability to adhere to specific receptors on mucosal 
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surfaces, their presence on the surface of bacteria and the possibility to prepare them 
in large amounts. 
A first approach to use fimbrial subunits as carrier molecules includes 
insertion of heterologous epitopes. This is mostly performed by insertion of epitopes 
in known hypervariable domains (Thiry et al., 1989; Bakker et al., 1990; van Die et 
al., 1990; Bousquet et al., 1994) or predicted surface-exposed domains of fimbrial 
proteins (Hedegaard and Klemm 1989; Pedersen et al., 1991; Steidler et al., 1993; 
Stentebjerg-Olesen et al., 1997; Yakhchali and Manning, 1997; Gao et al., 2001). 
However, random linker insertion mutagenesis can be used to identify new insertion 
sites in fimbrial subunits (Rani et al., 1999).  
The peptides that have been inserted in fimbrial subunits of E. coli are mainly 
immunogenic virulence antigens (Table 1). However, none of these chimeric fimbriae 
has been purified and subsequently analysed on its ability to induce a protective 
antibody response against a subsequent challenge infection. In addition to E. coli 
fimbrial subunits, fimbrial subunits of Bacteroides nodosus (Jennings et al., 1989), 
Pseudomonas aeruginosa (Hertle et al, 2001) and Salmonella (McEwen et al., 1992; 
White et al., 1999; Luna et al., 2000) as well as the flagellin subunit of flagella 
(Westerlund-Wikström, 2000) have been used as carriers for heterologous epitopes. 
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Table 1 : Overview of heterologous peptides inserted in fimbrial subunits of E. coli. 
Fimbrial 
subunit 
Heterologous 
epitope 
Length 
epitope 
Expression 
fimbriae 
Adhesion Induction 
antibodies 
Reference 
FimA 
(Type 1) 
HBsAg 9 + + - Hedegaard and 
Klemm, 1989 
 HBsAg 20 - - - Hedegaard and 
Klemm, 1989 
 VP1 (FMDV) 19 + + + Hedegaard and 
Klemm, 1989 
 VP1 (polio) 11 + + + Hedegaard and 
Klemm, 1989 
 CT-B 34 + + + Stentebjerg-Olesen 
et al., 1997 
FimH  HbsAg 56 + + + Pallesen et al., 1995 
(Type 1) CT-B 34 + + + Pallesen et al., 1995 
ClpG 
(CS31A) 
TGEV-S 9 + ND + Bousquet et al., 
1994 
 TGEV-S 10 + ND + Bousquet et al., 
1994 
 TGEV-S363-371 
TGEV-S522-531 
tandems 
up to 51 + ND ND Méchin et al., 1996 
 TGEV-S363-371 
TGEV-S522-531 
25 + ND + Der Vartanian et al., 
1997 
CstH(CS3) ST 15  + ND ND Yakhchali and 
Manning, 1997 
 LT-B 20 + ND ND Yakhchali and 
Manning, 1997 
 VP1 (FMDV) 12 + ND + Gao et al., 2001 
 c-Myc 10 + ND + Gao et al., 2001 
PapA (P) FMDV 9 + ND + van Die et al., 1988 
 SPA 58 + ND  Steidler et al., 1993 
 GnRH 10 + ND + van der Zee et al., 
1995 
FaeG (F4) IP 1 12 + ND ± Thiry et al., 1989 
 IP 2 7 + ND ND Thiry et al., 1989 
 SH 14 + ND ND Thiry et al., 1989 
 GP 11 + ND ND Bakker et al., 1990 
 VP1 (FMDV) 11 + ND + Bakker et al., 1990 
 HIV-1 11 + ND + Bakker et al., 1990 
FasA (F6) HSV-1 gD 9 + + + Rani et al., 1999 
 HSV-1 gD 8 + + ND Rani et al., 1999 
 TGEV-S 10 + + + Rani et al., 1999 
 
ND, not determined; VP1 capsid protein of type 1 polio-virus; FMDV, foot-and-mouth disease virus; 
HBsAg, hepatitis B surface antigen; IP, peptide derived from influenza; GP, peptide derived from a 
pilin subunit of Neisseria gonorrhoeae; HSV 1, human immunodeficiency virus type 1; SH, 
somatostatin hormone; TGEV, transmissible gastroenteritis virus; GnRH, gonadotropin releasing 
hormone; ST, heat-stable enterotoxins; LT-B, heat-labile enterotoxins subunit B; CT-B, cholera toxin 
subunit B; SPA, Staphylococcus aureus protein A 
 
Chapter 1 : Fimbriae as immunogens and carrier molecules 
12 
The length of the inserted heterologous epitopes is limited as the folding and 
stability of fimbrial subunits may not be disturbed. Therefore, a second approach to 
use fimbriae as carriers for heterologous epitopes is to conjugate them. For instance, 
F5 has been chemically coupled to 6-methylprednisolone (Bernkop-Schnurch et al., 
1997) and both F5 and F6 have been chemically linked to dinitrophenyl and bovine 
serum albumin (BSA) (Russell-Jones, 2001). Feeding fimbriae-BSA complexes to 
mice generates an anti-BSA antibody response. However, the ratio of fimbrial carrier 
for heterologous antigen and the chemical coupling both influence the immune 
response against both carrier and heterologous antigen (Kirkley et al., 2001; Russell-
Jones, 2001). Therefore, recent approaches consists of constructing genetic fusions 
between fimbrial adhesins and heterologous antigens (Batisson et al., 2000a and 
2000b; Zavialov et al., 2001). 
 
1.5. Conclusion 
 F4 fimbriae are highly immunogenic molecules when administered parenteral 
or mucosal. Moreover, oral F4 immunization of pigs results in a protective FaeG-
specific immune response. Therefore, it would be worthwhile to determine the 
potential of F4 fimbriae or its adhesin FaeG to function as a mucosal carrier molecule, 
inducing antibodies against a coupled or fused heterologous antigen or peptide. 
 
  
 
 
 
Chapter 2 
 
Expression and assembly of F4 fimbriae by Escherichia 
coli, a molecular overview1 
 
 
                                                 
1 Based on : Verdonck F, Cox E and Goddeeris BM. 2004. F4 (K88) fimbriae expressed by porcine 
enterotoxigenic Escherichia coli, an example of an eccentric fimbrial system ? J.  Mol. Microbiol. 
Biotechnol., accepted. 
Chapter 2 : Expression and assembly of F4, an overview 
14 
2.1. Introduction 
Enterotoxigenic Escherichia coli (ETEC) strains that express F4 fimbriae are 
an important cause of diarrhoea in newborn and weaned piglets (Gyles, 1994). The 
fimbriae mediate adhesion of bacteria to F4-receptors on porcine small intestinal 
epithelial cells, the initial step in colonization and disease (Jones and Rutter, 1972). 
 
2.2. Genetic organisation of the F4 operon  
Fimbriae are encoded by operons or gene clusters that are either located on a 
plasmid or on the bacterial chromosome. The F4 operon is located on a plasmid with a 
ranging molecular weight of 50 to 177 MDa (Shipley et al., 1978; de Graaf, 1990; 
Wasteson and Olsvik, 1991; Bertin, 1992; Mainil et al., 1998). The smaller plasmids 
were nonconjugative, whereas larger F4-containing plasmids were conjugative 
(Shipley et al., 1978). Therefore, F4 expression by E. coli can be spontaneously lost 
(∅rskov and ∅rskov, 1966). Mainil et al. (1998) found that F4 operon containing 
plasmids are mainly mono- or bireplicon plasmids. It is interesting to note that the 
genes encoding fimbriae and toxins of ETEC are often located on the same plasmids 
(Tschäpe et al., 1987; de Graaf, 1990; Mainil et al., 1992 and 1998; Gyles, 1994; 
Smyth et al., 1994). In addition, this plasmid also encodes the enzyme that enables 
bacteria to utilize raffinose (Raf) as energy source (∅rskov and ∅rskov, 1966; 
Shipley et al, 1978). The F4 and Raf genes are not closely linked, but separated by 30 
kbp (Mooi et al., 1979). The association of F4 and Raf genes might endow porcine 
ETEC with a selective advantage, which could explain the tendency of F4+ ETEC 
strains to dominate the E. coli flora in the porcine intestinal flora (Hinton et al., 1985).  
The F4 operon (Fig. 1) contains genes encoding the regulatory proteins FaeA 
and FaeB, the usher FaeD, the chaperone FaeE, the minor subunits FaeC, FaeF, FaeH, 
FaeI and the major subunit FaeG that constitutes also the adhesin (Van den Broeck et 
al., 2000). It is not clear whether FaeJ is expressed at all (Bakker et al., 1992b).  
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Figure 1 : Comparison of the gene clusters encoding the biogenesis of P pili, type 1 pili, F4, 
F5, F17 and F18 fimbriae. The boxes present genes. The function of the genes is indicated by 
the shading of the boxes. The letters below the boxes are symbols used for the genes. 
 
 
Fimbrial operons share more or less the same genetic organisation (Fig. 1). 
However, the organisation of the F4 operon shows some differences in comparison 
with other fimbrial operons. First, the location of faeC in the F4 operon corresponds 
with the location of the major subunit gene in F5, F6, P, S and type 1 fimbrial systems 
(Mol and Oudega, 1996). In addition, FaeC is the only protein of the fae gene locus 
that shows the characteristics that are common to major subunits of other fimbrial 
systems. Indeed, FaeC is about 16 kDa, shows homology at the N- and C-terminal 
ends with other major fimbrial subunits (e.g. the major subunits FanC (Roosendaal et 
al., 1984), FimA (Klemm, 1984), and PapA (Baga et al., 1984)) and is the only 
protein encoded by the F4 operon that contains the conserved cysteine residues. It 
seems likely that FaeC used to be the major subunit of F4 fimbriae, but that during 
evolution this role has been taken over by the adhesin FaeG (Oudega et al., 1989). 
Major subunit 
Adhesin Local regulator 
Minor subunit 
Usher 
Chaperone 
? 
F17 (F17) 
F5 (fan) 
F4 (fae) 
Type 1 (fim) 
P (pap) 
B A C H D J K E I F G 
E A D I F G B H C 
B D C F G A H     I E     J
B D C F A H E 
C D F A E 
C G A D 
F18 (fed) 
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Second, the faeG gene encoding the major subunit of F4 fimbriae is located 
upstream of the gene encoding the usher, in contrast to most gene clusters analysed to 
date (Pap, Type 1, S, F5, F17, F18, F6, CFA-I) (Imberechts et al., 1992; Mol and 
Oudega, 1996; Buts et al., 2003a). Only the operons encoding the F4-related F41 and 
CS31A fimbriae have an organization similar to that of F4 (Moseley et al., 1986; 
Casey et al., 1990; Girardeau et al., 1991; Martin, 1996).  
Third, the major fimbrial subunit FaeG and the minor subunits FaeH and FaeI 
are much larger than the corresponding subunits of most other fimbrial subunits.  
 
2.3. Regulation of F4 expression 
The biosynthesis of fimbriae is influenced by growth rate (Jacobs et al., 1985; 
Van Verseveld et al., 1985; Van der Woude et al., 1990; Blomberg et al., 1991 and 
1993a; Payne et al., 1993) and environmental conditions such as carbon source 
(Shipley et al., 1978; Blomberg et al., 1991; White-Ziegler et al., 2000), temperature 
(Mooi et al., 1979 and 1985; Göransson, 1984; Klemm, 1985; Göransson et al., 1990; 
Schmoll et al., 1990; White-Ziegler et al., 1990, 1992, 2000 and 2002; Gally et al., 
1993; Huisman et al., 1994;), pH (Van Verseveld et al., 1985; White-Ziegler et al., 
2000; Schwan et al., 2002), osmolarity (Spears et al., 1986; Göransson et al., 1990; 
White-Ziegler et al., 2000; Schwan et al., 2002), oxygen levels (White-Ziegler et al., 
2000) and presence of alanine or leucine (Girardeau et al., 1982b; De Graaf and Mooi, 
1986; Martin et al., 1991; Braaten et al., 1992; Gally et al., 1993). Indeed, pathogenic 
bacteria only fully express virulence factors like fimbriae when the conditions are 
appropriate for adherence and subsequent colonization (Pourbakhsh et al., 1997; Zhao 
et al., 1997; Struve and Krogfelt, 1999). To this end, the bacteria have regulatory 
systems at their disposal that enable them to recognize the environmental 
circumstances and to adapt fimbriae biosynthesis according to these conditions. In the 
case of F4 fimbriae, expression is optimal at a temperature of 37°C, a pH ranging 
from 6.5 to 8.0, reflecting the intestinal conditions, and at the end of the exponential 
growth (Jacobs et al., 1985; Mooi and de Graaf 1985; Van Verseveld et al., 1985; 
Blomberg, 1991; Payne et al., 1993). This regulation of fimbrial expression is 
mediated by several factors like global regulators, local regulators, crosstalk between 
fimbriae and posttranscriptional mechanisms. 
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2.3.1. Global regulators 
Global regulators control the expression of a variety of operons. The global 
regulators that affect fimbriae biosynthesis are leucine-responsive regulatory protein 
(Lrp) (Braaten et al., 1991 and 1992; Huisman et al., 1994 and 1995; van der Woude 
et al., 1994 and 1995; Nou et al., 1995), the DNA methylating enzyme 
deoxyadenosine methylase (Dam) (Blyn et al., 1990; Göransson et al., 1990; Braaten 
et al., 1991 and 1994; van der Woude and Low, 1994; Huisman and de Graaf, 1995), 
the histone-like protein (Göransson et al., 1990; Jordi et al., 1992, Olsen et al., 1994; 
Atlung et al., 1997; Olsen et al., 1998; White-Ziegler et al., 1998 and 2000), 
integration host factor (Dorman et al., 1987; Eisenstein et al., 1987) and catabolite 
gene activator protein (Baga et al., 1985; Göransson et al., 1989; Forsman et al., 
1992). However, little is known about the exact influence of these global regulators on 
F4 expression. 
2.3.2. Local regulators 
Local regulators are encoded by a fimbrial operon of which they subsequently 
regulate the expression. The local regulators of the F4 operon are FaeA and FaeB. 
Two IS1 insertion sequences (IS1(A) and IS1(B)) are found between faeA and faeB, 
which are independently inserted in the regulatory region of the F4 operon (Fig. 2). In 
the fas operon encoding the genes for the biogenesis of 987P fimbriae, insertions of 
IS1 were found to turn on adjacent genes, thereby permitting a cryptic promoter 
sequence to function (Klaasen et al., 1990). However, the IS1(A) insertion in the F4 
operon was shown to only have a very limited effect on the level of faeA transcription 
(Huisman et al., 1994). Indeed, the putative original faeA promoter is suggested to be 
separated from the FaeA coding region by IS1(A), whereafter transcription of faeA 
became directed from the IS1(A) sequence upstream of the gene. Upstream of faeB, a 
putative promoter region is detected, with –35 and –10 regions resembling a typical 
σ70 promoter (Bakker et al., 1991b). The activity of the faeB promoter determines not 
only the FaeB expression, but also the level of F4 fimbriae expression since no 
significant promoter activity was observed in the non-coding regions between other 
fae genes downstream of faeB (Mooi et al., 1981 and 1986; Huisman et al., 1994, 
Verdonck, unpublished data).  
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Figure 2 : The regulation of F4 expression is regulated by competition between Dam and Lrp, 
FaeA or Lrp/FaeA to bind to GATC631 (symbol III). Binding of Dam results in methylation of 
GATC631 and subsequent expression of the F4 fimbrial subunits, whereas binding of Lrp, 
FaeA or Lrp/FaeA inhibits transcription of the F4 open reading frame. A more detailed 
explanation can be found in the text.   
 
The expression of faeA is positively controlled by an autoregulation 
mechanism of FaeA, whereas this protein represses F4 expression from the faeB 
promoter (Fig. 2) (Huisman et al., 1994). On the other hand, mutations in faeB had no 
effect on F4 fimbriae production (Huisman et al., 1994 and 1995). Since the FaeB 
homologue of P pili preferentially binds sequences upstream of the promoter of the 
FaeA homologue in P pili and stimulates transcription of the latter (Forsman et al., 
1989; Göransson et al., 1989), Huisman et al. (1995) suggest that the effect of FaeB is 
probably absent because of the disruption of the original faeA promoter region by the 
two IS1 insertion sequences. 
The fae operon contains two conserved GATC-sites (GATC497 and GATC600) 
between the regulatory faeA and faeB genes (Huisman et al., 1994; Bakker et al., 
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1991b). GATC-sites has been shown to play an essential role in the regulation of 
several fimbrial operons, for instance those encoding P, F1845, CS31A and S 
fimbriae (Blyn et al., 1990; Bilge et al., 1993; Morschhäuser et al., 1993; Martin, 
1996; Hale et al., 1998). GATC-sites are important target sites of methylation by 
Dam, influencing DNA transcription. The region containing the GATC497 (symbol I 
in Fig. 2) in vivo is always methylated, whereas GATC600 (symbol II in Fig. 2) is non-
methylated and this independent of the presence of FaeA (Huisman and de Graaf, 
1995). In contrast to other fimbrial operons, an additional third GATC site (GATC631; 
symbol III in Fig. 2) is present in the F4 operon (Huisman et al., 1994). GATC631 
methylation is variable in vivo. When this site is methylated, Lrp, FaeA or, most 
likely, Lrp/FaeA cannot bind to the region encompassing this site, resulting in F4 
biosynthesis (Fig. 2). On the other hand, when it is not methylated, Lrp, FaeA or 
Lrp/FaeA can bind, resulting in a subsequent reduction of fimbriae production. 
Therefore, F4 expression in E. coli is carefully balanced mainly by the methylation 
status of GATC631 (Huisman et al., 1994 and 1995). Perhaps, the methylation status of 
GATC631 is regulated by competition between Dam and Lrp, FaeA or Lrp/FaeA to 
bind this site since competition between Dam and Lrp to bind a GATC site in the P 
pilus regulatory region is reported to influence P pilus expression (Hale et al., 1998), 
but further experiments are needed to confirm or deny this hypothesis. 
Some additional differences are reported in the regulation of F4 fimbriae in 
comparison with other fimbrial systems. First, the expression of F4 fimbriae is not 
regulated by phase variation, a process by which individual cells switch between 
expression (phase ON) and non-expression (phase OFF) states (Blomfield, 2001). 
This is even in contrast to the F4-related CS31A fimbriae  (Crost et al., 2003). 
Second, FaeA interacts with Lrp to suppress the F4 fimbriae production, whereas the 
FaeA homologue of P pili, S and F1845 fimbriae bind with Lrp to induce fimbriae 
expression (Baga et al., 1985; Van der Woude et al., 1992 and 1994; Braaten et al., 
1994; Huisman and de Graaf, 1995). The opposite activity of these regulators is likely 
the result of the binding of these regulators at different locations in the respective 
operons (Huisman et al., 1994 and 1995; Kaltenbach et al., 1995; Nou et al., 1995; 
van der Woude et al., 1995).  
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2.3.3. Regulatory crosstalk between fimbriae 
A third mechanism that controls fimbrial expression is crosstalk between 
fimbrial operons. For instance, when faeA is inserted in the F5 operon, FaeA functions 
as a repressor on F5 fimbrial biosynthesis (Bakker et al., 1991b). In contrast, FaeB has 
no influence on type 1 phase switching (Holden et al., 2001). Probably, type 1 
fimbriae and F4 fimbriae are non-communicating fimbrial systems as they are 
expressed under different environmental conditions (Huisman et al., 1994; Roesch et 
al., 1998). There is no information on crosstalk between F4 fimbriae and other 
fimbriae. 
2.3.4. Post-transcriptional regulation 
Only a low percentage of the surface located fimbrial proteins are minor 
proteins. The relative concentration of each subunit type in the periplasm is shown to 
be an important factor in fimbriae assembly (Jacob-Dubuisson et al., 1993), which fits 
with the observation that the major subunits of fimbriae are produced in much larger 
amounts than the minor subunits (Schembri et al., 2002).  
(Post)-transcriptional regulation is supposed to determine the level of 
expression of the different F4 fimbrial proteins, since it is thought that only one 
polycistronic mRNA from faeB to faeJ is produced (Rosenberg et al., 1979). In 
several other fimbrial systems, gene expression is controlled by processing and 
differential degradation of mRNA (Baga et al., 1988; Bilge et al., 1993; Jordi et al., 
1993; Morschhäuser er al., 1993; Hacker and Morschhäuser, 1994; Bricker and 
Belasco, 1999; Schembri et al., 2002). Most fimbrial transcripts terminate directly 
downstream from the major subunit genes (Baga et al., 1987; Morschhäuser et al., 
1993) but the localization of faeG in the F4 operon suggests that this is not likely in 
the F4 operon (Fig. 1). 
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2.4. Biogenesis of F4 fimbriae 
 
The assembly of F4 fimbriae can be divided into three distinct stages : 
translocation of the fimbrial subunits across the inner membrane, interaction of the 
fimbrial subunits with the chaperone in the periplasm and translocation of the fimbrial 
subunits across the outer membrane by the outer membrane usher. 
2.4.1. Translocation of fimbrial subunits across the inner 
membrane 
 
The N-termini of fimbrial subunits that take part in the fimbrial biogenesis 
harbour characteristic features of signal sequences that mediate translocation across 
the cytoplasmic membrane (Nielsen et al., 1997; Pugsley et al., 1997). Highly 
conserved signal sequences are present in the subunits of F4 fimbriae and the related 
CS31A and F41 fimbriae (Girardeau et al., 1991). A serine(Ser)-flanked cryptic 
consensus sequence forming an alpha-helical conformation in the hydrophobic region 
of the signal sequence, mediates the accessibility of the cleavage site to signal 
peptidase I (Der Vartanian et al., 1994; Pugsley et al., 1997) (Fig. 3).  
 
FaeC      6 LACVFFLTGGGVSHA 20 
 
FaeD        23 VMSAVLGSASVIA 35 
 
FaeE     22 TLALMMTCQSAMA 34 
 
FaeF          10 LVLSALSIQSALA 22 
 
FaeG  6 IALAIAASAASGMAHA 21 
 
FaeH           12 SAIISVALFYSAA 24 
 
FaeI           8 LFAASLLPSCVLA 20 
 
 
Figure 3 : Part of the signal sequences of the F4 fimbrial proteins containing 
the serine(S)-flanked consensus sequence (underlined) and the processing 
site (arrow). The number represents the amino acid residue position. 
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Once Fae subunits are translocated by the general secretory pathway into the 
periplasmic space (Dodd and Eisenstein, 1984; Pugsley et al., 1997), they probably 
interact with the F4 fimbrial chaperone FaeE. Indeed, FaeE seems capable to interact 
with the signal sequences of F4-fimbrial subunits as well as with their native form. 
The signal sequences of the F4 fimbrial minor and major subunits, except FaeC, 
contain a Ser-flanked segment near the peptide cleavage site (Fig. 3). In contrast, 
there is no Ser-flanked region in the chaperone FaeE signal sequence. This suggests 
that FaeE can be involved in the Ser-flanked sequence recognition and subsequently 
ameliorate the accessibility of the cleavage site to signal peptidase I. This is in 
agreement with the P pilus chaperone PapD that aids in the release of the pilin 
subunits from the inner membrane (Hultgren et al., 1989). Indeed, 80% of P pili 
subunits remained anchored to the inner membrane in the absence of their chaperone 
(Jones et al., 1997).  
The C-terminal sequences of the fimbrial subunits are extremely hydrophobic 
(Klemm, 1981; Kuehn et al., 1993; Hung et al., 1996) and may insert into the 
cytoplasmic membrane. Alternatively, the C-terminus may be part of an edge strand 
of a β-sheet that lies on top of the membrane, inserting the hydrophobic side chains of 
its amino acid residues into the membrane. As a result, the C-terminus cannot interact 
with the chaperone. It is suggested that the P-pilus chaperone PapD recognizes a 
binding site on the P pilus subunit PapG separate from the C-terminus (Xu et al., 
1995), triggering a conformational change in the subunit that results in exposure of its 
C-terminus to the chaperone (Hung et al., 1999b). This mechanism of interaction, 
suggests that subunits change their membrane-associated state directly to a chaperone-
associated state in the periplasm (Soto et al., 1998; Thanassi and Hultgren, 2000b). 
2.4.2. Interaction of fimbrial subunits with their chaperone 
FaeE in the periplasm 
2.4.2.1. Donor strand complementation 
The interaction between fimbrial subunits and their specific chaperone has 
been most intensively studied in the P- and type 1 pilus systems. Crystallography of 
the P pilus chaperone PapD revealed two globular domains with an 
immunoglobulin(Ig)-like fold (Holmgren and Bränden, 1992). These domains are 
oriented towards one another in a way that gives the molecule the overall shape of a 
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boomerang (Kuehn et al., 1993). The crystal structure of the PapD-PapK chaperone-
subunit complex indicated that the PapK subunit had an incomplete Ig-like fold, 
lacking the C-terminal seventh β-strand G (Sauer et al., 1999). In the PapD-PapK 
complex, the chaperone donates its G1β-strand to complete the Ig-fold of the PapK 
subunit (Fig. 4). This mechanism is called ‘donor strand complementation’. However, 
an atypical Ig fold is produced as the donated strand runs parallel to the C-terminal 
strand F of PapK rather than anti-parallel in a typical Ig fold. The interaction of the 
type 1 FimC-FimH chaperone-adhesin complex was found to be identical to that of 
the PapD-PapK complex (Choudhury et al., 1999). 
 
 
 
Figure 4 : Model for the molecular interactions between subunit and chaperone 
(donor strand complementation) or between two subunits (donor strand exchange). 
The C- and N-termini of the subunits are indicated, as well as the names of the β-
strands. The names of the strands are according to the P-pilus subunits (according 
to Justice et al., 2003). 
Donor strand 
complementation 
Donor strand 
exchange 
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The crystal structure of the F4 fimbrial chaperone FaeE has not been 
elucidated to this moment. However, sequence alignment reveals that the functional 
important amino acid residues Arg8, Thr53, Arg68, Glu83, Lys112, Arg116, Gly167, 
Met172 and Asp196 of PapD are conserved in FaeE (Slonim et al., 1992; Kuehn et 
al., 1993; Hung et al., 1999a). Alternating hydrophobic amino acid residues were 
found in FaeE (Ile99, Val101 and Leu103) at the same position as alternating 
hydrophobic residues found in the G1β-strand of PapD (Leu103, Ile105 and Leu107). 
The presence of these conserved amino acid residues in FaeE suggests that a donor 
strand complementation mechanism may also be involved in F4 biogenesis. 
During donor strand complementation, the alternating hydrophobic amino acid 
residues of the PapD G1β-strand bind to a region composed of alternating 
hydrophobic amino acid residues at the C-terminus of each P-pilus subunit (Hultgren 
et al., 1989, Kuehn et al., 1993; Sauer et al., 1998 and 2000). In line with this typical 
mechanism of donor strand complementation, most Fae subunits constitute such 
conserved C-terminus flanked by a glycine at position –14 from the C-terminus and a 
penultimate tyrosine, which may allow their interaction with FaeE (Soto et al., 1998). 
However, two Fae subunits, FaeF and FaeC, do not interact with FaeE. The carboxyl-
terminal structure of FaeF does not match with the consensus sequence for chaperone 
binding (Fig. 5), which perhaps may explain the lack of interaction between FaeE and 
FaeF (Mol et al., 2001). The C-terminus of FaeC is in reasonable agreement with the 
consensus sequence, but some specific differences are apparent. The alanine at 
position –9 is specific for FaeC and differs from the residues in the other subunits. In  
 
FaeC : GEYSGALTFVVTYQ 
 
FaeF :   SYRGNLQIALQVED 
 
FaeG : TQWSAPLNVAITYY 
 
FaeH : ARWQAGLNVTVTVQ 
 
FaeI :     ERWRVSLPVSIEYQ  
   
FaeJ : KRWQGNLTPVVVYF 
 
Figure 5 : The C-termini of the F4 fimbrial subunits. The conserved 
alternating hydrophobic amino acid residues are indicated (bold symbols). 
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addition, the negatively charged glutamic acid residue at position –13 and the 
positively charged lysine residue at –16 are quite unique at these positions. These 
changes may possibly explain the absence of interaction with FaeE (Mol et al., 2001).  
A second site of interaction between PapD and PapK during donor strand 
complementation was found at the 310C-helix in the center of PapK (Sauer et al., 
1999). A similar region was also found in the center of the F4 fimbrial adhesin FaeG 
and probably serves to interact with the chaperone FaeE (Gaastra et al., 1983; 
Verdonck et al., 2004c). 
It is noteworthy that all fimbrial operons express their own chaperone, 
suggesting that the fimbrial chaperones bind their subunits in a sequence dependent 
manner (Kuehn et al., 1993; Bonci et al., 1997). In agreement with this, FaeE cannot 
replace the F5 fimbrial chaperone FanE in F5 fimbrial biosynthesis and vice versa 
(Bakker et al., 1991a). 
2.4.2.2. FaeE functions as dimer 
Gel filtration experiments combined with protein cross-linking analysis and a 
biophysical approach in which the rotation diffusion coefficient of purified FaeE was 
determined, indicate that FaeE functions as a homodimer (Mol et al., 1994 and 
1996b). Indeed, heterotrimeric complexes, consisting of two subunits of FaeE on the 
one hand and one subunit of FaeG, FaeH or FaeI on the other hand, are present in the 
periplasm (Mooi et al., 1983; Mol et al., 1994 and 1995). This characteristic of FaeE 
is unique to all fimbrial chaperones. Although, PapD and the S fimbrial chaperone 
SfaE were also found as dimers, albeit only transiently when they are not engaged in 
binding to subunits (Hung et al., 1999b; Knight et al., 2002), Walse et al. (1997) could 
not detect PapD dimers or higher aggregates in solution, indicating that the dimer 
observed in the crystal was an artefact caused by crystal packing. Studies using 
hybrids of FaeE and the K99 chaperone FanE revealed that the N-terminal domain of 
FaeE determines the dimerization of the protein (Bakker et al., 1991a). Indeed, 
although FaeE has 9 amino acids more in comparison to PapD and 18 to 19 amino 
acid residues in comparison with several other fimbrial chaperones (Holmgren et al., 
1992), truncation of the 19 C-terminal amino acid residues of FaeE did not influence 
FaeE dimerization or F4 biogenesis (Mol et al., 1996a).  
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2.4.2.3. Chaperone-subunit complexes are folded native-like and 
prevent subunit degradation and premature polymerisation 
The fimbrial subunits exist in a native-like folded state in the chaperone-
subunit complex. For instance, the periplasmic complex of FaeG and FaeE is able to 
agglutinate erythrocytes (Mol et al., 2001) and is recognised by monoclonal 
antibodies directed against conformational epitopes of F4 fimbriae (Bakker et al., 
1991a). This observation is in agreement with other fimbrial systems of which 
chaperone-adhesin complexes bind to their receptor (Kuehn et al., 1991; Mahmood et 
al., 2000; Zhou et al., 2001). However, expression of most fimbrial subunits also 
needs the periplasmic disulfide isomerase DsbA that catalyses disulfide bound 
formation (Jacob-Dubuisson et al., 1994a; Hung and Hultgren, 1998), but FaeG does 
not have cysteine residues (Klemm, 1981). 
The highly folded chaperone-subunit complexes prevent degradation of the 
fimbrial subunit. Indeed, faeE deletion mutants do not contain FaeG subunits, whereas 
the FaeG precursor is not affected (Mooi et al., 1982). Also type 1 and P pilus 
subunits are misfolded and unstable in the absence of their chaperone or the missing 
strand and collapse into off-pathway aggregates that are proteolytically degraded 
(Tewari et al., 1993; Bullitt et al., 1996; Barnhart et al., 2000). It is reported that the 
presence of unfolded PapG subunits stimulates transcription of the periplasmic 
protease DegP by activating the Cpx, σE and BaeSR modulator pathways (Jones et al., 
1997; Hung et al., 2001; Raffia and Ravioli, 2002). In agreement, DegP degrades 
FaeG subunits in the absence of its chaperone FaeE (Bakker et al., 1991a). In the case 
of the P-pilus subunit PapA, the conserved C-terminal strand is exposed to the solvent 
in the absence of the chaperone and activates the DegP protease, although it is not a 
cleavable substrate for DegP. The preferential cleavage sites occur between paired 
hydrophobic amino acids in three separate regions of PapA (Jones et al., 2002). 
Another function attributed to the FaeE chaperone is to prevent polymerisation 
of the F4 fimbrial subunits in the periplasm (Mooi et al., 1983), which is in 
accordance with observations made in other fimbrial systems (Kuehn et al., 1993, 
Bullitt et al., 1996; Thanassi and Hultgren, 2000a). Indeed, Bakker et al. (1991a) 
reported the presence of FaeG multimers containing conformational epitopes in 
degP/faeE double deletion mutants. On the other hand, the P pilus chaperone PapD is 
necessary to assemble adhesive P-pili in vivo because less than 10% of the P pilus 
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PapG subunits recovered from periplasmic extracts of a degP/PapD double mutant 
strain bind to their receptor (Jones et al., 1997; Sauer et al., 2002). 
2.4.3. Translocation of fimbrial subunits across the outer 
membrane 
2.4.3.1. The F4 fimbrial usher FaeD 
 During assembly of F4 fimbriae, the chaperone-subunit complexes are 
targeted to the outer membrane usher FaeD (Van Doorn et al., 1982). This protein has 
a high content of glycine and serine residues, in agreement with the ushers of type 1 
pili, P pili and several other fimbrial systems (Kuehn et al., 1994). In addition, FaeD 
contains four conserved cysteine residues, two at the N-terminus and two at the C-
terminus of the proteins (Schifferli and Alrutz, 1994).  
Two folding models propose an amino-terminal periplasmic domain of 126 
(Harms et al., 1999) or 133 (Valent et al., 1995) amino acid residues for FaeD 
respectively. Deletion mutations in this domain did not alter the localization or 
stability of the usher, but inhibited fimbriae biosynthesis. The central domain contains 
22 (Harms et al., 1999) to 24 (Valent et al., 1995) membrane spanning β-strands. The 
carboxyl-terminal periplasmic domain is predicted to contain 167 (Valent et al., 1995) 
or 255 (Harms et al., 1999) amino acid residues and is proposed to be important for 
the structural organisation of the protein as well as for its functioning in fimbriae 
biosynthesis (Harms et al., 1999). 
2.4.3.2. Formation of the initiation complex 
FaeD is involved in the translocation of the fimbrial subunits across the outer 
membrane and for the anchoring of the fimbrial structure to the outer membrane 
(Mooi et al., 1983; de Graaf and Mooi, 1986) (Fig. 6). It is not clear how the ordered 
assembly of F4 fimbrial subunits is accomplished, but difference in the relative 
affinities of the various subunits towards FaeD probably play an important role in this 
process. A direct interaction of FaeC with the 215 amino-terminal amino acid residues 
of FaeD has been shown to occur which is not the case for other F4 fimbrial subunits 
(Mol et al., 2001). It is therefore likely that FaeC is the first protein that interacts with 
FaeD in the process of fimbriae biosynthesis, especially since this subunit is present at 
the tip of the fimbriae (Oudega et al., 1989). In type 1 and P pili, the relative affinity 
of each chaperone-subunit complex for the usher correlates with the final position of 
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the respective subunit in the pilus (Dodson et al., 1993; Jacob-Dubuisson et al., 1993; 
Saulino et al., 1998). In addition, it is discovered that the information necessary for 
targeting the chaperone-subunit complex to the usher resides mainly in the subunit 
protein (Barnhart et al., 2003; Nishiyama et al., 2003).  
 
 
 
Figure 6 : Expression of the F4 fimbrial subunits and subsequent assembly of F4 fimbriae. 
The chaperone FaeE transports the subunits, except FaeC and FaeF, to the outer membrane 
usher FaeD where they are incorporated in the growing fimbriae. Thereafter, the chaperone 
FaeE recycles in the cytoplasm to transport another subunit. A more detailed explanation on 
the F4 fimbrial assembly can be found in the text. (Based on Van den Broeck et al., 2000) 
 
 
 
 
In the P pilus, binding of the PapD-PapG chaperone-adhesin complex to the 
PapC usher alters the conformation of the latter and stabilizes it in an assembly-
competent structure allowing initiation of pilus assembly (Saulino et al., 1998). 
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Probably, this also happens with the F4 fimbrial usher FaeD as the protease sensitivity 
of FaeD alters in the presence or absence of F4 fimbrial subunits (Valent et al., 1995). 
After binding of the F4 fimbrial tip subunit FaeC, FaeF binds the FaeD-FaeC 
complexes, resulting in the formation of the initiation FaeD-FaeC-FaeF complexes 
(Fig. 6) (Mol et al., 2001). FaeF functions as adaptor molecule, coupling the major 
subunit FaeG to the tip subunit FaeC. At regular intervals, the minor subunits FaeF, 
FaeH and probably also FaeI are incorporated in the F4 fimbrial structure (Bakker et 
al., 1992b). 
2.4.3.3. Subunit-subunit interaction 
In several fimbrial systems, the mechanism of interaction between subunits 
relies on the highly conserved N-terminus of the subunits. This N-terminal amino acid 
sequence contains an alternating hydrophobic amino acid residue motif that is 
analogous to the “G” β-strand of the chaperone and is exposed in chaperone-subunit 
complexes (Soto et al., 1998; Choudhury et al., 1999; Sauer et al., 1999; Zavialov et 
al., 2002). Such alternating hydrophobic amino acid residues are also present in the F4 
fimbrial subunits. Moreover, the N-terminus of FaeG is very conserved between the 
three F4 antigenic variants (Gaastra et al., 1983; Verdonck et al., 2004c). Therefore, 
like for several fimbrial systems, the subunit-subunit interactions between F4 fimbriae 
are also supposed to rely on the mechanism of donor strand exchange (Barnhart et al., 
2000; Knight et al., 2000). This mechanism is best characterized in P pili and type 1 
fimbriae of E. coli and in F1 fimbriae of Yersinia pestis (Soto et al., 1998; Barnhart et 
al., 2003; Zavialov et al., 2003a and 2003b) (Fig. 4). During assembly of these 
fimbriae, the “G” β-strand of the chaperone is exchanged for an N-terminal extension 
from the subunit of an incoming chaperone-subunit complex. The incoming N-
terminus during donor strand exchange runs anti-parallel to the subunit “F” β-strand, 
in contrast to the “G” β-strand of the chaperone. So, the subunit undergoes a 
topological transition from a non-canonical to a canonical Ig fold, resulting in more 
closed conformation of the groove and driving subunit assembly into a fiber (Sauer et 
al., 2002; Barnhart et al., 2003; Zavialov et al., 2003b). These energetically favourable 
conformational changes during pilus assembly are very important since the mode of 
action of fimbrial chaperones is independent of cellular energy (Jacob-Dubuisson et 
al., 1994b). 
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2.4.3.4. Translocation of subunits across the outer membrane 
The mechanism of translocation of F4 fimbrial subunits across the outer 
membrane is not determined. Thanassi et al. (1998) showed that the P-pilus usher 
PapC forms an oligomeric channel. This channel, probably a hexamer, has a diameter 
of approximately 2 nm and is large enough to accommodate a pilus subunit or the 
linear form of the pilus (Saulino et al., 2000). Similarly, in type IV pilus biogenesis, 
large oligomeric structures are found that consist of 10-12 monomers with a large 
central diameter of approximately 5.3 nm (Bitter et al., 1998). However, Harms et al. 
(1999) did not detect oligomeric FaeD complexes. Possibly, the putative quaternary 
structure of FaeD in the outer membrane is less stable or FaeD is different from the 
other molecular ushers studied so far in that it does not function as an oligomer. 
Indeed, the estimated copy number of FaeD per cell equals the number of fimbriae per 
cell (Mooi et al., 1981) and does not support a model in which the functional FaeD 
unit in the outer membrane contains 6 or 10-12 FaeD subunits.  
2.5. The major subunit FaeG mediates F4-receptor 
binding 
Although the adhesin of most fimbriae is a minor subunit located at the tip, the 
adhesin of F4 fimbriae is the major subunit FaeG. The receptor-binding site of FaeG 
has not been exactly characterised at the moment. The three F4 antigenic variants 
F4ab, F4ac and F4ad show small differences in the amino acid sequence of their 
adhesin FaeG (Guinée and Jansen, 1979; Mooi et al., 1979; Bakker et al., 1992a). The 
epitopes a1 to a7 are common epitopes and are present on two or on all three antigenic 
different FaeG subunits, whereas each of the three antigenic different FaeG subunits 
has a variant-specific “b”, “c” or “d” epitope (van Zijderveld et al., 1990). Although 
conserved common regions in FaeG are suggested to be involved in F4 receptor 
binding, the variant-specific epitopes mediate, at least partly, the binding of the three 
F4 antigenic variants to different receptors (Wilson and Hohmann, 1974; Jacobs et al., 
1987; Bakker et al., 1992a; Jin and Zhao, 2000; Sun et al., 2000). Indeed, six different 
porcine F4-receptor phenotypes can be distinguished based on the variability of the 
three F4 antigenic variants to adhere to porcine intestinal brush borders (Bijlsma et 
al., 1982; Baker et al., 1997). 
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In F4 fimbriae, the major subunit FaeG functions as adhesin and presents 
receptor-binding sites at different places along the fimbriae (Bakker et al., 1992a; Van 
den Broeck et al., 1999c). In contrast, the adhesins of P pili, type 1 pili and F17 are 
minor subunits that are only present at the tip. Moreover, these tip located adhesins 
have twice the molecular weight of the other fimbrial subunits as they are composed 
of an N-terminal lectin domain that mediates the receptor binding and a C-terminal 
pilin domain that couples the adhesin to the fimbrial shaft during assembly (Hultgren 
et al., 1989; Thankavel et al., 1997; Schembri et al., 2000; Dodson et al., 2001; 
Tanskanen et al., 2001; Hung et al., 2002; Buts et al., 2003a and 2003b; Merckel et 
al., 2003). The presence of a single adhesin subunit located at the tip of these fimbriae 
agrees with the lack of an N-terminal extension in the lectin domain and its resulting 
inability to mediate donor strand exchange with a preceding subunit (Hahn et al., 
2002). The molecular weight of FaeG is not twice that of the other F4 fimbrial 
subunits and it is not clear to this time if FaeG is composed of two domains (Méchin 
et al., 1995). 
2.6. Conclusion 
 In addition to characteristics that were identical to other E. coli fimbriae or 
pili, several unique mechanisms are discussed that are only present in F4 fimbrial 
induction, expression or assembly. Importantly, in contrast to the adhesins of most 
fimbrial systems, the F4 major fimbrial subunit FaeG also constitutes the adhesin. 
Therefore, the F4 fimbrial system could offer an opportunity to study the 
immunogenic potential of  monomeric and multimeric adhesins.  
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3.1. Introduction 
Enterotoxigenic Escherichia coli (ETEC) colonize the small intestine, release 
their heat-labile (LT) and/or heat-stable (ST) enterotoxins and induce diarrhoea. 
Similarly, colonization of the small intestine by Vibrio cholerae and secretion of 
cholera toxin (CT) results in diarrhoea. Besides functioning as a toxin, both LT and 
CT function as mucosal adjuvants. 
There are two major antigenic variants of LT, LT-I and LT-II, which do not 
cross-react immunologically (Nataro and Kaper, 1998). LT-I is highly similar to CT, 
whereas LT-II differs in amino acid sequence and carbohydrate binding specificities 
(Jobling and Holmes, 1991). The human (hLT-I) and porcine (pLT-I) variants of LT-I 
differ only by four amino acids (Domenighini et al., 1995) and in their binding to 
paragloboside (Karlsson et al., 1996). LT-I is further referred as LT. LT-II is not 
discussed in this review since its role in disease has not been established. 
 
3.2. Toxin structure 
The amino acid sequences of LT and CT are approximately 80% identical, 
resulting in similar three-dimensional structures (Fig. 1) (Dallas and Falkow, 1980; 
Sixma et al., 1991 and 1993; Zhang et al., 1995a and 1995b). The receptor-binding 
part is comprised of five identical B subunits that noncovalently associate into a 
highly stable pentameric ring (Cheesman et al., 2004). Each B-subunit (10.5 kDa) has 
a receptor-binding place but pentamerization improves receptor-binding (De Wolf et 
al., 1981a and 1981b; Iida et al., 1989; Streatfield et al., 1992; Jobling and Holmes, 
2002). The A-subunit (27 kDa) is a single polypeptide comprised of two major 
domains (A1 and A2) that are linked by a surface exposed loop which contains a site 
for proteolytic cleavage and a single disulfide bond which bridges the cleavage site 
(Sixma et al., 1991; Spangler 1992; Zhang et al., 1995a and 1995b). The A1-peptide 
contains an ADP-ribosyltransferase active pocket that binds NAD and catalyses ADP 
ribosylation of Gsα (Gill and King, 1975) and the A2-peptide non-covalently anchors 
the A subunit to the central cavity of the B pentamer (Sixma et al, 1991; Tinker et al., 
2003). The C-terminal motif of A2 protrudes from the pentameric B-subunit on the 
side that binds the cell surface (Zhang et al., 1995a and 1995b). 
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Figure 1 :  Crystal structures of cholera toxin (CT) and Escherichia coli heat-labile 
enterotoxins (LT). The A1- and A2-chains are linked by a flexible loop (not 
resolved in the crystal structure) that contains a proteolytic cleavage site subtended 
by a disulphide bond. Arrows mark the site of the loop and proteolytic cleavage. 
The K(R)DEL motif is indicated by an asterisk. (Figure obtained from W.I. Lencer 
and W. Hol). 
  
  
3.3. Toxin expression and assembly 
Chromosomal genes of V. cholerae encode CT (Vasil et al., 1975; Mekalanos 
et al., 1983; Miller and Mekalanos, 1984), whereas the genes encoding LT in E. coli 
are plasmid borne (So et al., 1978; Dallas et al., 1979). They both belong to the family 
of the AB5 toxins, characterized by an enzymatically active A subunit and five 
receptor binding B subunits (Fig. 1) (Merrit and Hol, 1995). The genes for the A and 
the B subunits are transcribed in a single mRNA (Dallas et al., 1979; Spicer et al., 
1981; Finkelstein And LoSpalluto, 1987) and expression of excess B over A subunits 
is the result of a more efficient ribosome-binding site of the B subunit (Mekalanos et 
al., 1983).  
The A and B subunits are synthesized in the cytoplasm and co-translationally 
transported to the periplasm, where assembly of the AB5 holotoxin takes place 
(Holmes and Twiddy, 1983; Hirst and Holmgren 1987a; Hardy et al., 1988; 
Streatfield et al., 1992). In contrast to CT (Finkelstein et al., 1970; Richardson 
andNoftle, 1970), LT is not secreted but remains in the periplasm or is located on the 
surface of LT-producing bacteria (Wensink et al., 1978; Kunkel and Robertson, 1979; 
Hirst et al., 1984; Horstman and Kuehn, 2000 and 2002; Tauschek et al., 2002). 
 
A1-chain 
B-subunits 
CT 
* * 
LT 
 A2-chain
Chapter 3 : Heat-labile enterotoxin and cholera toxin 
36 
Furthermore, the A subunit of CT (CT-A) is activated by a V. cholerae-encoded 
protease (Booth et al., 1984), whereas the A subunit of LT (LT-A) is nicked by 
proteases in the intestinal lumen (Clements and Finkelstein, 1979). 
 
3.4. Toxin receptors 
Receptor binding is critical for the biological effects of CT and LT. The main 
receptor for both LT-B and CT-B is GM1-ganglioside [Gal(β1-3)GalNAc(β1-
4)(NeuAc(α2-3))Gal(β1-4)Glc(β1-1)ceramide], a glycosphingolipid found 
ubiquitously on the surface of mammalian cells (Lencer et al., 1992). Hydrogen bond 
interactions within each of five pockets formed by the B-subunit pentamer allow CT-
B and LT-B to cross-link GM1 with extremely high affinity for GM1 (dissociation 
constants of 7.3 x 10-10 and 5.7 x 10-10 for LT-B and CT-B, respectively) (Kuziemko 
et al., 1996; Turnbull et al., 2004). In addition, both toxins interact with ganglioside-
GD1b and LT-B also binds with lower affinity to polyglycosylceramides, asialo-
GM1, GM2 and polylactosamine-containing glycoproteins (Holmgren et al., 1982; 
Fukuta et al., 1988). After toxin binding to intact cells, there is a lag time of 15 to 60 
min before adenylate cyclase is activated (Gill and King, 1975). The lag time is 
necessary to allow the A1 peptide to translocate through the membrane and to come 
into contact with the Gs protein. 
 
3.5. Mechanism of toxin action 
LT and CT bind with their B subunits to GM1 at the cell surface, resulting in 
the association of toxin with specialized membrane microdomains rich in cholesterol 
and glycosphingolipids, known as lipid rafts (Orlandi, 1993 and 1998; Wolf et al., 
1998 and 2002; Shogomori and Futerman, 2001a and 2001b). The toxin is 
endocytosed by invagination of the plasma membrane, forming pits that can be non-
coated or coated with clathrin on their cytosolic surface (Shogomori and Futerman, 
2001a and 2001b; Parton et al., 1994a and 1994b; Schnitzer et al., 1995; Nichols et 
al., 2001; Le and Nabi, 2003; Singh et al., 2003). The pits invaginate into the cell and 
pinch off to form (clathrin-coated) vesicles. Following internalisation, the vesicles 
shed their coat (if present) and are able to fuse with early endosomes. Then, the toxin 
moves via early and recycling endosomes into the trans-Golgi (Tran et al., 1987; 
Parton et al., 1994; Schnitzer et al., 1996; Henley et al., 1998) (Fig. 2). After 
Chapter 3 : Heat-labile enterotoxin and cholera toxin 
37 
subsequent dissociation of the A and the B subunit (Fig. 2), the A subunit undergoes 
retrograde transport to the endoplasmic reticulum (ER), while the B subunit recycles 
from the Golgi compartment to late endosomes and lysosomes (Cosson and 
Letourneur, 1994; Bastiaens et al., 1996; Majoul et al., 1996 and 1998; Orci et al., 
1997; Aoe et al., 1998; Richards et al., 2002; Chen et al., 2002a). The movement of 
the A-subunit from the Golgi to the ER is facilitated by a short, four-amin acid ER-
sorting signal (KDEL in CT-A, RDEL in LT-A; Fig. 1), present at the C-terminus of 
the A-subunit (Cieplak et al., 1995b; Lencer et al., 1995b; Bastiaens et al., 1996; 
Majoul et al., 1996; Sandvig et al., 1996; Henley et al., 1998). In the Golgi network 
the specific membrane-bound receptor ERD2 binds to the ER-sorting signal, resulting 
in package of the A-subunit into special transport vesicles that are transferred to the 
ER (Pelham, 1991). In the ER, disulphide isomerase reduces the disulphide bond 
between the A1- and A2-fragments (Majoul et al., 1997; Orlandi, 1997). 
Subsequently, the A1-peptide behaves as a misfolded protein that exits the ER via 
reverse translocation through the sec61p complex and reaches the cytosol (Hazes and 
Read, 1997; Schmitz et al., 2000; Teter et al., 2002; Winkeler et al., 2003).  
 
 
 
Figure 2 : Schematic representation of LT and CT internalisation 
(left) and induction of cAMP production (right). ER, endoplasmic 
reticulum. 
Tight  
junction 
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Alternatively, Lencer et al. (2001) support the view that the B subunit would 
be the transport vesicle for the A subunit and that the A and B subunits of the 
holotoxin only dissociate when they have reached the ER (Fig. 2) (Tsai et al., 2001; 
Fujinaga et al., 2003). In this alternative model, the B subunit is not unfolded, remains 
membrane associated and moves to the basolateral membrane by traffic back out the 
secretory pathway by anterograde vesicles (Lencer et al., 1995b). 
The events following A1-peptide translocation to the cytosol that lead to 
binding of the A1-peptide to the basolateral located Gsαβγ complex, remain 
incompletely defined. A first possible mechanism (Fig. 2) is that the A1-peptide 
diffuses through the cytosol and escapes from degradation by the proteasome due to 
the absence or near absence of lysines in the toxic peptide, together with its ability to 
rapidly refold (Rodighiero et al., 2002). Lysine residues are targets for covalent 
addition of ubiquitin, a peptide typically required for proteasome-dependent 
degradation. It is however not clear how the A1-peptide is subsequently targeted to 
the Gs/adenylate cyclase complex. A second potential mechanism (Fig. 2) is that the 
A1-peptide remains associated to the cytosolic side of the ER membrane following 
sec61p-mediated translocation and reaches the cytoplasmic surface of the basolateral 
membrane by membrane traffic back out the secretory pathway. In support of this 
mechanism, the A1-peptide binds in vitro with the family of GTP-binding ADP-
ribosylating factors (ARF) that are involved in vesicular trafficking (Tsai et al., 1988; 
Stevens et al., 1999; Jobling and Holmes, 2000; Zhu et al., 2001a and 2001b). Indeed, 
initiation of vesicle formation occurs when a membrane protein interacts with the 
ARF-GDP complex and catalyses the release of GDP and the binding of GTP. The 
ARF-GTP form mediates the assembly of cytosolic coat proteins (coatomers) to 
membranes, inducing budding of the transport vesicles (Donaldson and Klausner, 
1994; Boman and Kahn, 1995; Moss and Vaughan, 1995). Fusion of basolaterally-
targeted vesicles with the plasma membrane delivers the translocated A1-peptide to a 
site near the Gs/adenylate cyclase complex on the cytosolic surface of the basolateral 
membrane.  
The A1-peptide catalyses the transfer of the ADP-ribose moiety of NAD to a 
specific arginine residue of the basolaterally located G protein Gsα. The Gsα protein 
also contains a GTP binding site and an intrinsic GTPase activity (Hepler and Gilman, 
1992). Binding of GTP to the Gsα leads to dissociation of Gsα from the Gsβγ dimer 
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(Kahn and Gilman, 1984) and subsequent increased affinity of Gsα for adenylate 
cyclase. The resulting activation of adenylate cyclase continues until the intrinsic 
GTPase activity hydrolyzes GTP to GDP, thereby inactivating Gsα and adenylate 
cyclase. However, ADP-ribosylation of Gsα by the A1-peptide inhibits the hydrolysis 
of GTP to GDP, thus leaving the adenylate cyclase constitutively activated and 
causing an increase in cAMP (Cassel and Selinger, 1977). Increased cAMP activates 
cAMP-dependent protein kinase A, which in turns phosphorylates the regulatory 
domain of cystic fibrosis transmembrane conductance regulator (CFTR) located in the 
apical epithelial cell membranes (Barrett and Keely, 2000). This CFTR is the major 
chloride channel activated by LT and CT (Sears and Kaper, 1996; Thiagarajah et al., 
2004). The net result is stimulation of Cl- secretion from secretory crypt cells and 
inhibition of NaCl absorption by villous tip cells (Field et al., 1972). The net 
movement of electrolytes into the lumen results in a transepithelial osmotic gradient 
that causes water secretion into the lumen. The massive volume of water overwhelms 
the absorptive capacity of the intestine, resulting in diarrhoea. 
The activation of adenylate cyclase leading to increased cAMP and subsequent 
altered ion transport is the most reported mode of action of CT. However, data from 
several research groups suggest that the increased levels of cAMP and subsequent A 
kinase activation may not explain all of the secretory effects of CT. There is evidence 
that prostaglandins (Bennett, 1971; Beubler et al., 1989; Bearcroft et al., 1996; Rocha 
et al., 2003), secretion of mucin from goblet cells (Forstner et al., 1981; Jarry et al., 
1994; Flach et al., 2004) and the enteric nervous system (Cassuto et al., 1981; 
Lundgren, 1988; Banks et al., 2004) are also involved in the response to CT.  
 
3.6. LT and CT immunomodulating effects 
CT as well as LT are potent immunogens and induce antigen-specific sIgA 
and serum IgG antibody responses (Elson and Ealding 1984a and 1984b; Spangler, 
1992; Nakagawa et al., 1996; Takahashi et al., 1996). Moreover, both toxins can act 
as adjuvants for the enhancement of mucosal and serum antibody responses to 
mucosal co-administered protein antigen (Clements et al., 1988; Holmgren et al., 
1993; Di Tommaso et al., 1996; Okahashi et al., 1996; Takahashi et al., 1996; 
Yamamoto et al., 1997; Yamamoto et al., 1998; Namikoshi et al., 2003; Imai et al., 
2004). Indeed, LT and CT were found to induce long-term memory to itself and to co-
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administered protein antigens (Lycke et al., 1986 and1991; Vajdy and Lycke, 1992; 
Kamiya et al., 2001). Although high levels of toxin-specific IgA at the inductive site 
reduce the adjuvant effect, they do not inhibit the mucosal adjuvanticity of LT or CT 
in a subsequent immunization (Tamura et al., 1989 and 1997; Wu and Russel 1994). 
However, it has been shown that CT must be administered by the same route and at 
the same time for induction of immunity against the target antigen (Elson and 
Ealding, 1984). The induced mucosal immune response is best at the mucosal site 
directly exposed to the antigen and the adjuvant (Pierce and Cray, 1982). Homing of 
lymphocytes to the mucosal site of activation is probably enhanced by CT-B since a 
recent study reports that CT-B increased expression of the mucosal addressin cell 
adhesion molecule 1 (MAdCAM-1) on endothelial cells in cultured human gastric 
explants (Lindholm et al., 2004). Binding of MAdCAM-1 to its exclusive ligand, 
integrin α4β7, on lymphocytes represents a tissue-specific homing mechanism for the 
intestine and gut-associated lymphoid tissue (Briskin et al., 1997). 
An important strategy for utilizing the immune-stimulatory properties of LT 
and CT has been the use of the non-toxic B subunits. The results obtained with LT-B 
and CT-B alone as mucosal adjuvant are highly inconsistent. Studies have shown that 
neither LT-B nor CT-B enhances immune responses to mucosally co-administered 
protein antigens (Douce et al., 1995; Rappuoli et al., 1999; Yamamoto et al., 1999; 
Hirai et al., 2000), whereas some other reports have suggested that LT-B and CT-B 
display mucosal adjuvant activity when (large doses) given with proteins by the nasal 
route (Hazama et al., 1993; Douce et al., 1997; de Haan et al., 1998a and 1998b; 
Rappuoli et al., 1999; Rask et al., 2000; Larsson et al., 2004) or when LT-B or CT-B 
is directly conjugated to the antigen itself (Rappouli et al., 1999; Rask et al., 2000; 
Larsson et al., 2004). However, it is interesting to note that the holotoxin stimulates 
stronger responses on a dose for dose basis following intranasal delivery compared to 
the B subunit (Douce et al., 1997; Kang et al., 2003). On the other hand, there are 
studies that report the use of recombinant LT-B and CT-B subunits to induce 
tolerance following oral delivery, but only in the complete absence of holotoxin 
(Williams et al., 1999). Hereto, the B-subunits need to be directly coupled to the 
antigen so that it can function as a carrier. Following GM1-receptor-mediated uptake, 
the antigen reaches immature antigen presenting cells, resulting in the induction of 
TGF-β-secreting regulatory T cells (Sun et al., 2000b).  
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Despite the fact that LT and CT are of the most potent mucosal adjuvants, 
exactly how these toxins exert their immunomodulatory effect is poorly characterized. 
Following intestinal administration of LT and CT, both toxins bind intestinal 
epithelial cells, which subsequently secrete IL-1, IL-6, IL-10 and IL-1Rα (Hansson et 
al., 1984; Bromander et al., 1993; McGee et al., 1993; Vervelde et al., 1998; Soriani 
et al., 2002). Although this may be of significance for the observed adjuvant effect, 
further experiments are necessary to define the exact influence of intestinal epithelial 
cells in enterotoxin adjuvanticity. In addition with the interaction with intestinal 
epithelial cells, interaction of LT and CT with different leukocytes is thought to be of 
major importance for mediating the adjuvant effect. LT and CT have been shown to 
be present within monomorphonuclear cells in the lamina propria and both toxins are 
transported by M cells into Peyer’s patches following oral application (Hansson et al., 
1984; Kraehenbuhl and Neutra, 2000). The influence of both toxins on different 
leukocytes will be discussed below and schematically presented in Figure 3. 
 
3.6.1. Influence on dendritic cells (DCs) 
There is emerging evidence that DCs are one of the principal cell types that 
mediate the adjuvant effect of both LT and CT in vivo (Fig. 3). These toxins induce 
phenotypic and functional maturation of DCs, promoting upregulated expression of 
MHCII, B7.1 and B7.2 costimulatory molecules, downregulation of CD40 and 
ICAM-1 expression and increased secretion of IL-1β (Gagliardi et al., 2000; Bagley et 
al., 2002; Martin et al., 2002; Jang et al., 2003; Eriksson et al., 2003; Lavelle et al., 
2003 and 2004; Petrovska et al., 2003). Recent observations indicate that luminal CT 
attracts DCs to the intestinal epithelial layer, where DCs seem to take up luminal 
antigens (Rescigno et al., 2001; Lycke, 2004). LT-treated DCs also have an improved 
ability to present protein antigen (Petrovska et al., 2003). In addition, CT induces a 
cAMP-dependent upregulation of the chemokine receptors CXCR4 and CCR7 
(Gagliardi et al., 2000 and 2003), enabling the migration of DCs to lymph nodes to 
interact with naive T cells (Iwasaki and Kelsall, 2000; Salusto et al., 2000; Shreedhar 
et al., 2003). In vitro, CT-maturated DCs are able to prime native CD4+/CD45RA+ T 
cells, driving their polarization towards the Th2 phenotype (Gagliardi et al., 2000). 
The fact that CT-treated DCs inhibit the expression of the Th1-response promoting 
cytokine IL-12 has been implicated as the mechanism by which this toxin mediates 
Chapter 3 : Heat-labile enterotoxin and cholera toxin 
42 
the polarization of Th2 cells (Braun et al., 1999; Gagliardi et al., 2000; Bagley et al., 
2002; de Jong et al., 2002; Lavelle et al., 2003). The CT-mediated maturation of DCs 
for priming of a Th2 response requires catalytically active holotoxin, since 
recombinant CT-B or catalytically inactive holotoxin did not cause significant 
maturation of human DCs (Gagliardi et al., 2000; Shreedhar et al., 2003). This is in 
agreement with the mentioned capacity of CT-B to induce oral tolerance against a 
coupled antigen, in contrast to CT.  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.6.2. Influence on B cells 
Binding of the toxins to B cells leads to the upregulated expression of MHCII, 
B7.1 and B7.2, CD40, ICAM-1 and IL-2Rα (Fig. 3) (Anastassiou et al., 1990; Francis 
et al., 1992; Agren et al., 1997; Nashar et al., 1997 and 2001; Papadimitriou et al., 
1997, Bone et al., 2002; Martin et al., 2002). This activation of B cells enhances their 
role as MHC II-restricted antigen presenting cells and favours the induction of Th2-
dominated responses. In vitro studies indicate that CT facilitates B-cell switching to 
IgA through the action of TGF-β1 and increases the effects of IL-4 and IL-5 on IgG1 
and IgA synthesis in lipopolysaccharide(LPS)-triggered spleen B cells (Lebman et al., 
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Figure 3 : Immunomodulating effects of LT and CT 
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1988; Lycke et al., 1989 and 1990; Kim et al., 1998). Intraduodenal application of CT 
is also shown to enhance isotype switching of Peyer’s patch B cells to secrete IgA and 
IgG (Lebman et al., 1988). This IgA induction is independent of the A subunit (Wu 
and Russell, 1993; Stok et al., 1994; Kim et al., 1998). In contrast to the in vivo 
immunostimulatory effect of LT, in vitro incubation of murine B lymphoma cells 
inhibits their APC function in a cAMP-dependent way by increasing the intracellular 
pH and reducing antigen degradation (Tanaka et al., 1999). 
 
3.6.3. Influence on macrophages 
Treatment of both primary macrophages and macrophage cell lines with CT 
holotoxin suppresses production of TNF-α in response to LPS (Cong et al., 2001; 
Burkart et al., 2002; Chen et al., 2002b). Recent studies have revealed that CT-B may 
also suppress production of other proinflammatory cytokines. The expression of IL-6 
is influenced by altering the MAPK signalling pathways (Chen et al., 2002b) and 
suppression of IL-12 production is due to inhibition of transcription of both the IL-12 
p35 and p40 chains (Braun et al., 1999).  In addition, NO production is also reduced 
by CT treatment since the synthesis of NO requires signalling by TNF-α  (Cong et al., 
2001). These studies demonstrate that CT inhibits innate immunity at the early steps 
of infection. The enzyme and binding activity of LT differentially affect the 
production of pro- and anti-inflammatory cytokines.  The LT mutant LTK63 that is 
devoid of enzymatic activity stimulates IL-12 and TNF-α production by 
macrophages, whereas the LT holotoxin and the LT mutant LTR72, which retains 
partial enzymatic activity, suppressed LPS-induced IL-12 production (Ryan et al., 
2000). These distinct modulatory effects of the receptor binding and enzyme activity 
of LT may be related to their different effects on signaling pathways. The B subunits 
of LT bind to the GM1, leading to the acidic sphingomylinase-mediated activation of 
NF-κB (Ballou et al., 1996; Truitt et al., 1998). NF-κB controls the transcription of a 
number of genes involved in inflammatory responses such as IL-12 (Baeuerle and 
Henkel, 1994). On the other hand, the suppression of IL-12 by enzymatically active 
toxins is likely due to the higher mentioned accumulation of intracellular cAMP, since 
it has been reported that cAMP has inhibitory effects on the production of 
inflammatory cytokines by macrophages (Parry and Mackman, 1997). 
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Similarly to B cells, CT and LT upregulate the expression of B7.2 (B7.1 by 
enzyme inactivated mutant LT) on macrophages that in turn leads to the co-
stimulation of CD4+ T cells activated via the T cell receptor-CD3 complex (Cong et 
al., 1997; Foss et al., 1999b; Yamamoto et al., 1999 and 2000; Ryan et al., 2000; 
Martin et al., 2002). The toxins also induce the secretion of IL-10 by macrophages, 
favouring the induction of Th2 responses (Feng et al., 2000; Ryan et al., 2000). In 
addition to the mentioned reduction of IL-12 secretion by macrophages, CT also 
reduces responsiveness of T cells to the Th1-response promoting IL-12 by inhibiting 
expression of surface receptor chains IL-12Rβ1 and IL-12Rβ2 (Braun et al., 1999). 
Furthermore, CT induces macrophages to produce membrane-associated and secreted 
IL-1, and enhances peptide presentation (Lycke and Strober, 1989; Bromander et al., 
1991; Matousek et al., 1996; Foss et al., 1999b and 1999c). In contrast to these studies 
but in agreement with toxin effect on B cells and DCs, it has been shown that CT and 
LT inhibit antigen processing of soluble native antigen by macrophages (Matousek et 
al., 1998; Damiani and Colombo, 2001). Moreover, in vitro treatment of macrophages 
with CT resulted in a significant increased recycling of the phagosomal compartment 
to the cell membrane (Damiani and Colombo, 2001).  
 
3.6.4. Influence on CD4+ T cells 
The mentioned negative influence of both toxins on antigen processing 
resulted in a hypothesis that both toxins could have a mitogenic effect on Th2 cells 
(Ryan et al., 2000), analogous to the effect of pertussis toxin on Th1 cells (Ryan et al., 
1998). However, the addition of CT and LT to in vitro cultures of Peyer’s patch CD4+ 
T cells that were purified using a magnetic cell sorter system, reduces T cell 
proliferation (Yamamoto et al., 1999 and 2000; Lopes et al., 2000), suggesting that 
the in vivo toxin-induced T cell priming is due to indirect effects.  
Studies with Th1 and Th2 cell lines as well as studies with positively selected 
T cell populations demonstrate that CT significantly enhances IL-10 production and 
selectively inhibits proliferative responses and IFN-γ synthesis of Th1 clones (Munoz 
et al., 1990; Yamamoto et al., 1999; Lavelle et al., 2004; Ozegbe et al., 2004). In 
addition, CT is shown to abrogate IL-12R expression by T cells (Braun et al., 1999). 
Moreover, the initial event induced by CT in CD4+ T cells involves the upregulation 
of IL-4 (Vajdy et al., 1995; Okahashi et al., 1996; Yamamoto et al., 2000). This 
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results in the secretion of IL-5, IL-6 and IL-10, which provide helper signals for the 
induction of antigen-specific sIgA as well as serum IgG1, IgA and IgE antibody 
responses in mouse models (Hornquist and Lycke, 1993; Xu-Amano et al., 1993; 
Marinaro et al., 1995). In contrast, LT induces both Th1- and Th2-responses with 
subsequent mucosal sIgA as well as serum IgG1, IgG2a and IgA antibody responses 
(Takahashi et al., 1996). The LT-induced Th2-response is largely IL-4 independent 
(Yamamoto et al., 2000). This differences in CT and LT holotoxin adjuvanticity is 
suggested to rely on differences in the A subunit (Ryan et al., 1999 and 2000; 
Bowman and Clements, 2001) or the B subunit (Boyaka et al., 2003). 
 
3.6.5. Influence on CD8+ T cells 
Hornquist et al. (1996) reported that CD8+ T cells are not required for the 
mucosal adjuvant effect of CT. Indeed, LT and CT induce apoptosis of CD8+ T cells 
(Fig. 3) (Elson et al., 1995; Nashar et al., 1996; Yankelevich et al., 1996; Truitt et al., 
1998; Kim et al., 2001; Soriani et al., 2001; Salmond et al., 2002 and 2003). However, 
indirect activation of CD8+ cytotoxic T cells has been reported and probably relies on 
the toxin-induced stimulation of B7-1 expression on DCs (Porgador et al., 1998; 
Simmons et al., 1999 and 2001; Jang et al., 2003; Eriksson et al., 2004). 
 
3.6.6. Influence on intestinal permeability to macromolecules 
Besides the influence of LT and CT on leukocytes, Lycke et al. (1991) found 
that CT increases the intestinal permeability to fluorescein-labeled dextran particles of 
3 kDa. This suggests that CT acts on the epithelial layer to increase permeability to 
macromolecules, thereby delivering antigen into the underlying lamina propria and 
generating an immune response. Similar to CT, LT is reported to increase protein 
uptake (Verma et al., 1994 and 1995). Verma and co-workers (1994) suggested a 
change in tight junctional permeability following LT administration, which may be 
due to a change in the cytoskeletal microfilaments. 
However, the influence of LT and CT on intestinal permeability to 
macromolecules is controversial since there are also reports arguing against it. For 
instance, no increased uptake of orally administered hen egg lysozyme into the 
peripheral circulation was found (Nedrud and Sigmund, 1991). Furthermore, no 
polyclonal increase in antibody production was observed in the lamina propria after 
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CT is introduced (Jackson et al., 1993), nor is there any increase in antibody responses 
to food antigens (Nedrud and Sigmund, 1991).  
 
3.7. Conclusion 
 LT and CT are highly similar molecules which both function as virulence 
factor in E. coli and V. cholerae infections respectively and have the capacity to 
function as a mucosal adjuvant to co-administered antigens. Their immunomodulatory 
effects are suggested to be due to an increased antigen uptake of the co-administered 
antigens, a better induction of an antigen-specific immune response and an increased 
homing of antigen-specific effector cells to the original site of activation. However, 
further research will be necessary to elucidate the controversial hypotheses 
concerning the mechanisms of toxin endocytosis and adjuvanticity. 
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Aims of the study 
 
 
Oral immunizations with soluble non-replicating antigens most often result in 
oral tolerance. However, oral immunization of F4-receptor positive (F4R+) pigs with 
F4 fimbriae induces an F4-specific immune response protecting pigs against a 
subsequent challenge with F4+ enterotoxigenic Escherichia coli (Van den Broeck et 
al.,1999b). In F4R- pigs, F4 fimbriae seem to act as a normal food antigen (Van den 
Broeck et al., 2002), indicating that the F4-induced immune response is receptor-
dependent. 
The aim of the present work was to determine the potential of F4 fimbriae or 
its adhesin FaeG to function as a mucosal carrier for inducing antibodies against a 
coupled heterologous antigen or fused heterologous peptide.  
 
For the F4 fimbriae, the following questions were addressed : 
• Are F4 fimbriae conserved among F4+ E. coli field isolates ? In addition, are 
F4-specific antibodies induced by fimbriae isolated from the F4+ ETEC 
reference strain GIS26 able to inhibit binding of F4+ E. coli field isolates to the 
F4 receptor ?  
• Is the great immunogenicity of F4 fimbriae unique or does it also exist for F18 
fimbriae ? 
• Is it possible to screen the multimeric character and receptor-binding capacity 
of F4 fimbriae in a fast, specific and sensitive manner ? 
• Are F4 fimbriae able to induce an antibody response against the coupled 
model antigen human serum albumin, following oral immunization of pigs ? 
Has cholera toxin (CT) the potential to improve the mucosal carrier effect of 
F4 fimbriae following oral co-administration ? 
 
For the FaeG adhesin, the following issues were studied : 
• Is there a correlation between F4 bioactivity and its binding with an FaeG-
specific monoclonal antibody ? 
• Can the F4 fimbrial adhesin FaeG be produced in an E. coli expression 
system, retaining its F4R-binding conformation ? Furthermore, is there a 
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difference in the F4-specific immune response induced following oral 
administration of rFaeG or purified F4 fimbriae ? 
• Has recombinant FaeG the potential to function as a mucosal carrier to a N-
terminally fused heterologous peptide in the presence or absence of CT ?  
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Chapter 4 
 
Conserved regions in the sequence of the F4 fimbrial 
adhesin FaeG, suggest a donor strand mechanism in 
F4 assembly and the usefulness of FaeG in a vaccine 
against F4+ enterotoxigenic Escherichia coli1  
 
                                                 
1 Based on : Verdonck F, Cox E, Schepers E, Imberechts H, Joensuu JJ, Goddeeris 
BM. 2004c. Conserved regions in the sequence of the F4 fimbrial adhesin FaeG 
suggest a donor strand mechanism in F4 assembly. Vet. Microbiol., accepted. 
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Abstract 
To use FaeG subunits in an oral vaccine against F4+ enterotoxigenic E. coli, it 
is necessary to determine the conservation of the adhesin subunit. Hereto, the faeG 
sequence was determined of 21 F4ac+ E. coli field isolates from piglets with diarrhoea 
and subsequently compared with these of the reference strain GIS26 and previously 
reported FaeG sequences. The FaeG amino acid sequence was 96-100% homologue 
within each F4 serotype, but only 92% and 88% when the F4ab and F4ad serotypes 
were compared with the F4ac serotype. The conserved regions of the adhesin suggest 
a donor strand mechanism in F4 fimbriae assembly as reported for type 1 fimbriae and 
P pili. On the other hand, antibodies induced by purified GIS26 F4 fimbriae 
immunization were able to inhibit binding of all 21 isolates. In conclusion, the results 
of the reported experiments support the study of FaeG in an oral subunit vaccine 
against F4+ E. coli infections.  
4.1. Introduction 
F4 fimbriae are frequently detected on enterotoxigenic Escherichia coli 
(ETEC) strains causing neonatal or post-weaning diarrhoea in pigs (Wilson et al., 
1986; Harel et al., 1991). They are long thin proteinaceous appendages radiating from 
the surface of the bacterium to a length of 0.1 – 1 µm (Stirm et al., 1967), 
peritrichously distributed in numbers of 100 to 1000 per bacterium (Ottow, 1975; 
Klemm, 1985). Their flexible structure allows them to adhere to the F4 receptor (F4R) 
on brush borders of small intestinal enterocytes, resulting in colonization of the small 
intestinal mucosa (Jones et al., 1972). Subsequently, the heat-labile enterotoxin (LT), 
heat-stable enterotoxin a and/or b (STa, STb) produced by these strains induce a 
secretory diarrhoea  (Nataro and Kaper, 1998). 
F4 fimbriae are composed of the major subunit FaeG and the minor subunits 
FaeC, FaeF, FaeH and FaeI (Oudega et al., 1989; Bakker et al., 1992b). The major 
subunit is also the adhesin (Bakker et al., 1992a; Van den Broeck et al., 1999c), 
whereas for other E. coli fimbriae a minor subunit is involved in the adhesion (Mol 
and Oudega, 1996). In the latter E. coli fimbrial systems, the adhesins are reported as 
conserved proteins, whereas the major subunits are described as variable (Smeds et 
al., 2003; Vandemaele et al., 2003a and 2003b). 
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Immunization of mice with recombinant subunits of the conserved type 1 
adhesin FimH  was   reported   to   protect   against   a   subsequent   uropathogenic  
E.  coli   infection  
(Langermann et al., 1997). In agreement, oral immunization of newly weaned piglets 
with recombinant FaeG induced an F4-specific mucosal and systemic immune 
response, significantly reducing F4+ E. coli excretion following challenge (Verdonck 
et al., 2004a). However, before using the FaeG subunit as a vaccine, the conservation 
of FaeG has to be determined. Therefore, the faeG sequences of 21 F4+ E. coli isolates 
from piglets with diarrhoea were determined and compared with the faeG sequence of 
the F4+ ETEC reference strain GIS26 and nine reported faeG sequences. 
4.2. Material and methods 
4.2.1. Bacterial strains 
Twenty E. coli strains were isolated from animals that died from a neonatal 
(N) or post-weaning (PW) F4+ ETEC infection. They were collected on nineteen 
different pig farms in Flanders (Table 1). The 5/95 isolate was isolated in Finland and 
obtained from J. Joensuu, whereas strain GIS26 was used as reference strain. All 
strains were cultured on brain heart infusion agar (Oxoid, Basingstoke, Hampshire, 
England) for 18 hours at 37°C, whereafter the expression of F4ac fimbriae was tested 
using the c-epitope specific monoclonal antibody (MAb) CVI F4ac-5 (ID-DLO, 
Lelystad, The Netherlands) (van Zijderveld et al., 1990). 
To isolate F4 fimbriae or to determine the F4R binding, all strains were 
cultured during 18 h in Tryptone Soya Broth (TSB, Oxoid) at 37°C and 85 rpm. The 
bacteria were collected by centrifugation and washed with phosphate-buffered saline 
(PBS) (150mM, pH 7.4). The concentration of the bacteria was determined by 
measuring the optical density of 10-fold dilutions of the bacterial suspension at 
660nm (OD660). An OD660 of 1 equals 109 viable bacteria/ml, as determined by 
counting colony forming units. 
 
4.2.2. Serotyping, haemolysis and antibiotic resistance  
Serotyping was performed by agglutination with specific antisera directed 
against somatic antigens O138, O139, O141, O147 and O149 (Orskov et al, 1977). 
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The β-haemolytic phenotype of the isolated strains was determined by 
growing the bacteria 18 h at 37°C on blood (5% sheep red blood cells) agar plates 
(Difco Laboratories, Becton Dickinson, Le Pont de Claix, France). 
Diffusion sensitivity testing was conducted for the following antibiotics : 
amoxycillin-clavulanic acid (AC), chloramphenicol (CM), tetracycline (TC), 
sulfonamide-trimethoprim (TSU), apramycin (AP), ceftiofur (CF), minocycline (M), 
spectinomycin (SP) and nalidixin acid (NAL). 
 
4.2.3. PCR assays 
Multiplex PCR was performed to detect the presence of LT, STa, STb 
enterotoxin and the verotoxin (VT) coding gene (Bosworth and Casey, 1997). faeG 
was amplified from the isolates by PCR (Fig. 1) using the primers FaeGS1GMF (5’-
GGACTGAGGATTAATCTAGATAGTGATGCAAAACATCCG-3’) and 
FaeGS1GMR (5’-CGTATCAATAATAAATTGGGAGCTCATCACGAC-3’) to 
include the signal sequence. PCR was performed in a PTC-100TM (MJ Research, 
Watertown, USA) using Supertaq (HT Biotechnology Ltd, Cambridge, England) and 
the resulting PCR product was purified using the Qiaquick PCR purification Kit 
(Qiagen, Hilden, Germany) according to the manufacturers instructions. 
 
 
 
 
 
 
 
 
Figure 1 : Position of the primers used to sequence faeG of F4+ E. coli isolates. 
 
4.2.4. Sequencing and DNA analysis 
The nucleotide sequences of faeG genes were determined by the 
dideoxynucleotide chain termination method of Sanger using the ABI PRISM 
BigdyeTM Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems, 
Warrington, UK). To sequence the faeG signal sequence of isolates GIS26, IMM 02, 
F4seq1 FaeGacF FaeGacR 
FaeGS1GMR FaeGS1GMF 
faeG 5’ 3’ 
F4seq2 
mature sequence signal 
sequence 
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IMM 03 and IMM 14, purified PCR fragments were used in combination with the 
FaeGS1GMF primer. To identify the sequence coding for the mature FaeG (Fig 1), 
purified PCR fragments were used in combination with the primers FaeGacF (5’-
GACGACGACAAGATTGCACATGCCTGGATGACTGG-3’), FaeGacR (5’-
GAGGAGAAGCCCGGTAATAAATTGGCAGCTCATCACG-3’), F4seq1 (5’-
GCTTCTTTGGTTCGGCCTAAC-3’) and F4seq2 (5’-
CTCTTGTTGACGTCGCAGGTT-3’). The sequencing reaction was performed in a 
PTC-100TM following the manufacturers protocol. The resulting products were 
purified using the Qiagen Dye Ex kit (Qiagen) and sequenced on a Genetic Analyzer 
3100 (Applied Biosystems) according to the manufacturers manual. The 
chromatograms of the sequences were visualized using the CHROMAS 2.0 software 
(Technelysium Ltd., Australia) and the DNA sequences were analysed and 
transformed to amino acid sequences using the DNAMAN version 5.0 (Lynnon 
Biosoft, Vaudreuil, Canada). 
 
4.2.5. In vitro adhesion to the F4R 
The in vitro adhesion of the E. coli isolates to the F4R was determined in 
triplicate using small intestinal villi from three strong F4R+ and one F4R- pig, as 
described by Van den Broeck et al. (1999c). The villi were washed and suspended in 
PBS supplemented with 1% (wt/vol) D-mannose to prevent adhesion of E. coli by 
type 1 pili. Subsequently, 4.108 E. coli were added to an average of 50 villi in a final 
volume of 0.5 ml and incubated for 1 hour while being gently shaken. Villi were 
examined by phase-contrast microscopy at a magnification of 600 and adhesion of 
bacteria was quantified by counting the number of bacteria adhering along a 50 µm 
villous border at 20 different places, after which the mean bacterial adhesion per 250 
µm villous brush border length was calculated. Binding of GIS26 to F4R+ villi (mean 
of 72.5, 73.5 and 84 bacteria per 250 µm for the three used F4R+ villi) was used as 
reference and set at 100 %, whereafter the binding percentage of the isolates was 
calculated in comparison with GIS26 F4R-binding. No binding of the isolates to the 
F4R- villi was observed. 
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4.2.6. Isolation of F4 fimbriae 
The F4 fimbriae were purified as described by Van den Broeck et al. (1999c). 
Briefly, fimbriae were isolated by homogenising the bacterial suspension of E. coli 
using an Ultra Turrax (Janke & Kunkel, IKA Labortechnik, Staufen, Germany), 
followed by a purification using two centrifugation steps and an additional 
precipitation of the supernatans with 40% (wt/vol) ammonium sulphate. Thereafter 
the pellet was dissolved and dialysed overnight against ultra pure H2O. 
 
4.2.7. Multimeric FaeG character of F4 fimbriae 
The presence of FaeG multi- or monomers in purified F4 fimbriae of the 
different isolates, was determined by SDS-PAGE followed by Coomassie staining or 
Western blot using the FaeG-specific MAb IMM01 (Van der Stede et al., 2002b) as 
described by Van den Broeck et al. (1999c). The samples were diluted in 60 mM 
TrisHCl pH 6.8, 2% SDS, 10% glycerol and 0.02% bromophenol blue and loaded on 
SDS-PAGE without heating. 
 
4.2.8. Transmission electron microscopic analysis (TEM) 
E. coli grown in TSB as described above, were examined using a TEM2085 
transmission electron microscope (FEI, Eindhoven, The Netherlands) after rotary 
shadowing or negative staining with 2% uranylacetate as described by Imberechts et 
al. (1996). 
 
4.2.9. MALDI-TOF mass spectrometry (MS) 
To identify the proteins in the 50 kDa and 75 kDa protein bands in heat 
denaturated and non-heat denaturated purified GIS26 F4 fimbriae respectively (Fig. 
4), these protein bands were excised from a SDS-PAGE, incubated with trypsin and 
analysed by MALDI-TOF MS (Bruker Reflex IV). The obtained peptide mass 
fingerprint was then used for identity searching using the BLAST algorithm 
(http://www.ncbi.nlm.nih.gov/blast). The score of the identity match is -10*Log(P), 
where P is the probability that the observed match is a random event. Protein scores 
greater than 56 are significant (P<0.05). 
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4.2.10. Motility assay 
The presence of flagella on E. coli isolates was analysed using a motility assay 
(Schmitt et al., 2001). Motility was assessed by stabbing motility agar (1 % (wt/vol) 
tryptone (Oxoid), 0.5% (wt/vol) NaCl and 0.35% (wt/vol) agar (Oxoid), pH 7.4) with 
the bacterial strain and after incubation at 37°C for 18 h observing the agar for 
migration of bacteria away from the point of inoculation. 
 
4.2.11. Brush-border fragment (BBF) ELISA 
A BBF-ELISA was developed to analyse if the antibodies, induced by oral 
immunization of purified GIS26 F4 fimbriae, were able to inhibit in vitro adhesion of 
other F4ac+ E. coli isolates to the F4R. To obtain BBF, jejunal enterocytes of pigs 
were isolated as described by Verdonck et al. (2004b). The enterocytes were 
homogenized by squeezing them 20 times through an 18G needle. The homogenate 
was centrifuged at 27,000 g for 30 min whereafter the pellet was collected. This 
procedure was repeated twice and finally BBF were stored at –20°C until use in 
ELISA. 
A 96-well microtiter plate (NUNC, Maxisorp, Immuno Plates, Roskilde, 
Denmark) was coated with the FaeG-specific MAb IMM01 at a concentration of 1 
µg/ml in PBS. After 2 h incubation at 37°C, the remaining binding sites were blocked 
overnight at 4°C with PBS supplemented with 0,2% (v/v) Tween®80. Purified F4 
fimbriae were diluted in ELISA dilution buffer (PBS + 0,05% (v/v) Tween®20) to a 
concentration of 50 µg/ml and incubated for 1 h at 37°C. Thereafter, the plates were 
incubated with serum from a pig orally immunized with GIS26 F4 fimbriae (F4-
specific titer 1280) or serum from an F4-seronegative pig (F4-specific titer < 10), 
again for 1 h at 37°C. Subsequently, F4R+ or F4R- BBF were washed three times in 
PBS (400g, 10 min) and diluted to 1 mg/ml in PBS containing 5% (w/v) non-fat dry 
milk, were brought onto the plate for 1 h at 37°C. BBF-specific rabbit serum 
optimally diluted in ELISA dilution buffer was used for 1 h at 37°C. Thereafter, pig 
anti-rabbit HRP-conjugated serum (Dako, Denmark), optimally diluted in ELISA 
dilution buffer, was added. Following 1 h incubation at 37°C, an ABTS solution 
containing H2O2 was added for 1 h incubation at 37°C whereafter the optical density 
was spectrophotometrically measured at 405 nm (OD405). Between each incubation 
step, the plates were washed three times with washing buffer (PBS + 0,2% (v/v) 
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Tween®20), except after incubation with BBF when the plates were washed three 
times with an extra salt-containing buffer (PBS with 0,3 M NaCl + 0,2% (v/v) 
Tween®20). 
 
4.3. Results 
4.3.1. Phenotyping of isolates 
All isolates were β-haemolytic and resistant to one or more antibiotics (Table 1). 
Nineteen of the 22 isolates belonged to the serotype O147, whereas 5/95 and GIS26 
were O149 and isolate IMM 24 was not typable with the used serotype-specific 
antibodies. Furthermore, all isolates except IMM 24 bound the F4R in vitro and 
contained the genes coding for the enterotoxins LT and STb. Indeed, IMM 24 did not 
express F4 fimbriae as no agglutination with F4-specific MAb was observed and no 
F4 fimbriae could be obtained following purification. In addition, IMM 24 contained 
verotoxin instead of enterotoxin coding genes. However, this isolate did contain the 
faeG gene.  
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4.3.2. Analysis of FaeG sequence  
The faeG nucleotide sequence of all the F4ac+ E. coli isolates was determined 
to elucidate the degree of conservation. The nucleotide sequence coding for the FaeG 
signal sequence was identical for all the tested isolates, whereas mutations occurring 
at 29 different positions were detected in the 786 nucleotides coding for the mature 
FaeGac protein. Following deduction of the protein sequences from the obtained 
nucleotide sequences, silent mutations were seen at 4 positions each occurring in only 
one isolate. Most frequent nucleotide substitutions caused replacements by amino 
acids, which changed the hydrophobic, charged or polar character of the side chain.  
As shown in Figure 2, conservation was found in the central (106-134) as well 
as the N- and C-terminal region (1-37 and 236-262, respectively). Furthermore, the 
regions 162-171 and 206-216 were conserved in F4ac+ ETEC strains, but variable 
between the three antigenic variants as observed following comparison with the 
reported FaeG amino acid sequences of F4ab and F4ad strains (Josephsen et al., 1984; 
Dykes et al., 1985; Bakker et al. 1992a). In agreement, analysis of the identity 
between mature FaeG amino acid sequences of the isolates reported in this study and 
the previously reported FaeG sequences, revealed that the FaeG amino acid sequence 
is 96-100% identical within each antigenic variant, but only 92 and 88% when the 
mature FaeG amino acid sequence of F4ab and F4ad antigenic variants are compared 
with that of the F4ac antigenic variant, respectively (Fig. 3). Interesting to note is the 
observation that 12 of the 21 F4ac isolates revealed a deletion of amino acid residue 
105, identical to the FaeG sequence of F4ab and F4ad antigenic variants. Moreover, at 
5 positions amino acid residues differed from earlier reported F4ac isolates, but were 
identical to the corresponding amino acid residue in F4ab and/or F4ad sequences. 
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Figure 3 : Identity tree of the multiple FaeG alignment at protein level from the isolates 
studied here and sequences reported by Dykes et al. (1985), Josephsen et al. (1984), Bakker et 
al. (1992a). The percentages indicate the degree of identity. 
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 4.3.3. Mono- and polymer 
The F4 fimbriae of all isolates except of IMM 24, were purified for 
characterization. SDS-PAGE and Coomassie staining of heat-denaturated F4 fimbriae 
revealed a band of 27 kDa. This 27kDa band was identified as the FaeG monomer 
because it was recognized by the FaeG-specific MAb IMM01 in Western blot. On the 
other hand, a second band of 50 kDa was observed in several isolates, but this band 
was not recognized by the MAb IMM01 (data not shown). The 50 kDa band could 
reach up to 25-40% of the total protein amount in purified GIS26 F4 fimbriae and was 
identified as flagellin following MALDI-TOF MS analysis (score 301). Subsequently, 
the presence of flagella was analysed on all isolates using a motility assay. Seven of 
the 21 isolates appeared to express flagella (Table 1), but the GIS26 was most 
positive. Electron microscopy confirmed the presence of flagella on GIS26. 
The mono- or polymeric nature of FaeG in purified F4 fimbriae was determined 
by SDS-PAGE of native purified fimbriae followed by Coomassie staining or Western 
blot. Only the FaeG monomer band of 27 kDa was detected in the F4 fimbrial sample 
of the 5/95 isolate, whereas a ladder pattern of FaeG multimers was observed for the 
other F4ac+ E. coli isolates (Fig. 4). This ladder pattern indeed consisted of FaeG 
polymers since MALDI-TOF MS analysis confirmed that the 75 kDa band of non-
heat denaturated purified GIS26 F4 fimbriae contained FaeG (score 160). To 
determine whether 5/95 FaeG depolymerised due to SDS-PAGE or whether the FaeG 
monomers were already present following the fimbrial purification, 5/95 F4 fimbriae 
were analysed by TEM. A low number of fimbriae could be detected in between a 
huge amount of protein aggregates for 5/95 fimbriae (Fig. 4). In contrast, EM analysis 
of purified GIS26 F4 fimbriae revealed a lot of fimbriae with only a low amount of 
aggregates. 
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Figure 4 : (A) Coomassie stained SDS-PAGE of non heat-denaturated purified 5/95 (lane 1) 
and GIS26 (lane 2) F4 fimbriae, molecular weight marker : 250, 150, 100, 75, 50, 37, 25, 20, 
15 kDa (lane 3), heat-denaturated purified 5/95 (lane 4) and GIS26 (lane 5) F4 fimbriae. (B) 
Electron micrograph of purified 5/95 F4 fimbriae (same sample as in A). (C) Electron 
micrograph of purified GIS26 F4 fimbriae (same sample as in A).  
 
4.3.4. BBF ELISA 
A BBF-ELISA was developed to analyse if antibodies induced by oral 
immunization of purified GIS26 F4 fimbriae were able to inhibit in vitro adhesion of 
other F4ac+ E. coli isolates to the F4R. Binding of purified F4 from all isolates except 
IMM 24 was observed to BBF isolated of F4R+ villi, whereas only low OD405-signals 
(0.09 to 0.17) were obtained in the presence of F4R- BBF (data not shown). Addition 
of serum from a pig that was orally immunized with purified GIS26 F4 fimbriae, 
reduced the OD405-signals to the level observed with F4R- BBF (Fig. 5). In contrast, 
serum without F4-specific antibodies was not inhibiting the interaction between the 
F4R and the F4 fimbriae. So, it was shown that antibodies induced by purified GIS26 
F4 fimbriae were able to inhibit adhesion of 20 different F4ac+ ETEC isolates to F4R+ 
villi. 
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Figure 5 : The OD405-values obtained following brush border fragment 
(BBF) ELISA, represent binding of purified F4 from all F4+ E. coli 
isolates except IMM 24 to F4R+ BBF, in the presence of serum with 
(positive) or without (negative) F4-specific antibodies. 
 
4.4. Discussion 
 In the present study, the conservation of the F4 fimbrial adhesin FaeG 
sequence was evaluated. Twenty-one different F4+ E. coli were isolated from piglets 
with neonatal or post-weaning diarrhoea. These field strains were haemolytic and 
encoded the enterotoxins LT, STa and STb, in accordance to other reports on 
pathogenic F4+ ETEC isolates (Wilson et al., 1986; Osek, 2000; Frydendahl, 2002). 
The FaeG amino acid sequence of the 21 F4ac+ E. coli field isolates, the 
GIS26 reference strain and the strains reported in literature, were 96% identical. 
Similar high degrees of sequence identity have been reported for the adhesins of F18 
fimbriae (97%; Smeds et al., 2003; Tiels, unpublished results) and type 1 fimbriae 
(98%; Sokurenko et al., 1994; Vandemaele et al., 2003a), whereas the degree of 
sequence identity appeared lower for the F17 fimbrial lectin domain (90%; Buts et al., 
2003a) and the P pilus adhesin (87%; Vandemaele et al., 2003a). However, in contrast 
to F4 fimbriae, the adhesins of all these fimbriae are minor subunits and the degree of 
sequence identity for their respective major subunits is often lower (Garcia et al., 
1992; Vandemaele et al., 2003a). In the case of type 1 fimbriae, six variable regions 
are present in the major subunit, resulting in a 90% degree of sequence identity 
between different isolates (Vandemaele et al., 2003a). Garcia et al. (1992) reported 
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only 46.5% sequence identity between the major subunit PapA of different antigenic 
P pilus variants.  
In comparison with the degree of FaeG sequence identity within F4ac strains, 
lower identity levels were found between FaeG of F4ac strains and of F4ab and F4ad 
strains (92 and 88%, respectively). The amino acid sequence differences between the 
three antigenic variants are mainly located between amino acid residues 162-174 and 
206-216. However, these regions are conserved within the F4ac isolates, indicating a 
possible importance in F4R-binding. Indeed, this region has been reported to be a 
receptor-binding site (Bakker et al., 1992a) and to be the cause of differences in 
receptor binding among the three F4 antigenic variants (Bijlsma et al., 1982). 
In accordance with Gaastra et al. (1983), it was observed that the signal 
sequence, the N- and C-terminal regions (amino acid residue 1-37 and 236-262, 
respectively), as well as a central region of FaeG (106-134) were very conserved for 
the three F4 antigenic variants. These regions are probably very important for the 
structure and the function of the subunit as they are also conserved in subunits of 
other fimbriae such as type 1 fimbriae and P pili (Soto and Hultgren, 1999). The FaeG 
signal sequence has probably a regulatory function in FaeG production. Hultgren et al. 
(1999) reported that release of the mature PapG adhesin from its signal sequence by 
signal peptidase I is enhanced by its interaction with the PapD chaperone. 
Furthermore, the FaeG signal sequence is conserved in F4-related fimbriae F41 and 
CS31A (Girardeau et al., 1991), but different compared to other fimbrial systems. 
The N-terminal region of FaeG contains an alternating hydrophobic sequence. 
Crystal structures of subunits from type 1 and P pili and the lectin domain of the F17 
fimbrial adhesin revealed a folding like an immunoglobulin(Ig)-domain, but lacking 
the C-terminal strand (Choudhury et al., 1999; Sauer et al., 1999; Buts et al., 2003a). 
The missing strand results in a hydrophobic groove along the surface of the subunit. 
However, the Ig-like domain structure of fimbrial subunits is stabilized by a β-strand 
of the chaperone in the periplasm (donor strand complementation) or by the N-
terminal β-strand of a subunit in the fimbria (donor strand exchange). Therefore, 
changing the N-terminal sequence of fimbrial subunits inhibits the polymerisation of 
the subunits into a fimbria (Zavialov et al., 2003b). However, this cannot likely 
explain the observed weak interaction of FaeG subunits in 5/95 fimbriae, since its 
sequence only differs by the presence of a valine residue at position 201 but this 
amino acid has similar properties as the isoleucine found in all other isolates. The 
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weaker interaction between 5/95 FaeG subunits is still unknown, and may be due to a 
combination of certain amino acid residues at specific positions. 
 An alternating hydrophobic amino acid sequence was also observed in the 
FaeG C-terminus, containing a penultimate Tyr. In other fimbrial subunits like type 1 
fimbriae and P pili, the C-terminal alternating hydrophobic sequence is reported to 
interact with the chaperone in the periplasm (Kuehn et al., 1993; Soto et al., 1998). 
The penultimate Tyr is critical for the conformational stability of the protein and for 
its interaction with the chaperone (Simons et al., 1990; Bullitt et al., 1996; Krasan et 
al., 2000; Ogunniyi et al., 2002). However, a serine at position 14 from the carboxyl 
terminal motif is present in FaeG, in contrast to a glycine in most fimbrial subunits 
(Soto and Hultgren, 1999). Nevertheless, we suggest that the donor strand 
complementation system may also work in the F4 fimbrial system. Indeed, the critical 
amino acid residues that are needed for proper functioning of the P-pilus chaperone 
PapD are also present in the F4-fimbrial chaperone FaeE (Bakker et al., 1991; Slonim 
et al., 1992; Holmgren et al., 1992; Kuehn et al., 1993; Hung et al., 1999a). Moreover, 
the C-terminal alternating hydrophobic sequences are present in the F4 fimbrial 
subunits FaeC, FaeG, FaeH and FaeI that interact with the chaperone FaeE (Mol et al., 
2001). 
A third conserved region was determined in the centre of FaeG. This region 
was found to be highly similar to the corresponding region of the P-pilus subunit 
PapK, which is coding for a part of the B β-strand and of the loop between the 310C 
α-helix. This 310C α-helix forms part of a site that interacts with the chaperone PapD 
(Sauer et al., 1999). 
Isolate IMM 24 did not express F4 fimbriae and did not adhere to porcine 
enterocytes although the gene encoding FaeG was present. Probably, this could be due 
to a failure at another location in the F4 operon, like the gene encoding the chaperone 
or the usher. No study was performed on differences in adhesion efficiency among the 
other E. coli isolates or their purified F4 fimbriae to porcine enterocytes, because 
differences in numbers of fimbriae per cell and average lengths of fimbriae could 
occur and have an effect on adhesion. In addition, some isolates were found to express 
flagella and although flagella are not supposed to bind to the apical side of enterocytes 
(Gerwitz et al. 2001a and 2001b), these are known to influence the motility of an 
isolate and can subsequently enhance the likelihood to adhere (Jones et al., 1992; 
Schmitt et al., 2001).  
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The widely spread prevalence of F4+ E. coli isolates (Nagy et al., 1990; Harel 
et al., 1991; Osek and Svennerholm, 1991; Wray et al., 1993; Garabal et al., 1997; 
Van den Broeck et al., 1999d; Frydendahl, 2002) and their increasing ability to resist 
antibiotics (Amezcua et al., 2002; Bischoff et al., 2002; Lanz et al., 2003; Noamani et 
al., 2003), stress the need to develop a vaccine against F4+ ETEC. F4 fimbriae of the 
F4+ ETEC reference strain GIS26 seem to be good vaccine candidates. Indeed, the 
results of the present study indicate that the F4 fimbrial adhesin FaeG is conserved 
and that F4 purified from GIS26 induce FaeG-specific antibodies which were able to 
inhibit F4R-binding of 20 different F4+ E. coli isolates. In addition, the current results 
confirm the multimeric FaeG character of F4. Although the polymeric FaeG character 
of F4 fimbriae could be an advantage to improve the FaeG immunogenicity, FaeG 
monomers may perhaps bind more F4R than F4 fimbriae on a molar base. Therefore, 
further research on the usefulness of FaeG polymers or FaeG monomers in an oral 
vaccine against homologous and heterologous F4+ E. coli infections would be 
worthwhile.  
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Different kinetic of antibody responses following 
infection of newly weaned pigs with an F4 
enterotoxigenic Escherichia coli strain or an F18 
verotoxigenic Escherichia coli strain1 
 
 
                                                 
1 Based on : Verdonck F, Cox E, Van Gog K, Van der Stede Y, Duchateau L, Deprez 
P, Goddeeris BM. 2002. Different kinetic of antibody responses following infection of 
newly weaned pigs with an F4 enterotoxigenic Escherichia coli strain or an F18 
verotoxigenic Escherichia coli strain. Vaccine 20:2995-3004. 
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Abstract 
To develop a vaccine against Escherichia coli (E. coli) induced postweaning 
diarrhoea and oedema disease, insights in the induction of the protective immune 
response following infection with these pathogenic E. coli’s is needed. Therefore, the 
fimbriae-specific antibody response of newly weaned pigs following infection with 
the SLT-IIv producing F18+ verotoxigenic E. coli (VTEC) (strain 107/86) was 
compared with the response following an infection with LT producing F4+ 
enterotoxigenic E. coli (ETEC) (strain GIS26). F4+ ETEC were able to colonize the 
gut very soon after infection since peak excretion of F4+ Escherichia coli (E. coli) 
bacteria was seen 2 days post infection (dpi), but was already disappeared 7 dpi. On 
the other hand, F18+ VTEC infection resulted in a slower colonization of the gut as 
the peak excretion of F18+ E. coli was observed between 3 and 5 dpi, but this 
colonization remained longer as F18+ E. coli were detected till 9 dpi in feces. 
Furthermore, this fast colonization pattern of F4+ ETEC is accompanied with the 
presence of F4-specific antibodies in mucosal tissues and serum from 4 dpi onward, 
with maximal amounts of F4-specific IgA in the jejunal lamina propria and serum 7 
dpi. In contrast, F18-specific IgA was only readily detected in the jejunal lamina 
propria 15 dpi and showed a maximum serum titer 21 dpi. Besides this faster 
induction and higher antibody response, the switch from IgM to IgA and IgG was also 
earlier following the F4+ ETEC infection.  
 
 
5.1. Introduction 
 Intestinal infections with Escherichia coli (E. coli) are an important cause of 
diarrhoea and mortality in humans in developing countries and in domestic animals. 
Especially in pigs, enterotoxigenic E. coli (ETEC) infections immediately after birth 
(neonatal diarrhoea) and ETEC or verotoxigenic E. coli (VTEC) infections after 
weaning (postweaning diarrhoea or oedema disease) are responsible for significant 
economical losses due to diarrhoea, growth retardation and mortality. The infections 
are mainly caused by F4+ or F18+ ETEC or by F18+ VTEC (Nagy et al., 1990; Wittig 
et al., 1995), which have two important virulence factors : fimbriae and toxins. The 
fimbriae allow adhesion to specific receptors on small intestinal villi and consequently 
colonization can occur (Jones and Rutter, 1972; Bertschinger et al., 1990). The F4 
receptor (F4R) and F18R are different, based on comparative in vitro adhesion studies 
Chapter 5 : Comparison of ETEC and VTEC infection 
75 
(Nagy et al., 1997) and on the localization on different porcine chromosomes 
(Gibbons et al., 1977; Vögeli et al., 1996). The presence of the F4R and F18R is 
genetically determined by an autosomal dominant gene and their absence makes pigs 
resistant to infection (Rutter et al., 1975; Bertschinger et al., 1993). Following 
colonization, ETEC strains produce heat-labile enterotoxin (LT), heat-stable 
enterotoxin a (STa) and/or STb (Morris and Sojka, 1985) which induce a secretory 
diarrhoea (Nataro and Kaper, 1998). VTEC strains produce the Shiga-like toxin type 
II variant (SLT-IIv) (Marques et al., 1987; MacLeod et al., 1991), a vasotoxin that 
acts on vascular endothelial cells resulting in oedema and subsequent neurological 
signs including ataxia, recumbency and paddling movements, eventually leading to 
death (Clugston et al., 1974).  
F4+ ETEC infections mainly occur the first week after weaning, whereas F18+ 
VTEC infection occurs between a week and two weeks post weaning. Colonization 
begins after adhesion of the bacteria with their fimbriae to the small intestine and 
stops when anti-fimbrial antibodies can be detected in the intestinal lumen of the 
infected pig (Yokoyama et al., 1992; Imberechts et al., 1997b; Zuniga et al., 1997; de 
Geus et al., 1998; Van den Broeck et al., 1999b). To protect weaned pigs, an oral 
vaccine must be developed since parenteral immunization does not induce protective 
immunity at mucosal surfaces (Bianchi et al., 1996). Van den Broeck et al. (1999b) 
reported that oral immunization of weaned pigs with purified F4 fimbriae protects 
them against subsequent F4+ ETEC infection. For F18+ E. coli however, only an 
infection has been reported to induce protective F18-specific antibodies at the small 
intestinal mucosa (Sarrazin and Bertschinger, 1997; Bertschinger et al., 2000). In the 
present study, the kinetics and localization of the immune response following an 
infection with F4+ ETEC or F18+ VTEC were compared. Insights in the mucosal 
immune response following infection with these pathogenic E. coli’s can be helpful in 
the development of an effective vaccine.  
 
5.2. Material and methods 
5.2.1. Pigs  
Conventional bred pigs (Belgian Landrace x Piétrain) were weaned at the age 
of 4 weeks and subsequently housed in isolation units, fed at libitum and treated orally 
with colistine (Promycine pulvis, VMD, Berendonk, Belgium, 150,000 U/kg of body 
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weight/day) to prevent E. coli infections. One week post weaning, eighteen F18-
seronegative and F18-receptor positive (F18R+) pigs were infected with an F18+ 
VTEC strain and twenty F4-seronegative and F4R+ pigs were infected with an F4+ 
ETEC strain.  
 
5.2.2. Bacterial inoculum 
The VTEC strain 107/86 (O139:K12:H1, F18ab+, SLT-IIv+) and the ETEC 
strain GIS26 (O149:K91, F4ac+, LT+ STa+ STb+) were cultured during 18 hours in 
Tryptone Soya Broth at 37°C and 85 rpm. The bacteria were collected by 
centrifugation (2,000 x g, 35 minutes, 4°C) and washed with phosphate-buffered 
saline (PBS, 150 mM, pH 7.4). The concentration of the bacteria was determined by 
measuring the optical 10-fold dilutions of the bacterial suspension at 660 nm (OD660). 
An OD660 of 1 equals 109 bacteria per ml, as determined by counting colony forming 
units. Subsequently, the concentration of the bacteria was adjusted to 1010 bacteria per 
ml. 
 
5.2.3. Purification of F18 fimbriae   
A protocol to purify F18 fimbriae was developed. Bacteria of the E. coli strain 
107/86 were cultured in Tryptone Soya Broth (Oxoid, Basingstoke, Hampshire, 
England) at 37°C and 85 rpm for 18 hours. Subsequently, the bacteria were collected 
by centrifugation (3,000 x g, 35 minutes) and washed in PBS, after which the F18 
fimbriae were isolated by heat shock (60°C for 20 minutes). Larger fragments were 
removed by centrifugation (10,000 x g, 20 minutes) and the supernatant was further 
purified by a subsequent centrifugation (20,000 x g, 40 minutes), both at 4°C. The 
solubilized F18 fimbriae were precipitated with 20% (wt/vol) ammonium sulphate 
and the pellet was dissolved and dialysed overnight against ultra pure H2O.  
 
5.2.4. Purification of F4 fimbriae 
The F4 fimbriae were purified as described by Van den Broeck et al. (1999c). 
Briefly, fimbriae were isolated by homogenising the bacterial suspension of strain E. 
coli GIS26 using an Ultra Turrax (Janke & Kunkel, IKA Labortechnik, Staufen, 
Germany), followed by a purification using two centrifugation steps as for F18, a 
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precipitation step with 40% (wt/vol) ammonium sulphate. Thereafter the pellet was 
dissolved and dialysed overnight against ultra pure H2O.  
 
5.2.5. PCR of F18R linked FUT1  
In order to select F18R+ pigs, PCR amplification of the F18R linked FUT1 
gene on isolated DNA of blood leukocytes was performed as described by Meijerink 
et al. (1997).  
 
5.2.6. In vitro villous adhesion assay  
The presence of F18R was confirmed and the presence of F4R was determined 
by the in vitro villous adhesion assays previously described (Van den Broeck et al., 
1999c). Briefly, a 15-cm-long intestinal segment was excised of the mid jejunum at 
the moment of slaughter. The segment was washed twice with PBS and once with 
Krebs-Henseleit buffer (160 mM, pH 7.4) containing 1% vol/vol formaldehyde at 
4°C. Subsequently, the villi were scraped from the mucosa and suspended in the same 
solution. Before use, the villi were washed 4 times in Krebs-Henseleit buffer without 
formaldehyde whereafter they were resuspended in PBS supplemented with 1% 
(wt/vol) D-mannose (Fluka, Sigma-Aldrich, Bornem, Belgium) to prevent adhesion 
by type 1 pili. Subsequently 4 x 108 F18+ or F4+ E. coli were added to an average of 
50 villi in 0.5 ml buffer and incubated by room temperature for 1 hour while gently 
shaking. Then, villi were examined by phase-contrast microscopy at a magnification 
of 600 and the adhesion of bacteria was evaluated quantitatively by counting the 
number of bacteria adhering along a 50 µm villous brush border at 20 randomly 
selected places, after which the mean bacterial adhesion was calculated. Adhesion of 
more than 5 bacteria per 250 µm villous length was noted as positive (Cox and 
Houvenaghel, 1993).  
 
5.2.7. Experimental procedure 
5.2.7.1. VTEC experiment       
On 2 consecutive days, the 5-week-old F18R+ pigs (n = 18) were sedated using 
Stresnil (40 mg/ml; Janssen-Cilag, Berchem, Belgium), whereafter the acidic gastric 
pH was neutralized by intragastrical administration of 62 ml NaHCO3 (1.4% (wt/vol) 
in distilled water) using a stomach tube. Fifteen to thirty minutes later, 1011 F18+ 
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VTEC (in 10 ml PBS) were intragastrically inoculated using a stomach tube. Faecal 
excretion of the F18+ E. coli and presence of diarrhoea were determined daily from 2 
till 10 days after the first inoculation (dpi). The kinetics and the localization of the 
antibody response was analysed by enumerating the F18-specific antibody secreting 
cells (ASCs) in peripheral blood, mesenteric lymph nodes, jejunal and ileal Peyer’s 
patches, jejunal lamina propria, mesenteric lymph nodes and spleen 0, 4, 7, 11 and 15 
dpi, from 3, 3, 3, 2 and 2 pigs respectively. Tissues were taken following euthanasia 
of animals by intravenous injection of pentobarbital (24 mg/kg; Nembutal, Sanofi 
Santé Animale, Brussels, Belgium) and subsequent exsanguination. At euthanasia, 
duodenal, jejunal and ileal contents were also sampled for measuring F18-specific 
IgA. Furthermore, F18-specific serum IgM, IgA and IgG were determined 0, 4, 7, 11, 
15, 21 and 25 dpi, from 18, 15, 11, 7, 5, 3 and 3 pigs respectively. Finally, jejunal villi 
were isolated for the in vitro villous adhesion assay. 
 
5.2.7.2. ETEC experiment  
The experimental procedure was similar as for the VTEC experiment with 
minor differences. Firstly, 5-week-old F4R+ pigs (n = 20) were intragastrically 
inoculated on two consecutive days with 1011 F4+ ETEC. Secondly, the faecal 
excretion of the F4+ E. coli was daily determined until day 7 after infection. The 
kinetics and the localization of the antibody response were analysed 0, 4, 7, 11 and 15 
dpi, using 4, 3, 3, 3 and 4 pigs respectively. F4-specific serum IgM, IgA and IgG were 
determined 0, 4, 7, 11, 15, 21 and 25 dpi, from 20, 15, 12, 9, 5, 2 and 2 pigs 
respectively. 
 
5.2.8. Samples 
5.2.8.1. Serum 
Blood was taken form the jugular vein. After 18 hours incubation at room 
temperature, serum was collected, inactivated at 56°C during 30 minutes and 
subsequently treated with kaolin (Sigma, Sigma-Aldrich) to decrease the background 
reading in ELISA (Van den Broeck et al., 1999a). Subsequently, the serum was 
diluted in ELISA dilution buffer (PBS + 0.05% (vol/vol) Tween®20 (Merck, 
Hohenbrunn, Germany) + 3% (wt/vol) bovine serum albumin (BSA; Sigma)) to 
obtain a final serum dilution of 1/10. 
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5.2.8.2. Faeces 
Faecal samples were examined for the presence of F18+ (VTEC experiment) or 
F4+ E. coli (ETEC experiment). Therefore, 1% (wt/vol) suspensions of faecal samples 
in PBS were prepared at 4°C. Of these suspensions, four serial 10-fold dilutions were 
made in PBS and 50 µl drops of each dilution were spread onto plain blood agar 
plates. The plates were incubated at 37°C for 24 hours. F18+ or F4+ E. coli were 
identified using dot blotting as previously described (Van den Broeck et al., 1999b). 
F18 producing E. coli strains were detected using an F18-specific rabbit antiserum 
followed by incubation with a swine anti-rabbit immunoglobulin horseradish 
peroxidase (HRP)-conjugated antiserum (Dako, Denmark), the F4 producing E. coli 
strains were detected using an HRP-conjugated F4-specific Mab (IMM01; Van der 
Stede et al., 2002b). Binding of conjugate was visualized with a 3-amino-9-
ethylcarbazole containing substrate solution. The developed brown-red dots were 
counted and the average within both groups was calculated. Results are presented as 
the mean number ± standard error of the mean (SEM) of excreted E. coli per gram 
feces.   
 
5.2.8.3. Intestinal contents 
Intestinal contents of duodenum, jejunum and ileum were twofold diluted in 
PBS + 20% foetal calf serum (FCS (vol/vol) + penicillin (100 IU/ml) + streptomycin 
(100 µg/ml) + 0.2% (vol/vol) Tween®20 and incubated at 56°C for 30 minutes. 
Afterwards, the samples were centrifugated at 4°C and 9,500 x g. The supernatant was 
centrifugated once again and stored at -70°C until analysis.  
 
5.2.8.4. Peripheral blood monomorphonuclear cells (MC) 
 Peripheral blood MC were isolated as previously described (Van den Broeck 
et al., 1999a). Briefly, peripheral blood MC were isolated by density gradient 
centrifugation and erythrocytes were lysed in ammonium chloride (0.74% [wt/vol]). 
After washing at 4°C, the pelleted cells were resuspended at 107 cells/ml in leukocyte 
medium [RPMI-1640 (GIBCO BRL, Paisley, Scotland) containing FCS (10% 
[vol/vol]) (Seromed, International Medical, Berlin, Germany), 2-mercaptoethanol (5 x 
10-5 M) (GIBCO BRL), non-essential amino acids (GIBCO BRL), Na-pyruvate (100 
µg/ml) (GIBCO BRL), L-glutamine (292 µg/ml) (GIBCO BRL), penicillin (100 
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IU/ml) (GIBCO BRL), streptomycin (100 µg/ml) (GIBCO BRL) and kanamycin (100 
µg/ml) (GIBCO BRL)]. 
 
5.2.8.5. Spleen and mesenteric lymph node MC 
At the moment of slaughter, a part of the spleen and some mesenteric (jejunal 
and ileal) lymph nodes were aseptically dissected. After removing surrounding fat 
from the specimen, the MC were isolated by teasing the tissue apart, followed by lysis 
of erythrocytes in ammonium chloride. After washing, the pelleted cells were 
resuspended at 107 cells/ml in leukocyte medium.  
 
5.2.8.6. Jejunal lamina propria MC 
At the moment of slaughter, an intestinal segment without Peyer’s patches was 
excised of the jejunum and washed with PBS at room temperature. The segment was 
cut in 2-cm-long pieces which were washed with RPMI-1640 (GIBCO BRL) + 10 
mM HEPES (GIBCO BRL) + 5% (vol/vol) FCS. Then, the pieces were washed two 
times with PBS without calcium and magnesium (CMF buffer) at room temperature 
and once with warm (37°C) CMF buffer supplemented with EDTA (3.7% (wt/vol)) 
and 0.94 M dithiotreithol (GIBCO BRL). Subsequently, the 2-cm-long pieces were 
cut in very small pieces and incubated in RPMI-1640  + 10 mM HEPES + 2% 
(vol/vol) FCS + 0.015% (wt/vol) collagenase (SERVA, Polylab, Antwerp, Belgium) + 
0.01% (wt/vol) DNase I (Boehringer Mannheim, Brussels, Belgium) for 30 minutes at 
37°C and 200 rpm. The obtained cell suspension was filtered through cell collectors 
of 200, 150 and 80 mesh (Sigma). The isolated cells were washed and resuspended in 
leukocyte medium at 107 cells/ml. 
 
5.2.8.7. Peyer’s patches MC 
At the moment of slaughter, jejunal and ileal Peyer’s patches were excised 
from the intestine. The isolated tissue was washed at room temperature with PBS and 
CMF buffer and subsequently incubated with CMF buffer supplemented with EDTA 
for 15 minutes at 37°C and 200 rpm as described before. Then, Peyer’s patches MC 
were collected by scraping the Peyer’s patches at room temperature, washing the cells 
and resuspending the cells at 4°C in leukocyte medium at 107 cells/ml. 
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5.2.9. ELISA’s for F18- or F4-specific IgM, IgA and IgG 
An indirect ELISA was developed to detect F18-specific serum IgM, IgA and 
IgG titers in serum and IgA titers in intestinal content. Purified F18 fimbriae were 
coated at a concentration of 1.56 µg/ml in coating buffer (carbonate-bicarbonate 
buffer, 50 mM, pH 9.4) on a 96-well microtiter plate (NUNC, Maxisorp Immuno 
Plates, Roskilde, Denmark). After 2 h incubation at 37°C, the remaining binding sites 
were blocked overnight at 4°C with PBS supplemented with 0.2% (vol/vol) 
Tween®80. The serum or intestinal contents were diluted in ELISA dilution buffer 
(PBS + 0.05% (vol/vol) Tween®20 + 3% (wt/vol) BSA) and series of twofold 
dilutions, starting from 1/10 and 1/2 respectively, were made. The plates were 
incubated for 1 hour at 37°C. Thereafter, optimal dilutions of anti-swine IgM-, IgA- 
or IgG-specific MAb (Van Zaane and Hulst, 1987) were added to the wells for 1 h at 
37°C. Subsequently, rabbit anti-mouse HRP-conjugated serum (Dako, Denmark) 
optimally diluted in the ELISA dilution buffer and supplemented with 2% (vol/vol) 
pig serum was brought on the plate for 1 h at 37°C. An ABTS solution containing 
H2O2 was added and after 1 hr incubation at 37°C the optical density was 
spectrophotometrically measured at 405 nm (OD405). The plates were washed three 
times with ELISA washing buffer (PBS + 0.2% (vol/vol) Tween®20) between each 
incubation step. The IgM, IgA and IgG cut-off values were calculated as the mean 
OD405-value of all sera (dilution 1/10) at day 0, increased with 3 times the standard 
deviation. The antibody titer was the inverse of the highest dilution that still had an 
OD405 higher than the calculated cut-off value. 
For detection of F4-specific antibodies, the indirect ELISA described by (Van 
den Broeck et al., 1999a) was used. Briefly, the wells of a 96-well microtiter plate 
were coated with the F4-specific monoclonal antibody (IMM01) at a concentration of 
1µg/ml coating buffer. Subsequently, purified F4, the treated sera or intestinal 
contents, optimal dilutions of biotinylated-swine-specific IgM, IgA and IgG MAb and 
HRP-conjugated streptavidin (GIBCO BRL) were added. Incubation times and 
conditions were similar as for F18. 
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5.2.10. Elispot assays for antigen-specific IgM, IgA and IgG 
antibody-secreting cells  
F18 or F4 coated plates were prepared as described above. Thereafter, MC 
suspensions at a concentration of 106 cells/ml leukocyte medium were added (100 
µl/well), and plates were incubated for 14 hours at 37°C in a humidified 5% CO2 
atmosphere. Subsequently, the cells were removed by three washes with ELISA 
washing buffer and wells were sequentially incubated with anti-swine IgM, IgA and 
IgG Mab, rabbit anti-mouse antibodies (Dako) coupled to biotin and HRP-conjugated 
streptavidin (Dako) each time for 1 hour at 37°C. Between each step, the plates were 
washed with ELISA washing buffer. Subsequently, a substrate solution, consisting of 
4 volumes of 3-amino-9-ethylcarbazole (AEC) (Sigma) working solution (0.67 ml 
AEC stock solution (0.4% (wt/vol) in dimethylformamide) in 10 ml Na acetate (0.1 
M, pH 5.2) + 10 µl 30% H2O2) and 1 volume of 3% (wt/vol) low-melting-point 
agarose (BIOzym, Landgraaf, The Netherlands) was added. After overnight 
incubation in the dark at room temperature, spots were counted with an inverted 
microscope. For each MC suspension, spots in 3 wells (106 MC/well) were counted to 
obtain the number of isotype-specific ASCs per 3 x 105 MC. Results are presented as 
the mean number of ASCs per 106 MC ± SEM. 
 
5.2.11. Statistical analysis 
Statistical analysis (SAS, version 8) was done using mixed models with pig as 
random effect and the ETEC/VTEC strains, time and the interaction between 
ETEC/VTEC strains and time (categorized) as fixed effects. Firstly these fixed effects 
were tested for significance and secondly, the ETEC/VTEC infection was compared 
at each of the time points separately, adjusting for multiple comparison by Bonferoni, 
with each individual comparison being tested at α = 0.05 divided by the number of 
time points.  
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5.3. Results 
5.3.1. Clinical signs and excretion of F18+ VTEC or F4+ ETEC 
In the VTEC experiment, eighteen 5-week-old F18-seronegative but F18R+ 
pigs were intragastrically infected with F18+ VTEC, whereas in the ETEC 
experiment, twenty 5-week-old, F4-seronegative but F4R+ pigs were infected with F4+ 
ETEC. The presence of the F18R was demonstrated by PCR and confirmed by the in 
vitro villous adhesion assay. Indeed, all PCR-positive pigs were shown to be receptor 
positive (data not shown). Similarly, the presence of the F4R on enterocytes of all the 
pigs was demonstrated in the in vitro villous adhesion assay (data not shown).  
Following the F18+ VTEC infection only three pigs had diarrhoea 1 dpi, but 
following the F4+ ETEC infection ten pigs had severe watery diarrhoea 2 dpi, six pigs 
3 dpi and three pigs 4 dpi.  
Furthermore, two pigs died following the F18+ VTEC infection, one 6 dpi and 
another 10 dpi, without obvious clinical signs of disease. F18+ E. coli was isolated 
from their intestinal tract and hemorrhagic intestines and swollen mesenteric lymph 
nodes were found. In the F4 infection experiment, one of the pigs with severe 
diarrhoea died 3 dpi. F4+ E. coli was isolated from the intestinal content of this pig, 
but postmortem examination revealed no pathologic signs.  
F4+ and F18+ E. coli excretion were statistically significant different (p = 
0.0008) and the F4+ E. coli excretion evolved differently over time than F18+ E. coli 
excretion (significant time-strain interaction, p < 0.0001). Before infection, the 
examination of the faecal samples for F18+ and F4+ E. coli was negative. Following 
infection, F18+ E. coli were detected in pigs of the VTEC experiment from 2 till 9 dpi 
with a peak excretion 3 dpi (9.9 x 107 F18+ E. coli / g feces), whereafter the amount of 
F18+ E. coli gradually decreased (Fig. 1). The pigs of the ETEC experiment excreted 
2 dpi a very high number of F4+ E. coli (5.97 x 108 F4+ E. coli / g feces). 
Subsequently, this number rapidly decreased and F4+ E. coli could not be detected 
anymore from 7 dpi (Fig. 1). Moreover, the excretion of F4+ E. coli was significant 
lower (p < 0.0001) compared with the excretion of F18+ E. coli at 6 and 7 dpi.  
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Figure 1 : Mean faecal F18+ VTEC and F4+ ETEC excretion per
gram feces (± SEM) (* P<0.0001)
5.3.2. Localization of the fimbriae-specific antibody response
following infection
In order to localize the induced antibody response following the F18+ VTEC
and the F4+ ETEC infection, the number of fimbriae-specific IgM, IgA and IgG ASCs
was determined in bone marrow, peripheral blood, spleen, mesenteric lymph nodes,
jejunal and ileal Peyer’s patches and jejunal lamina propria. There were no F18-
specific ASCs present at the moment of infection (0 dpi), but F4-specific background
levels of IgM ASCs (Fig. 2) were detected at the moment of infection in the spleen (9
IgM ASCs per 106 MC) and the mesenteric lymph nodes (25 IgM ASCs per 106 MC)
as previously also observed by Van den Broeck et al. (1999a).
F18-specific IgM ASCs could already be detected 4 dpi. At that moment the
mean numbers of IgM ASCs (Fig. 2) peaked in the spleen (15 IgM ASCs per 106 MC)
whereas the peak occurred 3 days later in the mesenteric lymph nodes (7.5 IgM ASCs
per 106 MC) and the ileal Peyer’s patches (3.3 IgM ASCs per 106 MC) and 7 days
later in the jejunal Peyer’s patches (23 IgM ASCs per 106 MC), lamina propria (7 IgM
ASCs per 106 MC), peripheral blood (6.6 IgM ASCs per 106 MC) and bone marrow
(0.83 IgM ASCs per 106 MC). In the F4+ ETEC experiment, the spleen contained the
highest number of F4-specific IgM ASCs (100 per 106 MC) 4 dpi,
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Figure 2 : Mean F18-specific IgM, IgA and IgG and F4-specific IgM, IgA and IgG ASC per
106 MC (± SEM) in spleen (SP), mesenteric lymph node (MLN), jejunal Peyer’s patches
(JPP), and lamina propria (LP) at 0, 4, 7, 11 and 15 days post infection (dpi).
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whereas the other lymphoid tissues revealed maxima 7 dpi with the highest number in 
the jejunal Peyer’s patches (159 per 106 MC) (Fig. 2). However, the numbers F4-
specific IgM ASCs were several times higher than for F18-specific IgM ASCs.  
F18-specific IgA ASCs appeared later in the immune response. The first IgA 
ASCs were found in most tissues 11 dpi, but only 15 dpi substantial numbers of IgA 
ASCs were present in the jejunal Peyer’s patches (9 IgA ASCs per 106 MC) and in the 
lamina propria (35 IgA ASCs per 106 MC) (Fig. 2). In contrast to the F18+ VTEC 
infection, F4-specific IgA ASCs (Fig. 2) could already be detected 4 dpi in peripheral 
blood, the mesenteric lymph nodes, jejunal and ileal Peyer’s patches and jejunal 
lamina propria. Furthermore, the F4-specific IgA ASCs number already peaked in 
these tissues 7 dpi, except for the jejunal Peyer’s patches where a gradual increase 
was observed until 15 dpi (7 IgA ASCs per 106 MC). In the spleen and bone marrow 
F4-specific IgA ASCs were first seen 7 dpi, but remained low in number. 
Furthermore, the numbers of fimbriae-specific IgA ASCs were generally higher 
following the F4+ ETEC infection than following the F18+ VTEC infection. 
In accordance to the late appearance of F18-specific IgA, F18-specific IgG 
ASCs appeared in most tissues 15 dpi, but their mean numbers were almost 10 times 
lower than for IgA (0 to 28 IgG ASCs per 105 MC) (Fig. 2). However, F4-specific 
IgG ASCs (Fig. 2) were already observed in most tissues 4 dpi, but in general these 
numbers remained low. The highest numbers of F4-specific IgG ASCs per 106 MC 
were observed 7 dpi in the mesenteric lymph nodes (8) and 11 dpi in the jejunal 
lamina propria (11) and the jejunal Peyer’s patches (6).  
 
5.3.3. Fimbriae-specific serum antibody responses following 
infection 
The F18-specific serum antibody response following the F18+ VTEC infection 
was low (Fig. 3). F18-specific serum IgM only slightly increased till 7 dpi and 
decreased again from 15 dpi to reach the background level 21 dpi. Following the F4+ 
ETEC infection, F4-specific serum IgM peaked 7 dpi whereafter it gradually 
decreased again to baseline values. F4-specific IgM was however significantly higher 
(p < 0.0001) 4, 7 and 11 dpi in comparison with F18-specific IgM. 
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Figure 3 : Mean F4- and F18-specific IgM, IgA and IgG serum antibody titers
(± SEM) at 0, 4, 7, 11, 15, 21 and 25 days post infection (dpi) (* P<0.0009).
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F18-specific serum IgA and IgG were first detected 11 dpi (Fig. 3).  
Thereafter, IgA reached a maximum on 21 dpi whereas IgG was still increasing 25 
dpi. On the other hand, F4-specific IgA and IgG were already detected 4 and 7 dpi to 
reach a plateau on 7 and 11 dpi, respectively. Besides the faster appearance, F4-
specific IgA and IgG responses were also significantly higher (p < 0.0009) than F18-
specific IgA and IgG responses from 7 to 25 dpi.  
 
5.3.4. Fimbriae-specific IgA in intestinal contents following 
infection 
At euthanasia, the intestinal contents of duodenum, jejunum and ileum were 
collected for determining fimbriae-specific IgA. F18-specific IgA appeared relative 
late (11 to 15 dpi) in the jejunum and ileum. It could not be detected in duodenal 
content (Table 1). Only in 1 pig IgA was already detected 7 dpi in the jejunal content. 
The F4-specific IgA appeared earlier than the F18-specific IgA : two out of three 
jejunal samples were already positive 4 dpi (Table 1). Furthermore, IgA was not 
restricted to jejunum and ileum as most duodenal samples were also positive from 7 
dpi onwards. 
 
Table 1 : F18- and F4-specific IgA titers in intestinal contents of the duodenum, jejunum and 
ileum at  0, 4, 7, 11 and 15 days post infection (dpi). 
 
  
 
duodenum 
  
jejunum 
 
ileum 
    
duodenum 
 
jejunum
 
ileum 
 
0 dpi 0 0 0  0 dpi 0 0 0 
(n=3) 0 0 0  (n=4) 0 0 0 
  0 0 0    0 0 0 
4 dpi 0 0 0    0 0 0 
(n=3) 0 0 0  4 dpi 0 4 0 
  0 0 0  (n=3) 0 0 0 
7 dpi 0 0 0    0 4 0 
(n=3) 0 0 0  7 dpi 16 4 8 
  0 2 0  (n=3) 8 0 32 
11 dpi 0 0 4    8 32 8 
(n=2) 0 0 2  11 dpi 0 0 0 
15 dpi 0 4 2  (n=3) 32 128 4 
(n=2) 0 32 128    64 64 8 
     15 dpi 32 32 ND 
     (n=4) 32 ND 4 
       4 32 ND 
       64 128 16 
F18    F4 
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5.4. Discussion 
In the present study, infection of newly weaned pigs with F18+ VTEC and F4+ 
ETEC resulted in a significant different excretion of F18+ and F4+ E. coli. In 
accordance with previous studies (Bertschinger and Pohlenz, 1983; Bertschinger et 
al., 1990; Nagy et al., 1992), the peak excretion following the F4+ ETEC infection 
was observed 2 dpi, whereas 1 to 3 days later for the F18+ VTEC infection the 
maximal excretion occurred. Furthermore, the excretion of F4+ E. coli disappeared 7 
dpi whereas the F18+ E. coli could be detected till 9 dpi. A reason for the slower 
colonization of the F18+ VTEC than F4+ ETEC is not known. A factor that could play 
a role is the adhesion to the receptor. For F4 fimbriae, the adherent subunit is the 
major subunit whereas for F18 fimbriae this is a minor subunit of which the 
localization in the fimbrial structure is not known (Bakker et al., 1992a; Smeds et al., 
2001). This difference could account for a weaker adhesion of F18+ E. coli to the 
enterocytes brush border receptor. In the in vitro villous adhesion assay, the F18+ E. 
coli strain 107/86 always showed a weak adhesion (maximum 53 bacteria/250 µm 
brush border), in comparison with the F4+ E. coli strain GIS26 (> 80 bacteria/250 µm 
brush border). Other factors that could influence this adhesion are the amount of 
fimbriae expressed by the bacteria, the number of receptors on the surface of 
enterocytes, the strength of the binding and environmental factors influencing the 
interaction.  
The rapid colonization of the intestine with F4+ ETEC resulted in a fast F4-
specific mucosal immune response. Indeed, more than 30 F4-specific IgM ASCs per 
106 MC were seen 4 dpi in the mesenteric lymph nodes, the jejunal Peyer’s patches 
and the spleen followed only four days later in the mucosal tissues by maximal 
amounts of F4-specific IgA ASCs. On the other hand, the slower F18+ VTEC 
colonization induced a slower F18-specific mucosal immune response. First detection 
of F18-specific IgM ASCs occurred 4 to 7 dpi and maximal amounts of F18-specific 
IgA ASCs were observed only on 15 dpi. It is reported in several studies that 
fimbriae-specific mucosal antibodies prevent colonization (Yokoyama et al., 1992; 
Imberechts et al., 1997b; Zuniga et al., 1997; de Geus et al., 1998; Van den Broeck et 
al., 1999b). As a consequence, the rapid appearance of F4-specific ASCs in the lamina 
propria and F4-specific IgA in the small intestinal content resulted in an early 
decrease in faecal excretion of F4+ E. coli (6 dpi), whereas the slower response 
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against F18 fimbriae was accompanied with a longer excretion of the F18+ strain (9 
dpi). This slower immune response following the F18+ VTEC infection and the 
corresponding longer excretion increases the risk on spreading of an F18+ VTEC 
infection. This might explain why in a recent seroprevalence study 93% of the farms 
were F18-positive (Verdonck et al., 2003), whereas only 65% of the farms were F4-
positive (Van den Broeck et al., 1999d).  
In order to develop an oral vaccine against E. coli induced postweaning 
diarrhoea and oedema disease, it is important to elucidate why the F4+ ETEC 
infection is inducing such a rapid and high immune response.  
It has been demonstrated that oral immunization of pigs with purified F4 
fimbriae induces a protection against F4+ ETEC infections (Van den Broeck et al., 
1999b), whereas oral immunization of pigs with purified F18 fimbriae does not 
(unpublished data). In agreement, Felder et al. (2001) reported that oral immunization 
of pigs with poly(lactide-co-glycolide) microspheres containing F18 fimbriae could 
not induce significant F18-specific serum antibodies, nor reduced F18+ E. coli 
colonization following a challenge infection. These findings indicate that F18 is less 
immunogenic than F4 when given via the oral route. Here, the same mechanisms 
responsible for the differences in colonization might give an explanation.  
Furthermore, the F4+ ETEC strain GIS26 produces heat-labile (LT) and heat-
stable (STa, STb) enterotoxins, whereas the F18+ VTEC strain 107/86 expresses the 
verotoxin SLT-IIv. In contrast with SLT-IIv, the LT enterotoxin is known to possess 
adjuvant properties (Rappuoli et al., 1999). Several studies reported increased IgA and 
IgG but not IgM responses following an immunization with antigen in the presence of 
LT (Guidry et al., 1997; Hartman et al., 1999; de Haan et al., 2001). So, the 
adjuvanticity of LT is a second important factor that could be involved with the rapid 
F4-specific immune response and the early switch from IgM to IgA and IgG. Indeed, 
in different lymphoid tissues the F4-specific IgM ASCs following F4+ ETEC infection 
reached 4 days earlier their maximum number, which was more than twice as high as 
following oral F4 immunization with purified F4 fimbriae (without LT) (Van den 
Broeck et al., 1999a). Similar, the maximal amounts of F4-specific IgA and IgG ASCs 
were seen 4 days earlier and were ten times higher following F4+ ETEC infection as 
opposed to oral immunization with purified F4 fimbriae. One should however also 
consider that LPS has also adjuvant properties, which might influence fimbriae-
specific antibody responses in E. coli infections. 
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The reported results have useful implications for the development of an oral 
vaccine against E. coli induced postweaning diarrhoea and oedema disease. Oral 
immunization of newly weaned pigs with purified F4 fimbriae is already reported to 
induce a protective mucosal immune response against F4+ ETEC challenge (Van den 
Broeck et al., 1999b). However, in the case of post-weaning diarrhoea a very rapid 
immune response is needed since oral vaccination of the suckling piglets is probably 
impossible and infection with ETEC strains occurs during the first week after 
weaning. The results of the present study show that immune response against F4 can 
occur within 4 days following infection. So, factors such as dose of the antigen and 
the use of LT enterotoxin as oral adjuvant have to be considered for ameliorating the 
response against purified fimbriae. In case of F18 fimbriae, the antibody response is 
mainly directed against the major FedA subunit and not against the minor FedF 
subunit, which is responsible for adhesion. Therefore, vaccination with FedF in the 
absence of FedA could improve protection. Based on reported results of the 
recombinant adhesin FimH of type 1 fimbriae of uropathogenic E. coli, use of 
recombinant FedF adhesins could be envisaged. Indeed, vaccination of mice and 
monkeys with recombinant minor subunit FimH protects them against challenge with 
uropathogenic E. coli, whereas the antibodies evoked with purified type 1 fimbriae 
were directed primarily at the nonconserved major FimA subunit (Levine et al., 1982; 
Pecha et al., 1989; Langermann et al., 1997 and 2000; Thankavel et al., 1997). On the 
other hand, protection against VTEC infections has also been reported by 
immunization of pigs with recombinant SLT-IIv (Bosworth et al., 1996; Johansen et 
al., 1997; Makino et al., 2001). However, although these vasotoxin-specific antibodies 
can block the toxic effects of the SLT-IIv (Johansen et al., 2000), they will not 
influence the colonization of the intestine and subsequently the spread of the VTEC 
bacteria. Therefore, the induction of a protective F18-specific mucosal immune 
response against F18+ E. coli infections remains preferable.  
 
 
  
 
 
 
Chapter 6 
 
The interaction of F4 fimbriae with porcine 
enterocytes as analysed by surface plasmon 
resonance1 
 
 
 
                                                          
1 Based on : Verdonck F, Cox E, Vancaeneghem S, Goddeeris BM. 2004b. The 
interaction of F4 fimbriae with porcine enterocytes as analysed by surface plasmon 
resonance. FEMS Immunol. Med. Microbiol., in press. 
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Abstract 
Fimbriae often play a prominent role in anchoring bacterial cells to host tissue 
and mediate the first step in pathogenesis. As a consequence, there is a continuous 
development of new strategies to block the binding of fimbriae to their specific 
receptor on host cells. The present study demonstrates the specific interaction of F4 
(K88) fimbriae and porcine enterocytes using a real-time biomolecular interaction 
analysis system (BIAcore® 3000), based on the principles of surface plasmon 
resonance (SPR). This method offers new opportunities to screen therapeutics for 
prevention of adhesion and subsequent disease without receptor purification. 
 
6.1. Introduction 
F4+ ETEC are an important cause of neonatal and post-weaning diarrhoea in 
piglets. The F4 fimbriae allow attachment to F4R on enterocytes, enabling the 
bacteria to colonize the small intestine and to produce heat-labile (LT) and/or heat-
stable enterotoxins (STa, STb), resulting in diarrhoea (Gyles, 1994).  
F4 fimbriae are long proteinaceous appendages radiating from the surface of 
the bacteria and occur as three antigenic variants: F4ab, F4ac and F4ad (∅rskov et al., 
1964 ; Guinée and Jansen, 1979). The differences between these variants were found 
to be only located in the major F4 fimbrial subunit FaeG, which is also the adhesin. 
Conserved regions of FaeG form the “a” epitopes, whereas a variable region forms the 
“b”, “c” or “d” epitope (Bakker et al., 1992a). With these 3 variants, 6 porcine 
phenotypes (A through F) can be distinguished with regard to brush border 
adhesiveness (Bijlsma et al., 1982; Baker et al., 1997). The phenotypic difference 
between pigs has been shown to be genetic in origin, being inherited in a Mendelian 
way, with adhesion dominant over non-adhesion (Sellwood and Kearns, 1979).  
In vitro F4-mediated adhesion to isolated porcine small intestinal brush border 
membranes (Sellwood et al., 1975; Valpotic et al., 1989a), small intestinal enterocytes 
(Isaacson et al., 1978) or isolated villi (Girardeau, 1980) correlates with in vivo 
villous adhesion and colonization by F4+ ETEC. Furthermore, an indirect ELISA 
(Valpotic et al., 1989b) and a Western blot (Willemsen and de Graaf 1992; Erickson 
et al., 1992) are described to distinguish F4 adhesive and non-adhesive pigs. 
However, these assays analyse  
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the interaction between fimbriae and their receptor in a static way, in contrast to the in 
vivo situation. Therefore, the aim of the present study was to determine the interaction 
of host cells and fimbriae in a non-static situation and without previous receptor 
purification. Hereto, the interaction of F4 receptor positive (F4R+) and F4R- 
enterocytes with F4 fimbriae was determined in a continuous flow using the BIAcore® 
3000 (Uppsala, Sweden), a real-time biomolecular interaction analysis system based 
on the principles of surface plasmon resonance (SPR). 
 
6.2. Material and methods 
6.2.1. Isolation of F4 fimbriae  
F4ac fimbriae of the E. coli strain GIS26 (O149:K91:F4ac, LT+STa+STb+) 
were isolated by homogenizing a GIS26 bacterial suspension. Subsequently, fimbriae 
were purified by anion exchange chromatography using a Bio-Scale Q5 column (BIO-
RAD Laboratories) as described by Van den Broeck et al. (1999c). The protein 
concentration was determined using the bicinchoninic acid reaction with bovine 
serum albumin (BSA) as standard (ICN Biomedicals, Belgium) and the purity of the 
purified F4 fimbriae was assessed using a Coomassie stained 15% SDS-PAGE and 
the ImageMaster 1D prime software (Amersham Pharmacia Biotech, Belgium).  
 
6.2.2. In vitro villous adhesion assay 
The in vitro villous adhesion assay has been described by Van den Broeck et 
al. (1999c). Adhesion of more than 30 bacteria per 250 µm brush border length was 
noted as strong, less than 30 bacteria per 250 µm brush border length meant weak 
adhesion, and less than 5 was regarded as negative (Cox et al., 1991). 
 
6.2.3. Enterocyte isolation 
Enterocytes of nine pigs were isolated from the jejunum since the F4R is 
present in high amounts in the mid-small intestine (Cox and Houvenaghel, 1993; 
Chandler et al., 1994).  
Hereto, a 1-m-long intestinal segment was excised of the mid jejunum at the 
moment of slaughter. The segment was washed in Krebs-Henseleit buffer (160 mM, 
pH 7.4) containing 1% (vol/vol) formaldehyde, whereafter the segment was filled 
with EDTA-buffer (phosphate buffered saline (PBS; pH 7.4, 150 mM) + 0.01M 
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EDTA, pH 6.8). The ends were ligated and the segment was incubated 30 minutes on 
ice in a sucrose-buffer (PBS + 0.3 M sucrose, pH 6.8). The content of the segment 
was collected and the segment was refilled again with sucrose-buffer and incubated 
for 5-10 minutes at room temperature. The content of the segment was collected and 
centrifugated (10 min, 200 g, 4°C). Subsequently, the pellet was resuspended in 10 
volumes EDTA-buffer, pushed gently through an 18G needle and centrifugated (10 
min, 200 g, 4°C). Finally, the pellet was resuspended in Krebs-Henseleit buffer.  
 
6.2.4. Immobilization of F4 fimbriae on sensor chip 
The interaction between F4 fimbriae and the F4R on pig enterocytes was 
analyzed with the Biacore®3000 biosensor (Uppsala, Sweden) using the F1 chip. This 
has a short carboxymethyldextran surface to allow immobilization of F4 fimbriae via 
free NH2 using an amine coupling kit (Biacore, Uppsala, Sweden) containing N-
hydroxysuccinimide (NHS), N-ethyl-N’-[(3-dimethylamino)-propyl]-carbodiimide 
hydrochloride (EDC) and ethanolamine-HCl. Hereto, 50 µl of a mixture of NHS (290 
µg) and EDC (190 µg) was injected at a flow rate of 5 µl/ml at 25°C to activate the 
dextran matrix on the sensor chip, followed by purified F4 at a concentration of 100 
µg/ml in 10 mM sodium acetate buffer pH 3.5 until the amount (mol) of immobilized 
F4 equalized 2000 resonance units (RU). Thousand RU corresponds to a change in the 
surface concentration of 1 ng/mm2 (Fägerstam et al., 1992 ; Stenberg et al., 1991). 
Subsequently, the remaining active sites of the matrix were blocked with 
ethanolamine-HCl (1 M) and washed with HBS-EP (0.01 M HEPES, 0.15 M NaCl, 3 
mM EDTA, 0.005 % (v/v) polysorbate 20). One flow cell was activated and 
subsequently blocked without immobilization of F4 fimbriae and served as blanco. 
All samples used in further experiments were diluted in HBS-EP buffer, which also 
served as running buffer during the experiments. 
 
6.2.5. Analysis of the F4R phenotype of enterocytes 
  Enterocyte suspensions were injected at a concentration of 5.105 cells/ml and a 
flow rate of 5 µl/min during 240 seconds at 25°C. The binding of the enterocytes was 
monitored and registered as a sensogram (plot of RU versus time). To regenerate flow 
cells after binding of enterocytes to immobilized F4 fimbriae, 25 mM NaOH + 100 
mM CHAPS (3-[(3-cholamiindopropyl)dimethylammonio]-1-propane-sulphonate, 
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Sigma) was used. The experiments were always performed in duplicate and revealed 
identical results. 
 
6.2.6. Determining the specificity of F4R+ enterocyte binding 
The first approach was to block the c-epitope of immobilized F4 fimbriae. 
This epitope is involved in binding the F4R. Hereto, the F4ac-specific monoclonal 
antibody (MAb) CVI F4ac-5 (van Zijderveld et al., 1990; ID-DLO, Lelystad, The 
Netherlands) was diluted to concentrations of 1 µg/ml and 10 µg/ml and injected with 
a flow rate of 5 µl/min during 240 seconds. Subsequently, enterocytes of the F4R+ 
pigs were injected as described above. 
The second approach was to pre-incubate the F4R+ enterocytes with 0, 50, 
100, 200, 500 or 1000 µg/ml F4 fimbriae, while gently shaking. After 1 h pre-
incubation at room temperature, a gentle short spin centrifugation was performed. 
Subsequently, the supernatant was discharged, enterocytes were adjusted to the start 
volume (5.105 cells/ml) and injected as described above.  
The third approach was to destroy the carbohydrates of F4R+ enterocytes, 
which are reported to be part of the F4R (Erickson et al., 1992; Grange et al., 2002). 
Hereto, periodate oxidation of carbohydrates was performed by treating enterocytes 
for 1 h at room temperature with 0.2 M sodium acetate (pH 4.5) containing 10 mM 
sodium metaperiodate (Erickson et al., 1992). In addition, the enterocytes were 
similarly treated with 0.2 M sodium acetate (pH 4.5) as a control. After treatment, the 
enterocytes were washed three times with running buffer and injected as described 
above. All these experiments were performed in duplicate and revealed identical 
results. 
 
6.3. Results 
To determine the interaction of F4 fimbriae with the F4R on intestinal villi 
using SPR, purified F4 fimbriae were immobilized on a sensor chip F1. A dose 
dependent binding of the c-epitope specific MAb to F4 fimbriae was observed. This 
MAb has been shown to inhibit the binding of F4+ ETEC to F4R+ villi in an in vitro 
villous adhesion assay since the c-epitope is involved in the interaction with the F4R 
(Bakker et al., 1992a; Van den Broeck et al., 1999c). An irrelevant porcine IgG-
specific MAb of the same isotype (23.3.1b, Van Zaane and Hulst, 1987) was not able 
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to bind immobilized fimbriae and this up to a concentration of 100 µg/ml (data not
shown).
Nine piglets were tested for F4R presence in an in vitro villous adhesion assay
(Table 1). Subsequently, the enterocytes of three F4R- pigs (pigs 4, 5 and 6), one
weakly F4R+ pig (pig 2) and five strong F4R+ pigs (pigs 1, 3, 7, 8 and 9) were
examined in SPR for their F4-specific binding to immobilized F4 fimbriae. As shown
in figure 1, strong F4R+ enterocytes were able to bind to the F4 fimbriae (1500 to
2400 RU). This interaction was stable since no dissociation was observed when
flushing with running buffer. On the other hand, no interaction was observed using
weakly F4R+ or F4R- enterocytes.
Figure 1 : Sensogram showing the real-time interaction of
enterocytes with immobilized F4ac fimbriae. Enterocytes of pigs
that were adherent in the in vitro villous adhesion assay are shown
in A, whereas the non-adherent are shown in B. White arrow :
injection of enterocytes.
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Table 1 : Results of the in vitro villous adhesion assay.
Pig number Mean number of adhering F4ac+
ETEC bacteria per 250 µm length of
villous brush border
1 43.2
2 8.7
3 41.5
4 0.2
5 0.5
6 1.3
7 40.7
8 45.5
9 35.5
To prove that the observed binding between F4R+ enterocytes and
immobilized F4 fimbriae was F4-specific, the c-epitope specific MAb was injected
over the immobilized F4 fimbriae to block the F4R, whereafter the enterocytes were
injected. Figure 2 shows that a concentration of 10 µg/ml MAb was able to inhibit the
adhesion of F4R+ enterocytes to the immobilized F4 fimbriae. This inhibition was
dose dependent as a 10-fold lower amount of the MAb could not inhibit the adhesion
completely.
0
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3500
0 200 400 600 800
time (s)
RU
1 ug/ml
10 ug/ml
Figure 2 : Sensogram showing the interaction of the c-epitope specific MAb CVI
F4ac-5 (1 and 10 µg/ml) with immobilized F4 fimbriae and the effect of MAb
binding on subsequent binding of enterocytes. Injection of the MAb (black
arrow), injection of F4R+ enterocytes (white arrow).
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A second way to test the specificity of binding between immobilized F4
fimbriae and F4R+ enterocytes, was to pre-incubate the enterocytes with different
concentrations of purified F4 fimbriae. F4 fimbriae at a concentration of 50, 100 and
200 µg per ml inhibited the adhesion of enterocytes to immobilized F4 in a dose-
dependent way, resulting in 51.5 ± 6.5, 40.8 ± 8.2 and 8.3 ± 1.6 % binding of F4R+
enterocytes to immobilized F4, respectively (Fig. 3).
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Figure 3 : Sensogram showing the interaction of F4R+ enterocytes, pre-
incubated with different concentrations of purified F4 (0, 50, 100, 200, 500 or
1000 µg/ml), with immobilized F4 fimbriae. White arrow: injection of
enterocytes.
It has previously been demonstrated that a carbohydrate moiety on the
enterocytes is involved in the interaction between F4 fimbriae and the F4R (Erickson
et al., 1992; Grange et al., 2002). Therefore, a third way to test the specificity of the
obtained signal was to disrupt the carbohydrate molecules of the enterocytes with
sodium metaperiodate. Figure 4 shows that incubation of F4R+ enterocytes in sodium
acetate buffer reduced the binding ability to F4 fimbriae, but that binding was
completely lost following sodium metaperiodate treatment.
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Figure 4 : Sensogram showing the interaction of F4R+ enterocytes, previously
incubated in PBS, sodium acetate buffer or sodium acetate buffer supplemented
with sodium metaperiodate, with immobilized F4 fimbriae. White arrow:
injection of enterocytes.
6.4. Discussion
Results demonstrate that the SPR technique is useful to determine the F4-
specific interaction between fimbriae and small intestinal enterocytes isolated from
the mid jejunum of pigs. Indeed, immobilized F4 fimbriae retain enough free
receptor-binding c-epitopes to allow binding of strong F4R+ enterocytes. The
specificity of the binding is proven by blocking the interaction in three different ways.
First, a MAb specific for the c epitope is able to inhibit the binding in a dose-
dependent manner. Indeed, Bakker et al. (1992a) already demonstrated that there is at
least a partial overlap between the receptor-binding site of the F4 fimbriae and the c
epitope. Second, incubation of F4R+ enterocytes with purified F4 fimbriae is able to
inhibit a subsequent adhesion to immobilized F4 fimbriae in a dose dependent way.
These results are comparable to those seen in the in vitro villous adhesion assay
described by Van den Broeck et al. (1999c). Third, adhesion of F4R+ enterocytes to
immobilised F4 is inhibited following oxidation of the enterocyte carbohydrates using
sodium metaperiodate. Indeed, it is already reported that the binding activity of F4 to
the F4R is dependent on the presence of a carbohydrate structure (Erickson et al.,
1992; Grange et al., 2002).
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On the other hand, no interaction was observed with F4R- or weakly F4R+ 
enterocytes. In agreement, we observed in previous infection experiments that pigs 
with less than 15 bacteria per 250 µm brush border length in the in vitro villous 
adhesion assay, excreted only very few bacteria for 1 to 2 days following challenge 
with the pathogenic F4+ ETEC strain GIS26 (Verdonck et al., 2002; Vancaeneghem S, 
unpublished data). In the Biacore system, the binding strength between the few 
receptors on the weakly F4R+ enterocytes and the immobilized F4 fimbriae is 
probably so low that the enterocytes are flushed away by the flow of the running 
buffer. The used flow rate in the flow cell corresponds to 8.33 cm/min, but flow rates 
in the small intestine of pigs, which are fed ad libitum, can reach 20.6 ± 2.4 cm/min 
(Devinder et al., 1986). It is therefore likely that the biosensor can mimic the in vivo 
situation more than an in vitro villous adhesion assay.  
The biosensor has some well known advantages: the method is less subjective, 
is adaptable to automatization for processing a large number of samples and is also 
less time-consuming than the immunoblotting technique or the in vitro villous 
adhesion assay. Furthermore, the use of SPR to determine the interaction between 
adhesins and receptors on eukaryotic cells allows easy screening for blocking agents 
or receptor analogues to prevent infection. Indeed, one of the strategies to prevent F4+ 
ETEC-induced diarrhoea in neonatal or weaned piglets, is to prevent attachment of the 
bacteria to the intestinal F4R. Proteases (Chandler et al., 1994; Mynott et al., 1996), 
antibodies (Yokoyama et al., 1992; Jin et al. 1998) or lactic acid bacteria (Blomberg et 
al., 1993b; Ouwehand and Conway, 1996) have been used to inhibit the interaction 
between F4 fimbriae and the F4R and subsequent disease.  
In conclusion, this study shows that SPR can be used to distinguish strong 
F4R+ pigs from weak F4R+ or F4R- pigs and offers new opportunities to study the 
interaction between F4 fimbriae and the F4R. Furthermore, SPR opens new 
perspectives to screen therapeutics for prevention of ETEC adhesion.  
 
  
 
 
 
Chapter 7 
 
F4 fimbriae as carrier and cholera toxin as adjuvant 
synergistically improve the induction of a HSA-specific 
immune response following oral immunization of pigs1 
 
 
                                                 
1 Based on : Verdonck F, De Hauwere V, Bouckaert J, Goddeeris BM, Cox E. F4 
fimbriae as carrier and cholera toxin as adjuvant synergistically improve the 
induction of a HSA-specific immune response following oral immunization of pigs. 
Submitted. 
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Abstract 
Receptor-mediated uptake of orally administered antigen can lead to an 
antigen-specific immune response, whereas oral administration of most other non-
replicating soluble antigens results in the induction of oral tolerance. In the present 
study, it is shown that fimbriae purified from an F4+ enterotoxigenic Escherichia coli 
strain can function as a mucosal carrier molecule for the model antigen human serum 
albumin (HSA). Oral immunization of pigs with glutaraldehyde coupled F4/HSA 
conjugates induced a HSA-specific immune response. This mucosal carrier function 
of F4 fimbriae was improved following oral co-administration of the F4/HSA 
conjugates with the mucosal adjuvant cholera toxin (CT) to F4R+ pigs, since both 
humoral and cellular HSA-specific responses were significantly increased. In 
comparison with F4R+ pigs, the HSA-specific response was reduced following oral 
F4/HSA+CT immunization of F4R- pigs. This indicates that F4 fimbriae as carrier and 
CT as adjuvant synergistically improve the induction of a HSA-specific immune 
response following oral immunization of pigs. 
 
7.1. Introduction 
Most bacterial and viral infections of man and animals begin by the interaction 
of the pathogen with mucous membranes. It is generally accepted that protection of 
these mucosal surfaces is largely mediated by local production of IgA (Porter et al., 
1974; Mestecky and McGhee, 1987). To induce the secretion of antigen-specific IgA 
in the intestine, oral immunization is needed since parenteral immunization is not very 
effective for the induction of IgA (Bianchi et al., 1996; Van der Stede et al., 2002b). 
However, oral immunization with most soluble non-replicating antigens results in oral 
tolerance (Weiner, 2001). On the other hand, receptor-dependent uptake of soluble 
antigen by epithelial cells can result in an antigen-specific mucosal and systemic 
immune response. Indeed, oral immunization of F4-receptor positive (F4R+) pigs with 
purified F4 (K88) fimbriae induces an intestinal F4-specific antibody response 
protecting pigs against a subsequent challenge with F4+ enterotoxigenic Escherichia 
coli (ETEC) (Van den Broeck et al., 1999b). In F4R- pigs, F4 fimbriae behave as a 
normal food antigen (Van den Broeck et al., 2002). 
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Fimbriae are attractive structures to be used as carriers in vaccine design due 
to their polymeric character, their high immunogenicity, their ability to bind to 
specific receptors, the presence on the surface of bacteria and the possibility to 
prepare them in large amounts. F4 fimbriae have the same properties since they are 
surface exposed (Ørskov and Ørskov, 1961), immunogenic (Rutter and Jones, 1973), 
easy to purify in large amounts (Van den Broeck et al., 1999c; Wong et al., 2003), 
able to bind to the F4R on porcine small intestinal enterocytes (Sellwood et al., 1975) 
and are multimeric structures of the major fimbrial subunit FaeG that constitutes the 
adhesin and some minor subunits (Oudega et al., 1989). Moreover, the potential 
carrier function of F4 fimbriae has already been demonstrated by the induction of 
antibodies against a heterologous epitope that was inserted in the variable region of 
FaeG (Thiry et al., 1989; Bakker et al., 1990). However, the length of the inserted 
heterologous epitopes is limited as the folding and the stability of the fimbrial 
subunits may not be disturbed. On the other hand, fimbriae are able to function as 
carriers for larger heterologous antigens when chemically coupled. Indeed, F5 and F6 
fimbriae were already reported to have the potential to function as a mucosal carrier 
molecule, inducing an antibody response against chemically conjugated bovine serum 
albumin following oral immunization of mice (Russell-Jones, 2001).  
The aim of the present study was to determine for the first time the potential of 
F4 fimbriae to act as a mucosal carrier molecule, inducing a mucosal and systemic 
immune response against a chemically conjugated antigen following oral 
immunization in pigs. In the present study, the model antigen human serum albumin 
(HSA) was chosen since HSA is not known to interact with a specific receptor. In 
addition, it was determined whether the mucosal adjuvant cholera toxin (CT) could 
improve the mucosal immune response against the F4-conjugated HSA. The 
mechanisms of CT adjuvanticity are not completely known but include an enhanced 
antigen presentation by a variety of cell types, promotion of the isotype switch to IgA 
and an influence on cytokine production and T cell activation (Holmgren et al., 2003). 
 
Chapter 7 : F4 fimbriae as mucosal carrier 
 
106 
7.2. Material and methods 
7.2.1. Purification of F4 fimbriae 
 F4ac fimbriae of the E. coli strain GIS26 (O149:K91:F4ac, LT+STa+STb+) 
were isolated by homogenizing a GIS26 bacterial suspension. Subsequently, fimbriae 
were purified by anion exchange chromatography using a Bio-Scale Q5 column (BIO-
RAD Laboratories) as described by Van den Broeck et al. (1999c). The protein 
concentration was determined using the bicinchoninic acid reaction with bovine 
serum albumin (BSA) as a standard (ICN Biomedicals, Belgium). The purity of the 
purified F4 fimbriae was assessed using a Coomassie stained 15% SDS-PAGE and 
the ImageMaster 1D prime software (Amersham Pharmacia Biotech, Belgium). 
 
7.2.2. Conjugation of F4 fimbriae and HSA 
HSA (Sigma, Bornem, Belgium) was conjugated to purified F4 fimbriae 
(F4/HSA) in a molar ratio (HSA to FaeG subunits) of 0.5:1, 1:1, 2:1, 4:1 as described 
by Vervelde et al. (1998) with minor modifications. Briefly, HSA and purified F4 
were dissolved in 0.1 M phosphate buffer pH 8.0. Glutaraldehyde was slowly added 
to the mixture until a concentration of 0.5, 1, 2 or 4 mM was reached. Subsequently, 
the mixture was stirred for 2.5 h at room temperature. Thereafter, the reaction was 
stopped by adding glycine in a final concentration of 60 mM and by stirring the 
solution for another 45 min. Finally, the solution was dialysed for 18 h against PBS 
(27.5 mM NaCl, 0.54 mM KCl, 2 mM Na2HPO4, 0.4 mM KH2PO4, pH 7.4) at 4°C. 
Similar procedures were used to couple HSA to HSA (HSA/HSA) and F4 to F4 
(F4/F4).  
 
7.2.3. Characterization of conjugates 
7.2.3.1. Analysing coupling of F4 to HSA 
To analyse the effectiveness of the different conjugation conditions on cross-
linking F4 to HSA, the conjugated samples were analysed in ELISA. The wells of 96-
well microtiter plates (NUNC, Maxisorp Immuno Plates, Roskilde, Denmark) were 
coated with the F4-specific monoclonal antibody (MAb) IMM01 (Van der Stede et 
al., 2002b) or a HSA-specific polyclonal antibody (Serotec, Kidlington, England). 
Blocking and washing were performed according to the procedure described by Van 
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den Broeck et al. (1999a). Thereafter, serial dilutions of the conjugates starting from 
1/10 in PBS supplemented with 0.05% Tween®20 were added to both the F4- and the 
HSA-specific antibody coated plates and plates were incubated for 1 h at 37°C. 
Purified F4 fimbriae, HSA (both starting at 1 mg/ml) and plain conjugation buffers 
were used as controls. After several washes, the F4- and HSA-specific antibody-
coated plates were incubated with optimal dilutions of peroxidase-conjugated HSA- 
and F4-specific antibodies respectively for 1 h at 37°C. After several washes, an 
H2O2-containing ABTS solution was added and the optical density was 
spectrophotometrically measured at 405 nm (OD405) following 30 and 60 minutes of 
incubation at 37°C. 
 
7.2.3.2. Real-time interaction of conjugates with enterocytes 
The interaction between the conjugates and the F4R on small intestinal pig 
enterocytes was analysed with the BIAcore®3000 biosensor (Uppsala, Sweden) as 
described in chapter 6. Enterocytes of two F4R- and two F4R+ pigs were used, with a 
mean binding of 0.2, 1.3, 43.2 and 45.5 F4+ ETEC bacteria per 250 µm length of 
villous brush border respectively in the in vitro villous adhesion assay. The HSA-
specific polyclonal antibodies were immobilized in one flow cell of a F1 chip using a 
10 mM sodium acetate buffer pH 4.8 until the amount (mol) of immobilized 
antibodies equalized 13,000 resonance units (RU). Thousand RU corresponds to a 
change in the surface concentration of 1 ng/mm2 (Fägerstam et al., 1992). Another 
flow cell on the same chip was activated and subsequently blocked without 
immobilization of antibodies and served as control.  
 F4/HSA conjugates were injected at a flow rate of 5 µl/min during 120 
seconds at 25°C. Thereafter, enterocyte suspensions prepared as described in chapter 
6 were injected at a concentration of 5.105 cells/ml and a flow rate of 5 µl/min during 
240 seconds at 25°C. Binding of conjugates and enterocytes was monitored and 
registered as a sensogram (plot of RU versus time). To regenerate flow cells at the end 
of each experiment, 25 mM NaOH was used. The experiments were performed in 
duplicate. The duplicates gave similar results. 
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7.2.3.3. Determination of the hydrodynamic radius 
 The hydrodynamic radii of F4, HSA or conjugates were determined using 
dynamic light scattering (DLS). Following centrifugation of the samples at 18,000 g 
for 60 minutes at 4°C, 30 µl was injected into a flow cell of the Laser-spectroscatter 
(RiNA Netzwerk RNA-Technologien, Berlin, Germany) at room temperature and 
illuminated by a 30-mW, 660-nm-wavelength, solid-state laser. Data were collected of 
10 measurements, 20 seconds each. Two independent experiments were performed, 
resulting in identical results. 
 
7.2.4. Experimental procedure 
7.2.4.1. Pigs 
Twenty F4- and HSA-seronegative, conventionally bred pigs (Belgian 
Landrace x Piétrain) were weaned at the age of 4 weeks, transported to the 
experimental facilities at the faculty and subsequently housed in isolation units with 
water and feed ad libitum. These pigs were treated orally with colistine (Promycine 
pulvis, VMD, Berendonk, Belgium, 150,000 U/kg of body weight/day) from 2 days 
before till 3 days after weaning to prevent E. coli infections due to transport and 
handling. 
 
7.2.4.2. Immunization 
One week post weaning (0 days post primary immunization, dppi), pigs were 
orally immunized with the F4/HSA conjugate in the absence (F4/HSA group, n=6) or 
presence of 50 µg CT (F4/HSA+CT group, n=6) or with the HSA/HSA conjugate in 
the absence (HSA/HSA group, n=3) or presence of 50 µg CT (HSA/HSA+CT group, 
n=5). In fact, CT was added or not to 2 ml of the conjugation solutions (containing 2 
mg purified F4 and/or 4.8 mg HSA) which was subsequently adjusted with PBS to a 
final volume of 10 ml. The pigs were orally immunized at 0, 1 and 2 dppi, which is 
referred as the first oral immunization. The pigs were orally immunized for a second 
and a third time at 16 and 35 dppi, respectively. From three hours before till 2 h after 
oral immunization, all animals were deprived of food and water. At 48 dppi, all 
animals were intramuscularly (IM) immunized with 1 mg HSA to observe priming of 
the systemic immune system against HSA by the oral immunizations. Hereto, HSA 
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was dissolved in 0.5 ml PBS and suspended in an equal volume of incomplete 
Freund’s adjuvant (DIFCO Laboratories, Detroit, USA). 
 
7.2.4.3. Kinetics of F4-, HSA- and CT-specific immune response 
F4- and HSA-specific serum IgA, IgG and IgM antibodies were determined 0, 
7, 16, 21, 24, 35, 38, 42, 48, 52, 55, 62, 69 and 77 dppi, whereas F4- and HSA-
specific IgA mucosal antibodies were analysed in saliva 0, 16, 24, 35 and 41 dppi. 
Serum samples of 0, 16, 35 and 48 dppi were also tested for the presence of CT-
specific antibodies. The F4-specific lymphocyte proliferation was examined 42 and 55 
dppi and the HSA-specific lymphocyte proliferation was determined 42, 55 and 66 
dppi.  
 
7.2.4.4. Weight and average daily weight gain (ADWG) 
 All pigs were weighed at 0, 3, 7, 15 and 24 dppi. The daily weight gain of 
each pig was calculated at 3, 7, 15 and 24 dppi by calculating weight gain between 
two subsequent measurements divided by the number of days between both 
subsequent measurements. Subsequently, the average daily weight gain (ADWG) per 
group was calculated ± SEM. 
 
7.2.5. Samples 
To determine F4-specific serum and mucosal antibodies, serum and saliva 
were sampled as described by Van der Stede et al. (2002b).  
In order to analyse the F4- and HSA-specific lymphocyte proliferation, blood 
was collected from the jugular vein and peripheral blood monomorphonuclear cells 
(PBMC) were isolated as described by Van den Broeck et al. (1999a). 
At the end of the experiment, the pigs were euthanised and jejunal villi were 
isolated for determining the presence or absence of the F4R as described by Van den 
Broeck et al. (1999c). 
 
7.2.6. ELISA for F4-, HSA- and CT-specific antibodies 
For quantifying the F4-specific IgM, IgA and IgG antibody response, the 
indirect ELISA described by Van den Broeck et al. (1999a) was used and serial 
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dilution of serum and saliva samples were tested, starting from 1/10 and 1/2.5, 
respectively. 
The HSA-specific IgM, IgA and IgG antibody titers were determined with the 
indirect ELISA as described by Van der Stede et al. (2001), with some modifications. 
Briefly, the wells of a 96-well microtiter plate (NUNC®, Polysorb Immuno Plates, 
Roskilde, Denmark) were coated with HSA at a concentration of 30 µg/ml in PBS. 
After 2 h incubation at 37°C, the remaining binding sites were blocked overnight at 
4°C with PBS supplemented with 0.2 % Tween®80. Subsequently, the plates were 
incubated for 1 h at 37°C with twofold serial dilutions of the samples in ELISA 
dilution buffer (PBS + 0.05% Tween®20), followed by the swine-specific IgM, IgA 
and IgG MAb (Van Zaane and Hulst, 1987) and peroxidase-conjugated rabbit-anti-
mouse polyclonal antibodies (Dako, Denmark) supplemented with 2% (vol/vol) pig 
serum. Finally, ABTS and H2O2 were used as chromogen and substrate and the optical 
density was spectrophotometrically measured at 405 nm (OD405). 
An identical ELISA with minor modifications was used to determine the CT-
specific antibodies. The wells of microtiter plates (NUNC®, Polysorb Immuno Plates) 
were coated with 5 µg/ml CT (Sigma) in PBS and an optimal dilution of horseradish 
peroxidase conjugated rabbit-anti-swine polyclonal antibodies (Dako) was used as 
conjugate. 
The cut-off values were calculated as the mean OD405-value of all sera 
(dilution 1/10) or saliva (dilution 1/2.5) at day 0, increased with 3 times the standard 
deviation. The antibody titer was the inverse of the highest dilution that still had an 
OD405 higher than the calculated cut-off value. The cut-off values for F4-specific 
serum IgM, IgA, IgG and saliva IgA and IgM were 0.48, 0.26, 0.43, 0.31 and 0.35 
respectively. The cut-off values for HSA-specific serum IgM, IgA, IgG and saliva IgA 
and IgM were 0.20, 0.12, 0.15, 0.25 and 0.28 respectively, whereas the cut-off value 
for the CT-specific serum antibodies was 0.24. 
 
7.2.7. Presence of the F4R  
The presence or absence of the F4R on the brush border of small intestinal 
enterocytes was determined on isolated intestinal villi as described by Van den 
Broeck et al. (1999c).  Adhesion of more than five F4+ E. coli per 250 µm villous 
length was noted as positive (Cox and Houvenaghel, 1993). 
Chapter 7 : F4 fimbriae as mucosal carrier 
111 
7.2.8. F4- and HSA-specific lymphocyte proliferation 
The PBMC were diluted to a concentration of 5.106 cells/ml in leukocyte 
medium (RPMI-1640 supplemented with penicillin (100 IU/ml), streptomycin (100 
µg/ml), kanamycin (100 µg/ml), L-glutamin (200 mM), sodiumpyruvate (100 mM), 
non-essential amino acids (100 mM), β-mercaptoethanol (5.10-5 M) and 5% (vol/vol) 
F4-seronegative serum. Subsequently, the isolated PBMC (5.105 cells/well) were 
incubated in medium without (negative control) or with purified F4 (final 
concentration of 10 µg/ml), HSA (final concentration of 100 µg/ml) or concanavalin 
A (final concentration of 10 µg/ml, positive control) to determine their F4- and HSA-
specific proliferation as described by Van der Stede et al. (2002a and 2003). The 
results are presented as F4- and HSA-specific stimulation index (SI), obtained by 
dividing the mean counts per minute (cpm) of the F4- and HSA-stimulated cultures, 
respectively, by the mean cpm of the non-stimulated cultures. Mean background 
levels of about 350, 620 and 510 cpm were obtained in medium samples at 42, 55 and 
66 dppi, whereas positive controls of concanavalin A reached 130,000, 150,000 and 
150,000 cpm respectively. 
 
7.2.9. Statistical analysis 
Statistical analysis (SPSS 10.0 for Windows) of antibody titers was done using 
General Linear Model (Repeated Measures Analysis of Variance), adjusting for 
multiple comparison by Bonferoni. Differences between groups in F4- or HSA-
specific cell proliferation were analysed for statistical significance using the Kurskal-
Wallis test. Differences in the ADWG between the groups were tested for statistical 
significance using a two-sample T-test. P<0.05 was considered as statistically 
significant. 
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7.3. Results
7.3.1. Characterization of F4/HSA conjugates
Optimal covalent binding between F4 and HSA was obtained at a molar ratio
of 1:1 using 4 mM glutaraldehyde. Indeed, the F4/HSA molecules obtained at this
ratio were able to interact with both a F4- or HSA-specific antibody coating and were
subsequently detected by HSA- or F4-specific peroxidase labelled antibodies,
respectively, resulting in OD405-values of 1.47 and 1.7 at a 1/10 dilution of the
F4/HSA conjugates. In addition, these F4/HSA conjugates were able to bind F4R+ but
not F4R- enterocytes as determined by surface plasmon resonance (Fig. 1). Other
conjugation conditions resulted in lower OD405-values or in a reduced F4R-binding
(data not shown). In further experiments, only the optimally conjugated F4/HSA was
used.
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Figure 1 : Sensogram showing the interaction of the F4/HSA conjugate with
immobilized HSA-specific antibodies and subsequent with F4-receptor positive (white
symbols) and F4-receptor negative (black symbols) porcine enterocytes. Black arrow,
F4/HSA injection; White arrow, injection of enterocytes.
Binding of HSA to purified F4 fimbriae was also confirmed by determining
the hydrodynamic radii of the F4/HSA conjugates using the DLS technique (Fig. 2).
DLS measurements of non-conjugated HSA molecules revealed a single group of
particles with a radius of 4 to 7 nm (Fig. 2B). Measurements of purified F4 fimbriae
showed different particles with a radius ranging between 10 and 100 nm (Fig. 2A).
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When HSA and F4 were mixed (F4+HSA), particles were detected with a radius of 4 
to 7 nm as well as particles with a ratio of 10 to 100 nm (Fig. 2C). Conjugation of 
HSA to F4 fimbriae resulted in a clear reduction of the 4 to 7 nm particle group (Fig. 
2D), suggesting that HSA molecules were indeed coupled to F4. Since the linear F4 
fimbriae are measured as ellipsoid spheres by the DLS technique, conjugation of HSA 
molecules along the linear F4 fimbriae will result in a similar ellipsoid sphere and not 
in particles with a larger radius. SDS-PAGE and Coomassie staining of F4/HSA 
samples also showed a decrease in free HSA molecules as compared to samples of 
mixed F4 and HSA (data not shown). In contrast to the F4/HSA conjugation, coupling 
F4 to F4 and HSA to HSA seemed less effective since the hydrodynamic radii of the 
conjugates are similar to the uncoupled molecules (Fig. 2E and 2F). However, the 
glutaraldehyde treatment of F4 fimbriae seemed to result in the covalent linkage of its 
subunits since incubation of F4/F4 at 95°C for 5 minutes did not reduce the polymeric 
character of F4, whereas heating of non-coupled F4 resulted in the desintegration of 
F4 fimbriae as only its adhesin FaeG could be observed following SDS-PAGE and 
Coomassie staining (data not shown).  
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Figure 2 : Distribution of the hydrodynamic radii (nm) of the molecules present in F4 (A), HSA (B), 
F4+HSA (C), F4/HSA (D), F4/F4 (E) or HSA/HSA (F) samples as determined by the dynamic light 
scatter method and presented using a color gradient. Each sample was measured ten times (Y-axis). 
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7.3.2. Induction of F4-specific serum antibodies 
 The in vitro villous adhesion assay revealed that seventeen pigs were F4R+ 
whereas three pigs were F4R-. As a consequence, the six pigs that were orally 
immunized with F4/HSA  conjugates and CT were divided in two subgroups of three 
pigs each : three F4R+ pigs (F4/HSA+CT group) and three F4R- pigs (F4/HSA+CT 
F4R- group). 
As expected, pigs orally immunized with HSA/HSA in the presence or 
absence of CT (HSA/HSA+CT and HSA/HSA groups, respectively) did not have a 
F4-specific antibody responses. The F4R+ pigs immunized with plain F4/HSA only 
showed F4-specific IgA and IgG responses after the third oral immunization (Fig. 3), 
which became significantly higher (P≤0.031) than the background in the HSA groups 
42 and 48 dppi. On the other hand, oral co-administration of CT to F4/HSA in F4R+ 
pigs (F4/HSA+CT group) significantly increased the F4-specific antibody response. 
Indeed, a primary antibody response already occurred 7 days following the first oral 
immunization (7 dppi) with first IgM (log2 titer 4.85) and subsequently IgA and IgG 
antibodies, which reached maximal log2 titers of 8.32 and were significantly higher 
than these of other groups during a period of about 2 months (P≤0.046).  
In F4R- pigs, CT adjuvanticity also induced F4-specific antibodies following 
oral co-administration with F4/HSA (F4/HSA+CT F4R- group) from one week 
following the second oral immunization onwards (Fig. 4). Moreover, this 
immunization resulted in a faster appearance of F4-specific IgA and IgG titers than in 
F4R+ pigs immunized with plain F4/HSA (F4/HSA group). However, the F4-specific 
IgG and IgA serum antibody titers in the F4/HSA+CT F4R- group reached similar 
levels as in the F4/HSA group from the third oral immunization onwards and was 
significantly lower as compared to F4R+ pigs immunized with F4/HSA + CT 
(F4/HSA+CT group). These results demonstrated that CT functions as mucosal 
adjuvant in pigs and that the highest F4-specific response is obtained following 
mucosal targeting of F4 in the presence of CT. 
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Figure 3 : Mean F4-specific IgM, IgA and IgG serum antibody titers (± SEM) of immunized pigs. The
animals of the F4/HSA+CT F4R- group are F4R-, whereas all other animals are F4R+. Significant
difference (P<0.05) between F4/HSA+CT and F4/HSA, HSA/HSA, HSA/HSA+CT, F4/HSA+CT F4R-
(a), between F4/HSA+CT and HSA/HSA+CT (b), between F4/HSA+CT and HSA/HSA, F4/HSA (o),
between F4/HSA and HSA/HSA, HSA/HSA+CT (s), between F4/HSA+CT F4R- and F4/HSA, HSA/HSA
(t), between F4/HSA+CT F4R- and HSA/HSA, HSA/HSA+CT (u). Black arrow, oral immunization.
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Figure 4 : Mean HSA-specific IgM, IgA and IgG serum antibody titers (± SEM) of immunized pigs.
Significant difference (P<0.05) between F4/HSA+CT and HSA/HSA, HSA/HSA+CT, F4/HSA, F4/HSA+CT
F4R- (a), between F4/HSA+CT and HSA/HSA+CT (b), between F4/HSA+CT and HSA/HSA (c), between
HSA/HSA+CT and F4/HSA (f), between HSA/HSA+CT and F4/HSA+CT F4R- (h), between F4/HSA+CT and
F4/HSA, F4/HSA+CT F4R-, HSA/HSA (i), between HSA/HSA+CT and F4/HSA, F4/HSA+CT F4R-, HSA/HSA
(j), between HSA/HSA and F4/HSA+CT, F4/HSA+CT F4R-, HSA/HSA+CT, F4/HSA (k), between F4/HSA and
F4/HSA+CT, F4/HSA+CT F4R-, HSA/HSA+CT, HSA/HSA (l), between HSA/HSA and F4/HSA,
HSA/HSA+CT (m), between F4/HSA and HSA/HSA (n), between F4/HSA+CT and HSA/HSA, F4/HSA (o),
between HSA/HSA+CT and HSA/HSA, F4/HSA (p), between F4/HSA+CT and HSA/HSA+CT, F4/HSA,
F4/HSA+CT F4R- (r). Black arrow, oral immunization; white arrow, intramuscular HSA immunization
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7.3.3. Induction of HSA-specific serum antibodies
7.3.3.1. Oral immunization
To analyse the mucosal carrier function of F4 for the conjugated HSA, the
HSA-specific antibody response was determined. As expected, no HSA-specific
antibodies were observed following oral immunization of pigs with HSA/HSA
(HSA/HSA group) (Fig. 4), nor were HSA-specific serum antibodies detected
following oral administration of F4/HSA conjugates to F4R+ pigs (F4/HSA group).
On the other hand, oral co-administration of HSA/HSA or F4/HSA with CT
(HSA/HSA+CT and F4/HSA+CT group, respectively) induced a HSA-specific IgG
and IgA serum antibody response in F4R+ pigs around the moment of the second oral
immunization and following the third oral immunization, respectively (Fig. 4).
However, conjugation of HSA to F4 enhanced the induction of a HSA-specific
response since significantly higher HSA-specific IgG and IgA titers were observed in
the F4/HSA+CT group as compared to the HSA/HSA+CT group following the second
and the third oral immunization, respectively. Later on, the HSA-specific IgG titer in
the HSA/HSA+CT group reached the level of the F4/HSA+CT group at the moment
of the third oral immunization (35 dppi) and remained at this level till the IM
immunization at 48 dppi. The titers in the CT-supplemented groups were significantly
higher than for the groups without CT (F4/HSA and HSA/HSA groups) following the
third oral immunization (between 38 and 48 dppi).
In F4R- pigs orally immunized with F4/HSA+CT (F4/HSA+CT F4R- group), a
HSA-specific IgG serum response was only observed two weeks following the third
oral immunization (Fig. 4). These data indicate that the fast induction of a HSA-
specific serum response following oral co-administration of CT and F4/HSA in F4R+
pigs (F4/HSA+CT group) resulted from a complementary effect of CT as adjuvant
and F4 as mucosal carrier. A remarkable observation was the faster appearance of
HSA-specific serum IgG in the HSA/HSA+CT group than in the F4/HSA+CT F4R-
group.
7.3.3.2. Intramuscular HSA immunization
At 48 dppi, the pigs were IM immunized with HSA to determine whether oral
immunization had primed the animals systemically against HSA (Fig. 4). A
significant increase of the HSA-specific serum IgM titer between 7 and 14 days post
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IM immunization (55 and 62 dppi) was only observed in the HSA/HSA group,
confirming a primary antibody response in this group. The kinetics of HSA-specific
serum IgG confirms a primary response (Fig. 4), whereas no HSA-specific serum IgA
response could be detected in the HSA/HSA group.
In contrast to a primary response in the HSA/HSA group, secondary responses
were detected in the four other groups with significant increases in HSA-specific
serum IgG titers directly following IM immunization (between 48 and 52 dppi)
(P≤0.025). This resulted in a significantly higher IgG antibody titer in these four
groups than in the HSA/HSA group one week following IM immunization (55 dppi).
However, gradual differences in priming were observed between these four groups as
evidenced by the different kinetic of the HSA-specific serum IgG response. Indeed, a
HSA-specific serum IgG titer of 1280 (log2 titer > 10) was reached at 29, 14, 7 and 4
days following IM HSA immunization in the F4/HSA, F4/HSA+CT F4R-,
HSA/HSA+CT and F4/HSA+CT groups, respectively. A similar kinetic pattern was
obtained for the HSA-specific IgA serum response. These observations are in
agreement with those following oral immunization, confirming that conjugation of
HSA to F4 improved the targeting of HSA to the gut associated lymphoid tissue
following oral administration and that CT functioned as a mucosal adjuvant to orally
co-administered antigens. In addition, it is interesting to notice that HSA-specific
serum IgA also boosted in the F4/HSA group upon IM HSA immunization, This
observation revealed the priming of the gut-associated immune system by HSA that
was conjugated to F4, in contrast to non-mucosae-targeted HSA/HSA.
7.3.4. F4- and HSA-specific IgA response in saliva
The presence of F4-specific serum antibodies in F4/HSA, F4/HSA+CT and
F4/HSA+CT F4R- groups following oral immunization corresponded with the
presence of F4-specific IgA in saliva (Fig. 5). The HSA-specific IgA in saliva was
only detected in the F4/HSA+CT group one week after the second oral immunization
(24 dppi). At that moment, no HSA-specific IgA could be detected in serum. The
induced HSA-specific IgA in saliva was also significantly higher in the F4/HSA+CT
group than in the HSA/HSA, F4/HSA and F4/HSA+CT F4R- groups one week
following the third oral immunization (42 dppi) (P≤0.016).
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Figure 5 : Mean F4- and HSA-specific IgA antibody titer (± SEM) in saliva of
immunized pigs. The animals of the F4/HSA+CT F4R- group are F4R-, whereas all
other animals are F4R+. Significant difference (P<0.05) between F4/HSA+CT and
HSA/HSA, HSA/HSA+CT, F4/HSA, F4/HSA+CT F4R- (a), between F4/HSA+CT
and F4/HSA, F4/HSA+CT F4R-, HSA/HSA (i). Black arrow, oral immunization.
7.3.5. Induction of a F4- and HSA-specific lymphocyte
proliferation
The F4-specific cellular immune response is in accordance with the humoral
antibody response one week following the third oral immunization (42 dppi) in that
the F4-specific cellular immune response was significantly higher in the F4/HSA and
F4/HSA+CT groups than the background levels of the HSA/HSA and HSA/HSA+CT
groups (P≤0.020) (Fig. 6). A similar situation was observed 55 dppi, but then the SI
were lower suggesting a decreased F4-specific cellular immune response.
The HSA-specific lymphocyte proliferation was low after the third oral
immunization as well as one week after the IM HSA immunization (maximal mean SI
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of 2.3 and 2.8, respectively) (Fig. 6). However, the HSA-specific lymphocyte
proliferation was significantly increased (P≤0.022) in all groups except the HSA/HSA
group three weeks after IM immunization. At that moment, the HSA-specific SI was
significant lower in the HSA/HSA group as compared to the HSA/HSA+CT,
F4/HSA+CT and F4/HSA+CT F4R- groups (P≤0.030), resembling the HSA-specific
antibody response.
Figure 6 : Mean F4- and HSA-specific stimulation index (SI) (±  SEM). of
immunized pigs. The animals of the F4/HSA+CT F4R- group are F4R-, whereas all
other animals are F4R+. Bars with a different letter are significantly different
(P<0.05).
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7.3.6. Induction of CT-specific serum antibodies
The use of CT as mucosal adjuvant resulted in the improvement of the
antigen-specific immune responses as shown above. CT also induced toxin-specific
antibodies (Fig. 7). The use of CT did not result in diarrhoea or a reduced weight gain
(data not shown).
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Figure 7 : Mean CT-specific serum antibody titer (± SEM) of immunized pigs.
Bars with a different letter are significantly different (P<0.05).
7.4. Discussion
It is generally accepted that oral immunization with non-replicating antigens
that do not bind to the intestinal mucosae, does not result in the induction of antigen-
specific antibodies in serum or at mucosae (Foss and Murtaugh, 1999a; Van den
Broeck et al., 2002; Lauterslager et al., 2003). Oral immunization of animals with
proteins can lead to either oral tolerance or priming of the systemic immune system,
depending on the dose given (Lamont et al., 1989; Mowat, 1995; Van den Broeck et
al., 2002). In the present study, oral immunization of pigs with HSA-HSA at a dose of
4.8 mg per immunization did not result in oral tolerance, nor in a clear priming of the
systemic immune response since a primary HSA-specific serum antibody response
was observed following IM HSA immunization.
Mice orally immunized with antigen in the presence of CT showed an
enhanced induction of the antigen-specific humoral and cellular immune response
b
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(Clarke et al, 1991; Smith et al., 2002; Lauterslager et al., 2003). This has also been 
demonstrated in guinea pigs, chickens and rabbits (McKenzie and Halsey, 1984; 
Debard et al., 1996; Girard et al., 1999). The present study is the first to show that CT 
is also a mucosal adjuvant for an orally administered non-mucosa-targeted antigen in 
pigs. Indeed, the observed high HSA-specific serum IgG antibody titer following oral 
co-administration of antigen and CT indicate an antigen-specific priming of the 
systemic immune response. This observation is in line with previous studies using CT 
in mice, rabbits, guinea pigs and chickens (McKenzie and Halsey, 1984; Debard et al., 
1996; Benedetti et al., 1998; Girard et al., 1999; Lauterslager et al., 2002). Foss et al. 
(1999a), however, did not observe an antigen-specific immune response following 
oral co-administration of CT with non-mucosa-targeted albumin or keyhole limpet 
hemocyanin. This argues that the dose of antigen and the immunization schedule are 
probably very important since these were the major differences with the present study.  
The results of the present study indicate that F4 fimbriae can act as a mucosal 
carrier molecule for HSA, inducing a HSA-specific priming of the mucosal and 
systemic immune system. Indeed, the IM HSA immunization resulted in a secondary 
immune response in the orally F4/HSA immunized pigs as evidenced by a low HSA-
specific IgM response and a rapidly increasing HSA-specific IgG titer which reached 
a high titer. A primary HSA-specific antibody response appeared in the HSA/HSA 
immunized animals with a high HSA-specific IgM response and a slower IgG 
response reaching lower titers than in the F4/HSA immunized animals. This priming 
of a HSA-specific immune response following F4/HSA immunization is probably not 
due to an adjuvant effect of F4 since co-administration of F4 with ovalbumin did not 
induce an ovalbumin-specific immune response (Van den Broeck, unpublished data). 
The conjugation of HSA to purified F4 fimbriae in a 1:1 molar ratio resulted in 
F4/HSA complexes that are still able to bind to the F4R, as shown by the interaction 
of the complexes with F4R+ enterocytes using a biosensor. This suggests that the F4-
mediated binding of F4/HSA allows a more efficient uptake of the conjugated HSA 
across the intestinal epithelial barrier. Indeed, a recent study in our lab showed that F4 
fimbriae can be taken up in F4R+ pigs by both enterocytes and M cells thus reaching 
antigen presenting cells such as porcine SWC-3 positive myeloid cells in the lamina 
propria (Snoeck et al., 2004b). The F4-dependent uptake of F4/HSA in F4R+ pigs 
reaches the gut-associated lymphoid tissue as evidenced by the appearance of HSA-
specific serum IgA in the F4/HSA group following the IM booster immunization, in 
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contrast to the HSA/HSA immunized pigs. It has been reported that mucosal priming 
followed by a systemic booster immunization enhances not only the antigen-specific 
mucosal  response but also the systemic immune response (Vajdy et al., 2003).   
A negative effect of the conjugation of HSA to F4 fimbriae is the lower F4-
specific antibody response following the oral immunization with F4/HSA in the 
present study in comparison with oral immunization with purified F4 in a previous 
study (Van den Broeck et al., 1999b), despite the similar experimental design. This 
could be due to a reduced capacity of F4/HSA to bind the F4R since further increasing 
the molar amount of HSA conjugated to F4 clearly reduced the F4R binding in the 
biosensor assay. The conjugation could influence binding as shown for the dietary 
lectin wheat germ agglutinin (WGA). Increasing the molar ratio of WGA in a WGA-
albumin conjugation results in increased binding of the WGA-albumin complexes to 
Caco-2 cells (Gabor et al., 2002). A second factor influencing the immunogenicity 
could be the covalent linkage of adjacent FaeG subunits in the F4 fimbriae due to the 
glutaraldehyde-mediated conjugation, making the F4 fimbriae more rigid and perhaps 
influencing their immunogenicity. It has been reported that chemical conjugation of 
antigens can inhibit their degradation and subsequently reduce antigen presentation 
and induction of an antigen-specific immune response (Kobayashi et al., 2003). 
Oral co-administration of F4/HSA and CT significantly increased the F4-
specific serum IgA titer, whereas HSA/HSA with CT feeding did not significantly 
induce HSA-specific serum IgA antibodies. Oral co-administration of CT with other 
fimbriae like CFAI and CS6 also resulted in the induction of higher fimbriae-specific 
IgG and IgA serum responses and in higher amounts of faecal IgA (Byrd and Cassels, 
2003). In addition, the results of the present study show that the addition of CT 
significantly enhanced the immune response against the antigen that was targeted to 
the mucosa by F4 following the oral immunization. Indeed, significantly higher HSA-
specific serum IgG titers are present in F4R+ pigs immunized with F4/HSA+CT as 
compared to HSA/HSA+CT immunization. In addition, oral F4/HSA+CT 
immunization results in significantly higher HSA-specific antibody titers in F4R+ than 
in F4R- pigs. Thus, conjugation to F4  and addition of CT enhance synergistically the 
HSA-specific antibody response. This is in agreement with studies that report higher 
antigen-specific antibody responses following oral co-administration of CT with 
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mucosa-targeted antigen as compared to non-mucosa-targeted antigen (McKenzie and 
Halsey, 1984; Czerkinsky et al., 1989; Van der Heijden et al., 1991).  
In F4R- pigs, oral co-administration of F4/HSA with CT results in a 
significantly lower HSA-specific serum IgG antibody titer as compared to oral co-
administration of HSA/HSA with CT in F4R+ pigs. This difference in HSA-specific 
immune response is not due to a different efficiency of CT in both groups as the CT-
specific antibody response is identical in both groups. Frey et al. (1996) observed that 
smaller molecules could better pass the intestinal mucus layer than larger molecules. 
Probably, the smaller size of the HSA/HSA molecules that was observed in the DLS 
experiments could enable the uptake of these molecules through the intestinal mucus 
layer as compared to the larger F4/HSA molecules. Indeed, CT is suggested to attract 
dendritic cells to the epithelial cells lining the gut mucosa, subsequently enhancing 
uptake of luminal antigens (Lycke, 2004). In addition, Verma et al. (1994) reported 
that CT increases the intestinal permeability. Therefore, a more efficient passage of 
HSA/HSA through the intestinal mucus than of F4/HSA probably could result in a 
faster induction of an HSA-specific immune response.  
Nevertheless, the use of F4 fimbriae as mucosal carrier to heterologous 
antigens could open new perspectives in the development of a vaccine that 
simultaneously protects pigs against the widely spread F4+ ETEC and other 
enteropathogens such as rotavirus or verotoxigenic E. coli. In contrast to the insertion 
of heterologous epitopes in the variable region of FaeG (Thiry et al., 1989; Bakker et 
al., 1990), conjugation of antigens to fimbriae is not restricted to short peptides. In 
addition, conjugates can be obtained that retain their F4R-binding capacity and 
subsequently can be used as mucosal carrier molecule, whereas exchanging the 
variable region of FaeG seems to inhibit its F4R-binding (Bakker et al., 1992a). 
Perhaps, further improvement of the mucosal carrier capacity of F4 fimbriae could be 
obtained by altering the molar ratio of F4 to HSA in the conjugate (Russell-Jones, 
2001). On the other hand, fusion of a heterologous antigen to recombinant fimbrial 
adhesin subunits could be used as mucosal carrier system (Batisson et al., 2000a and 
2000b). Indeed, fusion of a heterologous peptide to the F4 fimbrial adhesin FaeG 
induces a peptide-specific antibody response following oral immunization of pigs 
with this fusion protein (Verdonck et al., 2004a). Perhaps, the fimbrial adhesin FaeG 
could be a better mucosal carrier than F4 fimbriae as no HSA-specific antibodies were 
found in this study following oral F4/HSA immunization of F4R+ pigs. However, it is 
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not known at the moment if FaeG has the potential to function as mucosal carrier for 
large antigens.  
In conclusion, the results of the present study show the potential of F4 
fimbriae to induce an immune response against a coupled heterologous antigen 
following oral administration in pigs. In addition, this potential of F4 fimbriae to 
function as a mucosal carrier can be improved by the adjuvant effect of CT. The 
combined use of CT as mucosal adjuvant and F4 fimbriae as mucosal carrier could 
open new perspectives in the development of vaccines against other enteropathogens 
in pigs. 
 
 
 
 
  
 
 
 
Chapter 8 
 
Altered bioactivity of purified F4 fimbriae by anionic 
detergents, temperature and pH: correlation with a 
monoclonal antibody based ELISA1 
 
 
                                                 
1 Based on : Verdonck F, Snoeck V, Goddeeris BM, Cox E. Binding of a monoclonal 
antibody positively correlates with bioactivity of the F4 fimbrial adhesin FaeG. 
Submitted 
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Abstract 
To develop a vaccine, a bioactive F4-receptor (F4R) binding FaeG molecule is 
required that binds to the F4R following oral immunization and induces a FaeG-specific 
immune response. The present study reports the altered binding of the FaeG-specific 
monoclonal antibody IMM01 with bioactive versus non-bioactive F4 fimbrial adhesin 
FaeG. The correlation of altered IMM01 binding with altered FaeG bioactivity, enables 
the use of an IMM01-based ELISA as a fast, specific and sensitive in vitro selection for 
potent F4 or (recombinant) FaeG antigen formulations, useful in an F4+ ETEC vaccine.  
 
8.1. Introduction 
Today, no commercial vaccine exists against post-weaning diarrhoea. However, 
orally administered F4 fimbriae bind to the F4R in the small intestine and induce local 
secretion of F4-specific IgA (Van den Broeck et al., 1999a) that inhibit subsequent 
colonization of F4+ ETEC (Van den Broeck et al., 1999b). Incorporation of F4 fimbriae 
in pellets or microspheres (Snoeck et al., 2003) or coupling of F4-fimbriae to an adjuvant 
could favour the induction of a protective mucosal F4-specific immune response and/or 
decrease the amount of antigen needed for immunization. On the other hand, the use of 
recombinant FaeG (rFaeG) subunits could perhaps be an alternative to the purified F4 
fimbriae to induce a mucosal F4-specific antibody response. Recently, expression of 
rFaeG is reported in tobacco (Huang et al., 2003; Joensuu et al., 2004) and in Escherichia 
coli (Verdonck et al., 2004a). 
To analyse the usefulness of formulations containing purified F4 fimbriae or 
rFaeG to induce a mucosal F4-specific immune response, or to study their capacity as 
mucosal carrier for heterologous antigens, it is important to analyse their bioactive 
properties in a fast, specific and sensitive way. First, multimerization of FaeG will be 
important, as the multimeric nature of an antigen is reported to induce better protection 
following immunization than its monomeric nature (Miller et al., 1998). Second, F4 
fimbriae or FaeG subunits need to bind to the F4R as purified F4 fimbriae only induce an 
F4-specific mucosal immune response when they bind to the F4R on small intestinal villi 
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(Van den Broeck et al., 1999b). At the moment, the inhibition adhesion assay described 
by Van den Broeck et al. (1999c) is the most accurate system to test the binding of F4 
fimbriae or FaeG subunits to the F4R. However, this assay is not very sensitive and is 
labour intensive. Haemagglutination assays are also reported to analyse adhesive 
properties of FaeG adhesins, but it is presently not known if this interaction reflects the 
interaction between FaeG and the F4R on intestinal villi (Gibbons et al., 1977; Bakker et 
al., 1992a). Furthermore, haemagglutination assays are not useful in the presence of 
contaminating molecules like detergents in the sample. On the other hand, the 
conformation of FaeG can be analysed using conformational epitope-specific monoclonal 
antibodies (MAb) (Bakker et al., 1992a). 
The aim of the present study was to determine the bioactivity of F4 fimbriae 
following incubation in a number of conditions, often used during protein purification 
and refolding, in encapsulation of antigens or during coupling procedures. Subsequently, 
an ELISA was developed that correlated the optical density of analysed F4 fimbrial 
samples with their bioactive properties in a fast, sensitive and specific manner. 
 
8.2. Materials and methods 
8.2.1. Isolation of F4 fimbriae 
  The F4 fimbriae were purified as described by Van den Broeck (1999c). Briefly, 
fimbriae were isolated by homogenizing the bacterial suspension of strain E. coli GIS26 
using an Ultra Turrax (Janke & Kunkel, IKA Labortechnik, Staufen, Germany), followed 
by a purification using two centrifugation steps and a precipitation step with 40 % (w/v) 
ammonium sulphate. Thereafter, the pellet was dissolved and dialyzed overnight against 
ultra-pure H2O. 
  
8.2.2. Incubation conditions 
  The protein concentration of purified F4 fimbriae was determined using the 
bicinchoninic acid reaction with bovine serum albumin (BSA) as a standard (ICN 
Biomedicals, Belgium). The purity of the purified F4 fimbriae was assessed in a 
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Coomassie stained 15 % SDS-PAGE with the ImageMaster 1D prime software 
(Amersham Pharmacia Biotech, Belgium).  
  Purified F4 fimbriae were incubated in different conditions to analyse 
conformational changes of F4 fimbriae or to study the influence of frequently used 
chemicals or physical conditions on its receptor-binding capacity, multimerization and 
conformation. Therefore, 500 µg of purified F4 fimbriae were incubated for 30 minutes at 
room temperature (25°C) in a total of 500 µl reaction volume, whereafter the treated F4 
sample was dialyzed overnight against PBS (137 mM NaCl, 2.7 mM KCl, 10.1 mM 
Na2HPO4, 1.8 mM KH2PO4, pH 7.4) at 4°C. In this way, F4 fimbriae were incubated in 
PBS supplemented with final concentrations of 5; 1.5; 0.5 or 0.15 % (v/v) SDS, Triton-X-
100, saponin or Tween®20. Furthermore, 500 µg of purified F4 fimbriae were incubated 
for 30 minutes at room temperature in 500 µl 50 mM TrisHCl-buffer with/without urea or 
guanidine hydrochloride (GuHCl) at a final concentration of 1, 2, 3 or 4 M. Additionally, 
F4 fimbriae were also incubated in PBS with adjusted pH values (using 1M HCl) of 2, 4, 
6, 8 or 10 in the presence/absence of 0.05 % SDS. Finally, F4 fimbriae were incubated 5 
minutes at room temperature (25°C), 50, 70, 85 or 100°C. All samples were also made 
without the addition of purified F4 fimbriae (further indicated as ‘treatment solution’) and 
analysed to determine the direct influence of the treatment solutions on the used test 
systems. Each condition of treating purified F4 samples were individually performed 
three times and were always dialyzed overnight against PBS following treatment.  
 
8.2.3. Multimeric FaeG character of F4 fimbriae 
  The multimeric nature of an antigen is reported to induce better protection 
following immunization than its monomeric nature (Miller et al., 1998). Therefore, the 
presence of FaeG multi- or monomers following incubation of F4 fimbriae was 
determined by SDS-PAGE followed by Western blot using the F4-specific MAb IMM01 
(Van der Stede et al., 2002b) as described by Van den Broeck (1999c). The samples were 
diluted in the same volume of 60 mM TrisHCl pH 6.8, 2 % SDS, 10 % glycerol and 0.02 
% bromophenol blue and loaded without heating the samples. The SDS concentration in 
the gel and the running buffer is 0.1%. 
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8.2.4. Turbidity analysis 
  The turbidity of a protein solution gives an indication of the amount of protein 
aggregates of a sufficient size to scatter visible light. Turbidity measurements were 
performed with a spectrophotometer (Ultrospec 4000, Pharmacia Biotech) at 550 nm 
(OD550) (Andersen, 2002), immediately after each of the incubations (done to induce 
conformational changes of F4) as well as after overnight dialysis to see if aggregates 
(dis)appeared. 
 
8.2.5. Bioactivity 
  The bioactivity of the treated F4 samples is correlated with its ability to bind to 
the F4R. Therefore, the binding of treated F4 fimbriae to the F4R was determined by the 
in vitro competitive villous adhesion assay, a variant of the method described by Van den 
Broeck et al. (1999c). Briefly, villi of F4R positive (F4R+) or F4R negative (F4R-) pigs 
were washed four times in Krebs-Henseleit buffer (160 mM, pH 7.4) whereafter they 
were resuspended in PBS supplemented with 1 % (w/v) D-mannose (Fluka, Sigma-
Aldrich, Bornem, Belgium) to prevent adhesion by type 1 pili. Subsequently, 4 x 108 F4+ 
E. coli and the test sample (200 µg treated F4 fimbriae or the treatment solution without 
F4 as negative control) were added to an average of 50 villi. The suspension was adjusted 
with PBS and D-mannose to a final volume of 0.5 ml containing 1 % (w/v) D-mannose. 
This suspension was incubated at room temperature for 1 h while gently shaking. Then, 
the adhesion of bacteria was evaluated quantitatively by counting the number of bacteria 
adhering along a 50 µm villous brush border at 20 randomly selected places using phase-
contrast microscopy at a magnification of 600x, after which the mean bacterial adhesion 
per 250 µm villous brush border was calculated. The percentage inhibition was calculated 
in comparison with F4R+ villi incubated only with F4+ E. coli. Villi of three different 
F4R+ pigs and one F4R- pig as negative control were used and the analyses were 
performed in triplicate. 
 
8.2.6. ELISA 
  An indirect ELISA was developed to analyse the conformation of FaeG. 
Therefore, a 96-well microtiter plate (NUNC, Maxisorp Immuno Plates, Roskilde, 
Chapter 8 : Bioactivity of F4 correlates with monoclonal antibody binding 
 
132 
Denmark) was coated with an optimal concentration of F4-specific swine polyclonal 
antibodies in PBS. This polyclonal antibody will bind native as well as denaturated F4. 
After 2 h incubation at 37°C, the remaining binding sites were blocked overnight at 4°C 
with PBS supplemented with 0.2 % (v/v) Tween®80. Following blocking, series of two-
fold dilutions (10 to 0.005 µg⁄ml) of native and treated F4 fimbriae in ELISA dilution 
buffer (PBS + 0.05 % (v/v) Tween®20 + 3 % (w/v) BSA) were incubated for 1 h at 37°C. 
In addition, native F4 was similarly diluted in the treatment solutions to determine their 
direct influence on the assay. Thereafter, an optimal dilution of the FaeG-specific 
monoclonal antibody (MAb) IMM01 was added to the wells for 1 h at 37°C. 
Subsequently, rabbit anti-mouse HRP-conjugated serum (Dako, Denmark) optimally 
diluted in ELISA dilution buffer and supplemented with 2 % (v/v) pig serum was brought 
onto the plates for 1 h at 37°C. An ABTS solution containing H2O2 was added and after 1 
h incubation at 37°C the optical density was spectrophotometrically measured at 405 nm 
(OD405). The plates were washed three times with ELISA washing buffer (PBS + 0.2 % 
(v/v) Tween®20) between each incubation step. The treated samples were independently 
analysed three times and data of a representative analysis are shown. 
 
8.3. Results 
Purified F4 fimbriae were incubated at different temperatures to induce 
conformational changes in the FaeG adhesins. Indeed, the bioactivity of the F4 fimbrial 
adhesin FaeG decreased following incubation of F4 fimbriae at high temperatures: F4 
fimbriae incubated at 70°C still inhibited the adhesion of F4+ E. coli to F4R+ villi by 89.4 
± 4.5 %, whereas F4 fimbriae incubated at 85°C and 100°C only inhibited by 34.4 ± 14.8 
% and 7.7 ± 6.8 %, respectively (Table 1). Western blotting of purified F4 fimbriae 
incubated at 85°C or higher temperatures revealed also a decreased polymerisation of the 
FaeG adhesins (Fig. 1), whereas turbidity measurements suggested the presence of non-
ordered protein aggregations as evidenced by their increase in OD550 (Table 1). However, 
these aggregates did not precipitate, neither influence the concentration of F4 in solution. 
Indeed, the protein concentration in the top fraction of an F4 fimbrial sample incubated 5 
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minutes at 95 °C is identical directly following heat treatment and mixing as compared to 
3 hours later. 
 
 
Table 1 : Effect of different incubation conditions for F4 fimbriae on formation of aggregates 
(OD550 ± standard deviation, SD) (directly following incubation or following dialysis of the 
test samples) and on inhibition of adhesion of F4+ E. coli adhesion to F4R+ 
 villi (% ± SD) (after dialysis). 
Incubation conditions* 
 
OD550 after 
incubation                     dialysis    
Percent inhibition of F4+ 
ETEC to F4R+ villi 
25°C 0.056 ± 0.005 0.008 ± 0.002 92.4 ± 3.4 
50°C 0.053 ± 0.004 0.008 ± 0.001 91.2 ± 3.6 
70°C 0.055 ± 0.006 0.007 ± 0.001 89.4 ± 4.5  
85°C 0.262 ± 0.022 0.347 ± 0.025 34.4 ± 14.8 
100°C 0.375 ± 0.037 0.466 ± 0.046 7.7 ± 6.8 
0.15% SDS 0.049 ± 0.004 0.062 ± 0.006 86.8 ± 4.1 
0.5% SDS 0.025 ± 0.010 0.013 ± 0.007 78.6 ± 7.8 
1.5% SDS 0.007 ± 0.005 0.005 ± 0.003 54.7 ± 9.0 
5% SDS 0.005 ± 0.003 0.004 ± 0.003 13.1 ± 6.3 
pH2 1.342 ± 0.069 0.081 ± 0.034 87.0 ± 7.1 
pH4 0.583 ± 0.021 0.050 ± 0.008 85.3 ± 4.6 
pH6 0.090 ± 0.009 0.061 ± 0.012 91.2 ± 5.3 
pH8 0.078 ± 0.007 0.051 ± 0.009 90.7 ± 4.7 
pH10 0.069 ± 0.012 0.032 ± 0.013 89.6 ± 6.2 
pH2 0.05% SDS 0.510 ± 0.037 0.004 ± 0.004 15.7 ± 3.3 
pH4 0.05% SDS 0.032 ± 0.005 0.006 ± 0.005 24.0 ± 8.1 
pH6 0.05% SDS 0.015 ± 0.003 0.006 ± 0.002 88.9 ± 4.4 
pH8 0.05% SDS 0.013 ± 0.004 0.007 ± 0.003 89.8 ± 5.2 
pH10 0.05% SDS 0.013 ± 0.005 0.004 ± 0.002 87.9 ± 5.6 
* 500 µg purified F4 fimbriae in 500 µl during 30 minutes 
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Figure 1 : Multimeric FaeG character of F4 fimbriae incubated for 5 minutes 
at 25°C (1), 50°C (2), 70°C (3), 85°C (4) and 100°C (5), determined in 
Western blot using the IMM01 MAb. M = molecular weight marker. 
 
 
Subsequently, interaction of the F4-specific MAb IMM01 with serial dilutions of 
these temperature treated F4 fimbriae were tested in ELISA. Purified F4 fimbriae 
incubated at 25 to 70°C resulted in near parallel sigmoid OD405-curves, characterized by 
an identical steep linear phase and a plateau phase decreasing with increasing incubation 
temperature (Fig. 2). However, F4 fimbriae incubated at a temperature of 85°C or higher, 
resulted in sigmoid OD405-curves with a very low plateau phase and a linear phase with a 
flat slope. These flat sigmoid OD405-curves indicate a lower affinity of the MAb for the 
high-temperature treated F4 fimbriae, most likely due to a conformational change in the 
epitope recognized by the MAb.  
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Figure 2 : Binding of the FaeG-specific MAb IMM01 with F4 fimbriae 
incubated for 5 minutes at 25°C, 50°C, 70°C, 85°C and 100°C. 
 
 
F4 fimbriae were analysed following treatment with urea, GuHCl, detergents or at 
different pH as these conditions are often used during purification and refolding of 
proteins, in encapsulation of antigens or during coupling procedures (Singh and O’Hagan, 
1998; De Bernandez, 2001; Tsumoto et al., 2003). Incubation with non-ionic detergents, 
urea or GuHCl did not influence the ELISA reactivity as well as the multimerization and 
the bioactivity of the treated F4 samples following dialysis (data not shown). However, 
incubation of F4 fimbriae with increasing SDS concentrations, resulted in a gradually 
altered binding of the IMM01 MAb to the treated F4 (Fig. 3) as no influence of the 
treatment solution containing SDS was observed. Indeed, conditions with 0.15 % and 0.5 
% SDS revealed both sigmoid OD405-curves with a decreased plateau phase but a quite 
parallel and steep linear phase as compared with native purified F4 fimbriae incubated 
without SDS. Higher concentrations of SDS resulted in linear-like, low value OD405-
curves. Furthermore, the incubation of F4 fimbriae with SDS reduced also its multimeric 
character (Fig. 4) and its bioactivity (% inhibition) in a SDS concentration-dependent 
manner (Table 1). However, the influence of SDS concentrations below 1 % on the 
multimeric character of F4 could not be determined by SDS-PAGE since the preparation 
of the samples resulted in a minimal final SDS-concentration of 1%. In agreement with 
the ELISA, no influence of the treatment solution on the in vitro competitive villous 
adhesion assay was noticed. Aggregate formation, as evidenced by turbidity, was 
however not increased (Table 1). 
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Figure 3 : Binding of the FaeG-specific MAb IMM01 with F4 fimbriae 
incubated for 5 minutes at 25°C or treated 30 minutes with 0.15 %, 0.5 %, 
1.5 % and 5 % SDS, followed by overnight dialysis against PBS. 
 
 
Figure 4 : Multimeric FaeG character of F4 fimbriae treated 30 minutes with 5 
% SDS (1), 1.5 % SDS (2), 0.5 % (3), 0.15 % (4) or incubated for 5 minutes at 
25°C (5) and both followed by overnight dialysis against PBS, determined in 
Western blot using the IMM01 MAb. M = molecular weight marker 
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Following incubation of F4 fimbriae at pH2 and 4, the turbidity increased, 
suggesting aggregation of proteins (Table 1). After dialysing these samples, aggregation 
disappeared and interaction of the treated F4 with the IMM01 MAb was identical as 
compared to native F4 fimbriae. Indeed, sigmoid OD405-curves were obtained in ELISA 
identical to those obtained with F4 fimbriae incubated at pH 7.4 (Fig. 5). Furthermore, 
FaeG multimerization was present with little more FaeG mono- and dimers and the 
bioactivity was only slightly decreased as compared to non-incubated purified F4 
fimbriae. These results suggest a reversible conformational change of F4 fimbriae in the 
presence of a low pH environment. In a subsequent experiment, F4 fimbriae were 
incubated at different pH in the presence of SDS at a concentration (0.05 %) that is not 
influencing characteristics of purified F4 fimbriae on its own. Following dialysis, samples 
of the pH2 SDS and the pH4 SDS conditions revealed linear instead of sigmoid OD405-
curves (Fig. 5), could only inhibit the binding of F4+ E. coli to the F4R by 15.7 ± 3.3 % 
and 24 ± 8.1 % respectively and showed reduced FaeG polymerisation (mono- to trimers 
and mono- to hexamers, respectively) as compared to non-incubated purified F4 fimbriae 
and the other pH conditions in the presence of 0.05 % SDS.  
 
0
0.5
1
1.5
2
2.5
0.0010.010.1110
µg/ml
0D405
pH2
pH4
pH6
pH2 SDS
pH4 SDS
pH6 SDS
pH7.4
 
Figure 5 : Binding of the FaeG-specific MAb IMM01 with F4 fimbriae incubated 
for 5 minutes at 25°C (pH7.4) or 30 minutes at pH2, pH4, pH6 in the 
presence/absence of 0.05 % SDS, both followed by overnight dialysis against PBS. 
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8.4. Discussion 
F4 fimbriae purified from the F4+ ETEC strain GIS26 seem to be very stable 
proteins since they retain their multimeric FaeG character and their F4R binding 
following incubation in the presence of 5 % (v/v) non-ionic detergents, 4 M urea or 
GuHCl and at temperatures up to 70°C. In agreement, treatment of F4ab fimbriae with 2 
M urea at 55°C is reported to remove all minor fimbrial subunits, but without dissociating 
and affecting the adhesive properties of the fimbriae (Oudega et al., 1989; Bakker et al., 
1992a). Also fimbriae of other bacteria are reported to be stable protein structures. For 
example, dissociation of type 1 pili requires 8.6 M GuHCl (Eshdat et al., 1981). In the 
present study, irreversibly reduced F4 bioactivity is observed following incubation with 
SDS at concentrations of 1.5 % or higher and at temperatures of 85 °C or higher. The 
high denaturation temperature of FaeG is associated with a high stabilizing Gibbs energy 
(Knörle and Hubner, 1995). However, the Yersinia pestis F1 capsular antigen is reported 
to dissociate after heating in the absence and presence of 0.1 % SDS, but to reassociate 
upon cooling and removal of SDS by dialysis against PBS, respectively (Miller et al., 
1998). This difference between F4 fimbriae and F1 antigen is probably due to structural 
differences and not due to a different multimerization mechanism. Indeed, the 
multimerization of FaeG subunits in F4 fimbriae as well as that of the non-fimbrial F1 
antigen, is mediated by the conserved chaperone-subunit pathway (Sauer et al., 2000; 
Zavialov et al., 2003b; Chapter 4).  
Exposure of type 1 pili to low pH does not affect the pili (McMichael and Ou, 
1979), but incubation of purified F4 fimbriae at low pH results in a reversible 
conformational change of fimbriae. In agreement, a number of research groups use this 
phenomenon as the basis for a method for purification of F4 fimbriae (Erickson et al., 
1994; Jin et al., 1998). However, this reversible conformational change became 
irreversible and stabilised in the presence of 0.05 % SDS, a concentration which did not 
affect the bioactivity at neutral pH. The addition of SDS itself is not harmful because 
samples were always dialyzed against PBS following treatment and no influence was 
observed in the analysis of control solutions. Furthermore, the results of Miller et al. 
Chapter 8 : Bioactivity of F4 correlates with monoclonal antibody binding 
139 
(1998) indicated that the bioactivity of F1 antigen can be altered following incubation 
with SDS, but can be restored following dialysis against PBS.  
The suggested conformational change of F4 fimbriae at low pH is probably not 
very detrimental for the fimbrial characteristics in vivo, since only very limited digestion 
of F4 fimbriae was observed following 2 h incubation in the presence of pepsin at pH 2 
(Snoeck et al, 2004a). In agreement, oral administration of purified F4 fimbriae can still 
immunize F4R+ pigs, indicating that the stomach is not destroying the binding capacity of 
F4 (Van den Broeck et al., 1999a en 1999b).  
 To develop an F4 fimbrial vaccine against F4+ ETEC-induced diarrhoea in post-
weaning piglet or to use the adhesin as a carrier molecule (Schembri et al., 1999), it is 
important to determine the bioactive-related characteristics of the F4 fimbrial adhesin 
FaeG in a specific and fast manner. Results of the present study reveal a correlation of 
FaeG bioactivity and binding of the FaeG-specific MAb IMM01, as no direct influences 
of the used treatment solutions on the ELISA or the in vitro competitive adhesion assay 
were observed. Therefore, reduced binding of the adhesin with its receptor and a reduced 
multimerization of FaeG adhesins seems to be correlated with altered interaction of the 
IMM01 MAb with FaeG.  However, this altered binding by IMM01 MAb upon antigen 
denaturation cannot be interpreted as an indication of complete antigen denaturation. It 
can only be considered as an indication that the conformational modifications that have 
occurred are important enough to disrupt the specific spatial arrangement necessary for 
antibody binding and bioactivity. The MAb IMM01 is able to block the binding of F4+ E. 
coli of the F4ab, F4ac and F4ad antigenic variants to the F4R (Van der Stede et al., 
unpublished data). Furthermore, the IMM01 MAb binds to fimbriae of more than 25 
haemolytic F4ac+ E. coli strains isolated from pigs with post-weaning diarrhoea 
(Verdonck et al, unpublished data). Thus, the epitope recognized by the IMM01 MAb is a 
conserved ‘a’-epitope present in all three different F4 antigenic variants.  
The interaction of FaeG with the F4R is not fully characterized, but both 
conserved and variable amino acids seem to contribute to the receptor-binding site 
(Bakker et al., 1992a). It is not clear if the receptor-binding site and the multimerization 
site are identical or located near to each other, as the protein structure of FaeG is not 
elucidated at the moment. Therefore, the present study cannot discriminate if the 
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observed reduction in binding of treated F4 fimbriae to the F4R is due to conformational 
changes in the receptor binding epitope or due to the reduced polymerisation of FaeG 
adhesins.  
 In conclusion, purified F4 fimbriae are very stable proteins but their bioactivity 
was observed to be reduced following incubation with SDS at concentrations of 1.5 % or 
higher, at temperatures of 85°C or higher and at pH 4 or lower. This reduced F4R-
binding and reduced FaeG multimerization of treated F4 fimbriae correlated with optical 
density determined in a newly developed ELISA using the FaeG-specific MAb IMM01. 
This assay will enable a fast, specific and sensitive in vitro selection for potent F4 or 
(r)FaeG antigen formulations, useful in an F4+ ETEC vaccine. 
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Bioactive recombinant F4 fimbrial adhesin FaeG 
monomers induce a fimbriae-specific immune response 
following oral immunization of piglets and function as 
mucosal carrier to an N-terminal fused peptide1 
 
 
                                                 
1 Based on : Verdonck F, Cox E, Van der Stede Y, Goddeeris BM. 2004a. Oral 
immunization of piglets with recombinant F4 fimbrial adhesin FaeG monomers induces a 
mucosal and systemic F4-specific immune response. Vaccine, in press. 
Chapter 9 : Bioactive rFaeG induces mucosal immune response 
 
142 
Abstract 
The importance of adhesins in the pathogenicity of several bacteria resulted in 
studies on their usefulness in vaccines. In this study, the gene of the F4(K88)-fimbrial 
adhesin FaeG of the pathogenic enterotoxigenic Escherichia coli (ETEC) strain GIS26 
was cloned in the pET30Ek-LIC vector and expressed with an N-terminal His- and S-tag 
in the cytoplasm of BL21(DE3). Recombinant FaeG (rFaeG) subunits were isolated from 
insoluble cytoplasmic aggregates and refolded into a native-like F4R-binding 
conformation. Indeed, the presence of conformational epitopes was shown by ELISA and 
the ability to bind the F4R was observed by inhibiting the adhesion of F4+ ETEC to F4R+ 
villi with increasing concentrations of native-like refolded rFaeG subunits. The rFaeG 
subunits appear as monomers, whereas the purified F4 fimbriae are multimers. Oral 
immunization of newly weaned piglets with native-like rFaeG induced a mucosal and 
systemic F4-specific immune response, significantly reducing F4+ E. coli excretion from 
2 till 5 days following challenge infection. However, improvement of stability and 
immunogenicity of rFaeG is necessary since a higher F4-specific response was obtained 
following immunization with purified F4 fimbriae. Furthermore, the presence of 
antibodies against the N-terminal fused His- and S-tag containing peptide support the use 
of (r)FaeG as a mucosal carrier.  
 
9.1. Introduction 
The importance of fimbriae as colonizing factors in the pathogenesis of ETEC 
induced diseases, led to the development of fimbriae-based vaccines. Rutter and Jones 
(1973) reported that parenteral vaccination of sows with fimbriae protected suckling 
piglets via passive lactogenic immunity. However, in the postweaning period, an active 
intestinal mucosal immune response is required. Since parenteral vaccination tends to 
stimulate the systemic rather than the mucosal immune system (Moon and Bunn, 1993; 
Bianchi et al., 1996; Van der Stede et al., 2003), it seems worthwhile to develop oral 
vaccines containing fimbriae that stimulate the intestinal mucosal immune system.  
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Van den Broeck et al. (1999a and 1999b) reported that oral immunization of 
weaned piglets with purified F4 fimbriae induced a protective FaeG-specific immune 
response in F4R+ piglets. On the other hand, purified F4 seemed to behave as a normal 
food antigen in F4R- pigs (Van den Broeck et al., 2002). In contrast to F4 fimbriae, oral 
immunization with most soluble antigens induces an immunohyporesponsive state, 
named oral tolerance (Strobel and Mowat, 1998; Stokes and Bailey, 2000). However, the 
conjugation of an antigen to a mucosal carrier molecule can result in the induction of an 
antigen-specific immune response (Holmgren et al., 1993; Foss and Murtaugh, 1999b; 
Ogra et al., 2001). 
The purpose of the present study was to determine whether recombinant FaeG 
(rFaeG) could be obtained in native-like conformation in the absence of the chaperone 
FaeE, allowing oral immunization of pigs and induction of an FaeG-specific immune 
response. In addition, it was analysed if rFaeG could be used as a mucosal carrier that is 
able to induce an immune response against an N-terminal fused heterologous peptide 
following oral immunization. 
 
9.2. Material and methods 
9.2.1. Bacterial inoculum  
The ETEC strain GIS26 (serotype O149:K91, F4ac+, LT+STa+STb+) was cultured 
during 18 h in Tryptone Soya Broth (Oxoid, Basingstoke, Hampshire, England) at 37°C 
and 85 rpm. The bacteria were collected by centrifugation and washed with phosphate-
buffered saline (PBS) (150mM, pH 7.4). The concentration of the bacteria was 
determined by measuring the optical density of 10-fold dilutions of the bacterial 
suspension at 660nm (OD660). An OD660 of 1 equals 109 viable bacteria/ml, as determined 
by counting colony-forming units. 
 
9.2.2. Purification of F4 fimbriae 
  F4 fimbriae were purified from an E. coli GIS26 bacterial suspension as described 
by Van den Broeck et al. (1999c). The purity of the purified F4 fimbriae was assessed 
using a Coomassie stained 15% SDS-PAGE and the ImageMaster 1D prime software 
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(Amersham Pharmacia Biotech, Belgium). The protein concentration of purified F4 
fimbriae was determined using the bicinchoninic acid reaction with bovine serum 
albumin (BSA) as a standard (ICN Biomedicals, Belgium), taking into account the purity 
of the purified F4 fimbriae. Furthermore, rFaeG or purified F4 fimbriae were identified 
by Western blot using the FaeG-specific MAb IMM01 (Van der Stede et al., 2002b) as 
described by Van den Broeck et al. (1999c). 
 
9.2.3. pETFaeG/7 construction  
faeG without its signal sequence was amplified from purified chromosomal DNA 
of strain GIS26 by the polymerase chain reaction (PCR), using the primers FaeGac Forw  
(5’-GACGACGACAAGATTGCACATGCCTGGATGACTGG-3’) and FaeGac Rev  (5’-
GAGGAGAAGCCCGGTAATAAATTGGCAGCTCATCACG-3’). The resulting 
product was purified (Quantum Prep PCR Kleen Spin Columns, BioRAD and made 
sticky by treating with T4 DNA polymerase (Promega, Madison, USA) in the presence of 
dATP. Subsequently, the sticky fragment was ligated in the pET-30 Ek/LIC vector 
(Novagen, Madison, USA) and transformed by heat shock in Nova Blue Singles 
competent cells (Novagen) according to the manufacturers instructions. The nucleotide 
sequence of purified plasmid (Midiprep, Qiagen) of the selected pETFaeG/7 clone was 
determined by the Sanger dideoxy chain termination method using the ABI PRISM Big 
DyeTM Terminator Cycle Sequencing Ready Reaction Kit (ABI) and the FaeGac and T7 
primer sets (T7 forward : TAATACGACTCACTATAGGG, T7 reverse: 
GCTAGTTATTGCGCGG), following the manufacturers protocol. After the cycle 
sequencing reaction, the products were sequenced on a 377 ABIPRISM automated DNA 
sequencer according to the manufacturers manual. The chromatograms of the sequences 
were visualised using the CHROMAS 2.0 software (Technelysium Ltd., Australia) and 
the DNA sequences were analysed using the DNAMAN version 5.0 (Lynnon Biosoft). 
Finally, BL21(DE3) host cells (Novagen) were transformed by heat shock with the 
selected construct pETFaeG/7. 
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9.2.4. rFaeG expression 
The rFaeG expressing BL21(DE3)[pETFaeG/7] E. coli were grown overnight in 
Luria broth (LB; Life Technologies, Paisley, Scotland) with 30 µg/ml kanamycin at 
28°C. Afterwards, the bacteria were diluted 100 times in fresh LB supplemented with 
kanamycin and incubated at 28°C, 200 rpm to an OD660 of 0,2 - 0,3. So, the bacteria 
could grow and the expression of rFaeG in the absence of induction was reduced. rFaeG 
expression was subsequently induced by adding 1mM isopropyl-β-D-thiogalactoside 
(IPTG, Sigma) to the cultures, which were further incubated during 4 hours at 37°C and 
200 rpm. 
 
9.2.5. Purification of different fractions of E. coli 
Spheroplasts of BL21(DE3)[pETFaeG/7] E. coli were prepared as described by 
Lindberg et al. (1989). In addition, the method described by Ausubel et al. (1989) was 
used to purify proteins from different fractions of E. coli. Briefly, 1010 induced bacteria 
were harvested by centrifugation at 10,000 x g for 10 min at 4°C. The resulting 
supernatant is the ‘medium fraction’. The pellet was resuspended in 30 ml Tris-HCl 
buffer (30 mM, pH 8) supplemented with 20% sucrose. Thereafter, EDTA was 
supplemented to a final concentration of 1 mM for 10 min at room temperature. The 
bacteria were collected by centrifugation at 10,000 x g and 4°C for 10 min. The pellet 
was resuspended in 30 ml ice-cold 5 mM MgSO4, shaken slowly for 10 min on ice and 
centrifugated again. The supernatant was the ‘periplasmic fraction’, the pellet contained 
the shocked cells and was resuspended for 15 min at 30°C in 4 ml of cold 20 mM Tris-
HCl pH 7.5, supplemented with 100 µg/ml lysozyme. Subsequently, the bacterial 
suspension was sonicated 20 seconds with power level 5, duty 50% (Vibra Cell, Sonics & 
Materials Inc., Danbury, Conneticut, USA) and centrifugated for 10 minutes by 14,000 x 
g at 4°C. The resulting supernatant was the ‘soluble cytoplasmatic fraction’, whereas the 
‘insoluble cytoplasmatic fraction’ (pellet) was washed twice with 20 mM Tris-HCl pH 
7.5 and finally resuspended in 1.5 ml Tris-HCl buffer containing 6M urea or PBS + 0.5 % 
SDS. Following overnight dialysis against PBS at 4°C, rFaeG of the urea- or SDS-
refolded insoluble cytoplasmic fraction (urea- and SDS-refolded rFaeG, respectively) was 
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used in tests to analyse its conformation or was used to immunize animals. The medium 
and periplasmic fraction were concentrated using saturated ammonium sulphate prior to 
SDS-PAGE. 
 
9.2.6. Determination of epitopes on rFaeG by ELISA 
An indirect ELISA was developed to determine the presence of different 
conformational epitopes on rFaeG. A 96-well microtiter plate (NUNC, Maxisorp Immuno 
Plates, Roskilde, Denmark) was coated with polyclonal F4-specific swine antibodies, 
optimally diluted in PBS. After 2 h incubation at 37°C, the remaining binding sites were 
blocked overnight at 4 °C with PBS supplemented with 0.2% (w/v) Tween®80. Then, the 
plates were incubated for 1 h at 37°C with serial two-fold dilutions of rFaeG, F4 fimbriae 
or heat-denaturated F4 fimbriae (5 min, 95°C) in ELISA dilution buffer (PBS + 0.05% 
(v/v) Tween®20 + 3% (w/v) BSA). Thereafter, optimal dilutions (determined in an assay 
with purified F4 fimbriae) of FaeG-specific MAb (IMM01, Van der Stede et al., 2002b; 
CVI-F4ac-5, CVI-F4ac-6 and CVI-F4ad-3, van Zijderveld et al. 1990) were added to the 
wells for 1 h at 37°C. Subsequently, rabbit anti-mouse HRP-conjugated serum (Dako, 
Denmark) optimally diluted (1/1000) in ELISA dilution buffer and supplemented with 
2% (v/v) pig serum was brought on the plate for 1 h at 37°C. An ABTS solution 
containing H2O2 was added and the optical density was spectrophotometrically measured 
at 405 nm (OD405). Between each incubation step, the plates were washed three times 
with ELISA washing buffer (PBS + 0.2% (v/v) Tween®20). 
 
9.2.7. In vitro villous adhesion assays 
The presence or absence of the F4R on the brush border of small intestinal 
enterocytes was determined on isolated intestinal villi as described by Van den Broeck et 
al. (1999c).   
The F4R-binding capacity of F4 fimbriae and rFaeG was analyzed by an in vitro 
competitive villous adhesion assay. Briefly, an average of 50 villi of F4R+ or F4R- pigs 
were incubated while gently shaking at room temperature with 800, 400, 200, 100, 50, 
25, 12.5 or 1.25 µg/ml F4 fimbriae or rFaeG together with 4 x 108 F4+ E. coli in a final 
volume of 0.5 ml. The suspension contained 1% (w/v) D-mannose (Fluka, Sigma-
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Aldrich, Bornem, Belgium) to prevent adhesion by type 1 pili. The adhesion of bacteria 
to villi was evaluated quantitatively by counting the number of bacteria adhering along a 
50 µm villous brush border at 20 randomly selected places by phase-contrast microscopy 
at a magnification of 600x. Then, the mean bacterial adhesion per 250 µm villous brush 
border was calculated. The percentage inhibition of adhesion was calculated for each 
sample by comparing with F4R+ villi incubated with only the F4+ E. coli.  
To demonstrate that rFaeG was responsible for the inhibition of adhesion of F4+ 
E. coli to F4R+ villi, 200 µg/ml SDS-refolded rFaeG was pre-incubated with 1 µg/ml of 
the c-epitope specific MAb CVI-F4ac-5 to block their adhesion to the F4R. After 
incubation with the F4R+ villi and washing, F4+ E. coli were added and the inhibition 
percentage was determined. Similarly, the inhibiting capacity of an irrelevant swine IgG-
specific MAb of the same isotype (clone 23.3.1b) (Van Zaane and Hulst, 1987) was 
tested at a concentration of 10 µg/ml as a control. 
Villi of three different F4R+ pigs were used and all analyses were performed in 
triplicate. F4R- villi of one pig served as negative control. These villi never bound F4+ 
ETEC. 
 
9.2.8. Oral immunization experiment 
Twenty-nine, F4R+ and F4-seronegative conventionally bred pigs (Belgian 
Landrace x Piétrain) were weaned at the age of 4 weeks, transported to the experimental 
facilities at the faculty and subsequently housed in isolation units where they obtained 
water and food at libitum. These piglets were treated orally with colistine (Promycine 
pulvis, VMD, Berendonk, Belgium, 150,000 U/kg of body weight/day) from 2 days 
before till 3 days after weaning to prevent E. coli infections due to transport and handling.  
One week post weaning, thirty-two pigs were orally given 20 mg rabeprazolum 
(Pariet, Janssen-Cilag, Berchem, Belgium) on 3 consecutive days and again 15 days post 
primary immunization (dppi) to neutralize the acidic gastric pH and thus reducing the 
possible alteration of fimbrial antigens during exposure to the low pH (Snoeck et al., 
2004a). Twenty-four hours following each rabeprazolum ingestion (0, 1, 2 and 16 dppi), 
the pigs were orally immunized with 2 mg purified F4 fimbriae (F4 group, n=10) or 8 mg 
SDS-refolded rFaeG (rFaeG (SDS) group, n=9) in 10 ml PBS. Three animals were orally 
Chapter 9 : Bioactive rFaeG induces mucosal immune response 
 
148 
immunized with 8 mg urea-refolded rFaeG (rFaeG (urea) group, n=3) in 10 ml PBS with 
2M urea to reduce the formation of rFaeG aggregates. Ten animals received PBS (PBS 
group) and served as negative control. Three hours before till 2 h after gastric pH 
neutralization or immunization, each animal was deprived of food and water. 
One week following the booster immunization (23 dppi), the local mucosal F4-
specific immune response was analysed in two pigs of the F4, the rFaeG (SDS) and the 
PBS groups and in all three pigs of the rFaeG (urea) group by enumerating the F4-
specific IgA, IgG and IgM antibody-secreting cells (ASCs) in mesenteric lymph nodes 
(MLN), jejunal and ileal Peyer’s patches (JPP and IPP) and jejunal lamina propria (LP). 
In addition, F4-specific IgA and IgM antibodies were determined in duodenal, jejunal and 
ileal contents. Tissues and intestinal content were sampled following euthanasia of 
animals by intravenous injection of pentobarbital (24 mg/kg; Nembutal, Sanofi Santé 
Animale, Brussels, Belgium) and subsequent exsanguination. The remaining animals 
were orally challenged with the virulent F4+ ETEC strain GIS26 as previously described 
(Cox et al., 1991) with minor modifications. Briefly, pigs were orally pre-treated at 21 
and 22 dppi with 300 mg florfenicol (Nuflor, Schering-Plough, Brussels, Belgium) to 
decrease colonization resistance. At 24 dppi, pigs were sedated with Stressnil (40 mg/ml; 
Janssen-Cilag, Berchem, Belgium), after which the gastric pH was neutralized by 
intragastrical administration of 62 ml NaHCO3 (1.4% (w/v) in distilled water). Fifteen to 
thirty min later, 1010 F4+ ETEC in 10 ml PBS was given intragastrically. Faecal samples 
were taken daily for determining the excretion of F4+ ETEC from challenge till 7 days 
post challenge (31 dppi). Furthermore, FaeG-specific serum IgA, IgG and IgM were 
determined 0, 7, 16, 24, 27, 31, 37 and 45 dppi. Three weeks following challenge (45 
dppi), the remaining pigs were euthanatised. Jejunal villi were isolated of all euthanatised 
pigs to confirm the presence of F4R as described by Van den Broeck et al. (1999c).  
 
9.2.9. Samples 
Serum and contents of duodenum, jejunum and ileum were sampled as described 
by Van den Broeck et al. (1999a) and Verdonck et al. (Chapter 5), respectively.  
F4+ E. coli were enumerated in faecal samples by dot blotting using the FaeG-
specific MAb IMM01 as previously described (Van den Broeck et al., 1999b). The 
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resulting brown-red dots were counted and the average within each group was calculated. 
Results are presented as the mean number ± standard error of the mean (SEM) of 
excreted E. coli per gram faeces.   
At the moment of slaughter, mesenteric (jejunal and ileal) lymph nodes, a mid 
jejunal intestinal segment without Peyer’s patches, and jejunal and ileal intestinal 
segments with Peyer’s patches were sampled. Subsequently, monomorphonuclear cells 
(MC) were isolated as described by Verdonck et al. (chapter 5) and finally resuspended at 
106 cells/ml.  
 
9.2.10. ELISA for FaeG-specific IgM, IgA and IgG 
For detection of FaeG-specific antibodies, the indirect ELISA described by Van 
den Broeck et al. (1999a) was used. The IgM, IgA and IgG cut-off values were calculated 
as the mean OD405-value of all sera (dilution 1/10) at day 0, increased with 3 times the 
standard deviation. In case of intestinal contents, the IgA and IgM cut-off values were 
calculated as the OD405-value of the dilution buffer, increased with 3 times the standard 
deviation. The antibody titer was the inverse of the highest dilution that still had an OD405 
higher than the calculated cut-off value. 
 
9.2.11. Elispot assays for FaeG-specific IgM, IgA and IgG ASCs 
FaeG-specific IgM, IgA and IgG ASCs were detected as described by Van den 
Broeck et al. (1999a). For each MC suspension, spots in 5 wells (105 MC/well) were 
counted to obtain the number of isotype-specific ASCs per 5 x 105 MC. Results are 
presented as the mean number of ASCs per 106 MC ± SEM. 
 
9.2.12. Analysis of His- and S-tag-specific antibodies 
To analyse the usefulness of rFaeG as mucosal carrier molecule, the presence of 
His- and S-tag-specific antibodies was determined in serum at 24 dppi using the His-S-
SctW fusion protein (Geens et al., unpublished data) that was kindly provided by Tom 
Geens et al. (Ghent University). The His-S-SctW protein is encoded by pET-HTSctW 
that is obtained from ligation of the Chlamydia psittaci type III secretion protein SctW in 
the pET-30 Ek/LIC vector. The His-S-tag fragment was cleaved from SctW using 
Chapter 9 : Bioactive rFaeG induces mucosal immune response 
 
150 
enterokinase (Sigma) according to the manufacturers instructions. Thereafter, the His-S-
tag-fragment and SctW were separated using a 10% SDS-PAGE and blotted onto a 
polyvinylidene fluoride membrane as described by Van den Broeck et al. (1999c). 
Following overnight blocking, the membranes were firstly incubated with undiluted 
serum samples, secondly with peroxidase-conjugated rabbit-anti-swine polyclonal 
antibodies (Dako, Denmark) and thirdly with a 3-amino-9-ethylcarbazole containing 
substrate solution to visualize binding of the conjugate in accordance to the procedure 
described by Van den Broeck et al. (1999c).  
 
9.2.13. Statistical analysis 
Statistical analysis (SPSS 10.0 for Windows) of serum antibody titers and F4+ E. 
coli excretion (log-values) was done using General Linear Model (Repeated Measures 
Analysis of Variance), adjusting for multiple comparison by Bonferoni. P < 0.05 was 
considered as statistically significant. 
 
9.3. Results  
9.3.1. Expression of rFaeG 
Since high yield expression of several recombinant proteins in the cytoplasm of E. 
coli are reported (Makrides, 1996), faeG from the pathogenic F4+ ETEC strain GIS26 
was cloned in the pET-30 Ek/LIC vector without its signal sequence to obtain expression 
in the cytoplasm of BL21(DE3). The cytoplasm allows extensive protein accumulation 
and the more reducing environment as compared to the periplasm was not expected to be 
harmful because FaeG does not contain disulfide bounds (Cornelis, 2000). rFaeG has a 
molecular weight of 32 kDa due to the presence of N-terminal His- and S-tag, whereas 
native FaeG is 27 kDa. As shown in Figure 1, rFaeG was found in the pellet fraction of 
induced BL21(DE3)[pET-FaeG/7] spheroplasts, and not in the supernatant containing the 
periplasmic proteins. Indeed, immunoblotting of proteins from the soluble and insoluble 
cytoplasmic fractions of induced BL21(DE3)[pET-FaeG/7] using the FaeG-specific MAb 
IMM01, indicated that rFaeG was expressed in the cytoplasm, but only in an insoluble 
form. Approximately 95 mg rFaeG was obtained following purification of the insoluble 
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cytoplasmic fraction of 1012 induced bacteria, with a purity of 90-94%. On the other 
hand, mechanical sharing of the same amount of GIS26 resulted in a protein mixture 
containing 1.7 mg F4 fimbriae with a purity of 75% (Van den Broeck et al., 1999c). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 : Coomassie stained SDS-PAGE of isolated fractions of induced 
BL21(DE3)[pETFaeG/7] : heat denaturated purified F4 fimbriae of GIS26 (lane 1), 
supernatant of spheroplast preparation (lane 2), pellet of spheroplast preparation (lane 3), 
molecular weight marker (lane 4), insoluble cytoplasmic fraction (lane 5), soluble 
cytoplasmic fraction (lane 6). Native FaeG (white arrow), rFaeG (black arrow). 
 
9.3.2. Optimalisation of rFaeG folding 
Purification and folding of rFaeG were optimised using an ELISA based on the 
FaeG-specific MAb IMM01 (Chapter 8). The epitope recognized by IMM01 is not 
defined but adhesion of F4+ ETEC to F4R+ villi is inhibited by IMM01 (Y. Van der 
Stede, unpublished data). Figure 2 shows that serial dilutions of heat-denaturated and 
native fimbriae, resulted in non-parallel OD405-lines. This must be due to a difference in 
affinity of F4 fimbriae and heat-denaturated F4 fimbriae for IMM01. Refolding of rFaeG 
using SDS resulted in a conformational structure that reacted similarly in this ELISA with 
IMM01 as native purified F4 fimbriae (parallel slopes, Fig. 2). However, to obtain 
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identical OD405 values, the protein concentration of rFaeG had to be 75 times higher than 
the F4 fimbriae concentration. This great difference between rFaeG and F4 fimbriae is 
probably an overestimation due to a higher signal for multimers than for monomers in the 
used ELISA. In contrast, refolding of rFaeG using urea did not result in OD405-lines 
parallel to this of native F4 fimbriae and removal of the denaturating agent caused 
aggregation of the rFaeG. Also the use of guanidine hydrochloride (GuHCl), non-ionic 
detergents (Tween, Triton-X-100), sonication or altered pH (pH 2 till 10) was not 
successful in refolding rFaeG and is therefore not discussed further. Furthermore, the 
SDS-refolded rFaeG as well as purified F4 fimbriae bound the c-, a6- and a7-specific 
MAb’s (CVI-F4ac-5, CVI-F4ac-6 and CVI-F4ad-3), whereas urea-refolded rFaeG did 
not. The fimbrial c epitope is reported to constitute at least partially the F4ac receptor-
binding site (Bakker et al., 1992a). 
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Figure 2 : OD405-lines represent the interaction of the FaeG-specific monoclonal 
antibody IMM01 with purified F4, heat-denaturated purified F4 fimbriae, SDS- 
or urea-refolded rFaeG. 
 
The ability of rFaeG monomers to bind the F4R was evaluated in a competitive 
villous adhesion assay. Intestinal villi of F4R+ pigs were incubated with different 
concentrations of F4 fimbriae or rFaeG and with 4.108 F4+ ETEC. A concentration 
dependent inhibition of F4+ ETEC adhesion to the F4R for both SDS-refolded rFaeG and 
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F4 fimbriae was observed (Fig. 3). However, 94.7 ± 4.93 % inhibition was obtained at a 
concentration of 800 µg/ml rFaeG, whereas 200 µg/ml F4 fimbriae already resulted in 
97.7 ± 3.21 % inhibition. In contrast, heat-denaturated F4 fimbriae and rFaeG refolded 
using urea, GuHCl, non-ionic detergents, sonication or altered pH were not inhibiting F4+ 
ETEC binding to F4R+ villi.  
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Figure 3 : Percentage inhibition of F4+ ETEC adhesion to F4R+ intestinal villi by 
competition with purified F4 fimbriae and SDS-refolded rFaeG. 
 
Preincubation of SDS-refolded rFaeG with MAb CVI F4ac-5, decreased the 
inhibition of F4+ ETEC adhesion from 37 % to 5.2 ± 4.1 %, indicating that the inhibition 
of adhesion is due to binding of rFaeG to the F4R. Indeed, pre-incubation with an 
irrelevant MAb had no effect (32 % adhesion). 
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9.3.3. rFaeG monomers  
As expected, rFaeG was only found as monomers in Western blot using the 
IMM01 MAb. Conversely, a ladder pattern consisting of FaeG multimers was observed 
when F4 fimbriae were not heat-denaturated (Fig. 4). The polymeric FaeG structure of F4 
fimbriae disintegrated into its FaeG monomers following heat-denaturation in the 
presence of SDS. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 : Western blot of purified F4 fimbriae and SDS-refolded rFaeG using the 
FaeG-specific monoclonal antibody IMM01 : molecular weight marker (lane 1), 
purified F4 fimbriae (lane 2), heat-denaturated purified F4 fimbriae (lane 3), rFaeG 
(lane 4), heat-denaturated rFaeG (lane 5). 
 
9.3.4. Oral immunization with rFaeG and challenge infection 
The capacity of rFaeG to induce an FaeG-specific mucosal immune response 
upon oral administration to newly-weaned piglets was determined. Based on the in vitro 
inhibition assays wherein four times more SDS-refolded rFaeG than F4 fimbriae was 
needed to inhibit the adhesion of F4+ ETEC to the F4R, a four times higher dose of rFaeG 
(8 mg) was used than F4 fimbriae (2 mg) to immunize the animals.  
From 7 and 16 dppi onwards, FaeG-specific IgM, IgG and IgA antibodies were 
detected in the F4 group and the rFaeG (SDS) group respectively, whereas no antibodies 
were observed in the PBS group (Fig. 5). The F4 immunization induced the highest 
response with all titers significantly higher (p≤0.017) 16 and 24 dppi as compared to the 
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response with all titers significantly higher (p≤0.017) 16 and 24 dppi as compared to the
PBS group and the IgM titer at 16 dpi (p=0.002) as well as the IgA titer at 16 (p=0.012)
and 24 dppi (p=0.002) significantly higher than for the rFaeG (SDS) group. The SDS-
refolded rFaeG immunization induced a weak antibody response and was only
significantly higher (p=0.017) for IgM at 24 dppi in comparison with the PBS group,
whereas urea-rFaeG immunization induced no FaeG-specific antibodies.
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Figure 5 : Mean FaeG-specific IgM, IgA and IgG serum antibody titers (± SEM) of weaned pigs immunized
with PBS, SDS-refolded rFaeG or purified F4 fimbriae at 0, 7, 16, 24, 27, 31, 37 and 45 days post primary
immunization (dppi). Significant difference (p<0.05) between PBS and rFaeG (a), between PBS and F4
group (b) and between rFaeG and F4 (c). Black arrow, immunization; white arrow, F4+ ETEC challenge.
Chapter 9 : Bioactive rFaeG induces mucosal immune response
156
Figure 6 : Mean FaeG-specific IgM, IgA and IgG ASCs per 106 MC in ileal Peyer’s patches
(IPP), jejunal Peyer’s patches (JPP), lamina propria (LP) and mesenteric lymph nodes (MLN) of
weaned pigs immunized with PBS (n=2), SDS-refolded rFaeG (n=2), urea refolded rFaeG (n=3)
or purified F4 fimbriae (n=2) at 23 dppi.
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One day before the challenge infection, the mucosal FaeG-specific immune 
response was analysed by determining the number of FaeG-specific IgA, IgG and IgM 
ASCs in MLN, JPP, IPP and LP and the presence of FaeG-specific IgA and IgM in 
intestinal contents of three piglets of the rFaeG (urea) group and two piglets of the F4, 
PBS and rFaeG (SDS) groups. As shown in Figure 6, IgA and IgM FaeG-specific ASCs 
were detected in all four tissues of piglets from the F4 and the rFaeG (SDS) groups, 
whereas a background signal of two FaeG-specific IgM ASCs per 106 MC was observed 
in the IPP of one piglet from the PBS group. However, the numbers of IgA and IgM 
FaeG-specific ASCs found in JPP, LP and MLN of the F4 group were higher (twice or 
more) than in the rFaeG group whereas IPP showed similar low numbers for both groups. 
On the other hand, FaeG-specific IgG ASCs were only clearly detected in JPP (22 and 16 
per 106 MC) and MLN (18 and 12 per 106 MC) of the F4 immunized piglets. No FaeG-
specific ASCs were found in the rFaeG (urea) group. 
In agreement with these results, FaeG-specific IgA and IgM were observed in 
small intestinal contents of rFaeG (SDS) as well as of F4 immunized piglets, with the 
highest titers in the F4 group (Table 1). These results indicate that oral immunization of 
pigs with rFaeG in an F4R-binding conformation induces an FaeG-specific mucosal 
antibody response, which is weaker than the immunization with F4 fimbriae.  
 
Table 1: FaeG-specific IgM and IgA titers in contents of the duodenum, jejunum, and 
ileum of weaned pigs immunized with PBS (n=2), SDS-refolded rFaeG (n=2), urea- 
refolded rFaeG (n=3) or purified F4 fimbriae (n=2) at 23 dppi.  
   
IgM 
      
IgA 
     
   
duodenum 
 
jejunum
 
ileum 
  
duodenum
 
jejunum 
 
ileum 
 
PBS <2 <2 ND  <2 <2 ND 
   ND <2 <2  ND 2 <2 
rFaeG (SDS) 2 32 <2  <2 32 <2 
   ND 16 32  ND 16 16 
rFaeG (urea) <2 <2 <2  <2 <2 <2 
 <2 <2 <2  <2 <2 <2 
   ND <2 <2  ND <2 <2 
F4 128 256 <2  64 128 64 
   ND 128 <2  ND 512 128 
        ND = not determined 
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To see if this response provided protection against an F4+ ETEC infection, piglets
of the PBS, F4 and rFaeG (SDS) groups were challenged 24 dppi with the F4+ ETEC
strain GIS26 and excretion of F4+ E. coli was daily analysed from 1 till 7 days post
challenge (dpc) (Fig. 7). In the rFaeG (SDS) group, F4+ E. coli excretion was detected till
3 dpc, whereas excretion in the PBS control group lasted till 6 dpc and was significantly
higher (p≤0.003) as compared to the rFaeG (SDS) group from 2 till 5 dpc. However, the
F4+ ETEC excretion in the rFaeG (SDS) group was significantly higher (p<0.001) than in
the F4 group 1 and 2 dpc. Indeed, immunization of weaned piglets with purified F4
resulted in protection against infection as only a low amount of F4+ E. coli (1.34 log10
F4+ E. coli per g faeces) was excreted 1 dpc.
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Figure 7 : Mean faecal F4+ E. coli (log 10) per gram faeces (± SEM) following F4+
ETEC challenge of weaned pigs immunized with PBS (n=8), SDS-refolded rFaeG
(n=7) or purified F4 fimbriae (n=8) at 0 to 7 days post challenge (dpc). Significant
difference (p<0.05) between PBS and rFaeG (a), between PBS and F4 group (b)
and between rFaeG and F4 (c).
The protection in the F4 group and the absence of protection in the PBS group
were reflected in their serum antibody responses. Upon challenge, the PBS group (Fig. 5)
showed a primary systemic FaeG-specific response with relatively high IgM titers
peaking 14 dpc, at the same time as the IgG and IgA titers (5.72 and 5.97, respectively).
In contrast, the F4 group did not show an antibody boost response after challenge : IgM
and IgA decreased and IgG did not change much. In the rFaeG (SDS) group, the boost
response upon challenge was also missing, as observed in the F4 group. Thus, the
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infection in the F4 and the rFaeG (SDS) group was not able to induce a secondary 
response, confirming the lack of colonization and multiplication by F4+ E. coli.  
 
9.3.5. The use of rFaeG as mucosal carrier 
To explore the usefulness of SDS-refolded rFaeG as mucosal carrier molecule, the 
presence of His-S-tag-specific antibodies was analysed in serum of two animals per 
group at 24 dppi. As shown in Figure 8, serum of SDS-refolded rFaeG immunized piglets 
bound to the His-S-SctW fusion protein but not to the SctW. Serum samples of F4 
immunized piglets and PBS control piglets did not react with His-S-SctW or SctW, 
whereas His-S-SctW-specific control serum bound to both proteins. Therefore, we 
suggest that SDS-refolded rFaeG can be used as a mucosal carrier molecule to induce an 
immune response against a fused heterologous antigen following oral immunization with 
the fusion protein. 
 
 
 
 
 
 
      Figure 8 
 
 
 
 
 
 
 
 
 
 
Figure 8 : Western blot of enterokinase digest from His-S-SctW using His-S-
SctW-specific control serum (lane 1), serum of pig immunized with SDS-
refolded rFaeG (lane 2) or purified F4 fimbriae (lane 3) or serum of a PBS 
control pig (lane 4). Black arrow : His-S-SctW protein (47.4 kDa); White 
arrow : SctW protein (43 kDa). 
   1         2          3         4
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9.4. Discussion 
The importance of adhesins in the pathogenicity of several bacteria resulted in 
studies on their usefulness in vaccines (Langermann et al., 1997 and 2000; Thankavel et 
al., 1997; Barnhart et al., 2000). Recently, oral immunization with recombinant 
pneumococcal surface adhesin A (rPSA) of Streptococcus pneumoniae induced systemic 
and mucosal rSPA-specific antibody responses, suggesting the utility of recombinant 
adhesins for mucosal immunizations (Seo et al., 2002). The present study reports the 
induction of a fimbriae-specific as well as a heterologous-antigen specific immune 
response following oral immunization of piglets with the SDS-refolded rFaeG fimbrial 
adhesin containing an N-terminal His- and S-tag peptide.  
The adhesin FaeG of the pathogenic F4+ ETEC strain GIS26 was cloned and 
expressed in the cytoplasm of BL21(DE3). Purification of cytoplasmic rFaeG inclusion 
bodies in denaturating conditions resulted mostly in aggregation of rFaeG during 
refolding or removal of the denaturating agents. Similarly, high level expression of the 
type 1 fimbrial adhesin FimH and the P-pili adhesin PapG, resulted in inclusion bodies in 
the cytoplasm and in aggregation when the denaturant urea was removed by dialysis 
(Kariyawasam et al., 2002). X-ray diffractions of type 1- and P-pili subunits revealed an 
immunoglobulin-like domain, but lacking the C-terminal β-strand. However, the groove 
along the surface of these subunits is filled by a β-strand of the chaperone in the 
periplasm or by a β-strand of a subunit in the fimbriae (Choudhury et al., 1999; Sauer et 
al., 1999). The conformation of the F4 fimbrial adhesin FaeG and the chaperone FaeE are 
not known at the moment, but sequence alignment with other fimbrial subunits and 
chaperones suggest a similar interaction. Therefore, a hydrophobic core of rFaeG could 
have caused the aggregation during refolding. 
The capacity of rFaeG to successfully assemble in a native-like receptor binding 
conformation in the presence of SDS was somewhat surprising since SDS is a known 
denaturating agent. However, FaeG and FimH subunits eluted from a SDS-
polyacrylamide gel were reported to bind the F4R and mannose respectively (Van den 
Broeck et al., 1999c; Tewari et al., 1993). In addition, several recombinant proteins with 
a high hydrophobic character or a high tendency to aggregate were also successfully 
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refolded in the presence of SDS (Juri et al., 2001; Niebla et al., 2001; Ohnishi and 
Kameyama, 2001; Tsetlin et al., 2002). Perhaps, the masking of hydrophobic protein 
interfaces by detergent molecules may explain the reduced aggregation (Schrooyen et al., 
2001).  
The SDS-refolded rFaeG appeared a good candidate vaccine against F4+ ETEC 
infections since it was able to bind to the F4R and to induce in rabbit antibodies, which 
could inhibit F4+ E. coli adhesion (data not shown). The conformation of the refolded 
rFaeG is important to bind the F4R and to induce a FaeG-specific immune response since 
FaeG-specific ASCs were detected in intestinal lymphoid tissues of piglets immunized 
with SDS-refolded rFaeG, but not with urea-refolded rFaeG. This result confirms the 
need for receptor-binding to induce an FaeG-specific immune response following oral 
immunization (Van den Broeck et al., 1999c).  
Piglets immunized with SDS-refolded rFaeG showed a FaeG-specific systemic 
and mucosal antibody response that significantly reduced the F4+ E. coli excretion from 2 
till 5 days following challenge infection. However, rFaeG immunization did not prevent 
infection as the F4 immunization did. Indeed, F4 immunized pigs excreted only few F4+ 
E. coli on 1 dpc, probably some remainder of the orally inoculated F4+ E. coli and 
showed higher serum and mucosal antibody responses than the rFaeG immunized pigs. It 
is important to note that it did not matter whether rFaeG or purified F4 fimbriae was used 
in the ELISA, as similar titers were obtained.  
The observed difference in the FaeG-specific immune response following oral 
immunization with F4 fimbriae versus SDS-refolded rFaeG can be multifactorial. Firstly, 
N-terminal fusion of the His- and S-tag to rFaeG is probably not favourable to form 
rFaeG polymers since the N-terminal strand of Fim and Pap subunits is reported to 
contribute in subunit-subunit interactions (Sauer et al., 1999, Choudhury et al., 1999). 
Indeed, rFaeG was shown to appear as monomers whereas purified F4 fimbriae have 
polymeric structures mainly composed of FaeG subunits (Bakker et al., 1992a). At the 
moment, differences in the interaction of monomeric versus polymeric E. coli adhesins 
with their receptor were not analysed and a number of questions remain. However, in the 
case of Porphyromonas gingivalis, the inhibitory effect of recombinant major subunit 
monomers on binding of the bacteria to their receptor is higher than that of the purified 
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native fimbriae on a molar basis (Sharma et al., 1993). On the other hand, it is well 
known that multimeric structures are more immunogenic as compared to monomers 
(Jackson et al., 1997). 
Secondly, the stability of SDS-refolded rFaeG is probably low since storage is 
best at 4°C and activity was found to decrease over time (>50% reduction after 72 h). 
Similarly, the lectin and pilin domain of FimH can both fold chaperone independently, 
but the thermodynamic stability of the pilin domain is very low and leads to unfolding of 
the pilin domain even in the absence of denaturant (Vetsch et al., 2002). However, the 
piglets were treated with rabeprazolum to neutralize the gastric pH at the moment of 
immunization, in order to prevent effects resulting from differences in resistance to low 
pH and proteolytic degradation between rFaeG and purified F4. 
Fimbriae have been used to display heterologous peptides because of their strong 
immunogenicity, strong adhesive properties and ease of purification (Klemm and 
Schembri, 2000). Unfortunately, the inserted peptides had to be short and the constructed 
F4 fimbriae lost their receptor-binding epitope (Thiry et al., 1989; Bakker et al., 1990). In 
contrast, the results of the present study indicate that a N-terminal fusion with a His- and 
S-tag containing 4.8 kDa peptide sequence to FaeG was not detrimental for its binding to 
the F4R. Moreover, the presence of antibodies against this His-S-tag peptide suggest that 
rFaeG can be used as mucosal carrier to induce an immune response against N-terminal 
fused peptides. In agreement, the major subunit ClpG of the F4-related CS31A fimbriae 
was coupled to peptides containing all or part of the E. coli human heat-stable enterotoxin 
(STh), by fusing the STh-encoding DNA sequence to the 5’ or 3’ extremity of the clpG 
gene. These ClpG-STh subunits were exported efficiently but none formed hybrid 
CS31A-STh fimbriae at the cell surface of E. coli (Batisson et al., 2000a and 2000b). 
However, the potential of rFaeG or other fimbrial adhesins to function as a mucosal 
carrier to antigens remains to be confirmed. 
  In conclusion, rFaeG can be produced in a correct bioactive form which is, by oral 
immunization, able to partly protect piglets against F4+ ETEC infection and functions as 
mucosal carrier to an N-terminal fused peptide. This opens new perspectives to 
simultaneously immunize pigs against F4+ ETEC infections and other intestinal 
pathogens. However, improvement of the stability and immunogenicity of rFaeG must be 
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considered since immunization with purified F4 fimbriae resulted in a more robust FaeG-
specific response. 
 
 
 
  
 
 
 
Chapter 10 
 
Mucosal carrier potential of recombinant F4 fimbrial 
adhesin FaeG is significantly improved following oral 
co-administration with cholera toxin in pigs1 
 
 
                                                 
1 Based on :Verdonck F, Snoeck V, Goddeeris BM, Cox E. Mucosal carrier potential 
of recombinant F4 fimbrial adhesin FaeG is significantly improved following oral co-
administration with cholera toxin in pigs. Submitted. 
Chapter 10 : CT improves mucosal carrier potential of rFaeG 
 
166 
Abstract 
Oral immunization of both humans and animals with non-replicating soluble 
antigens often results in the induction of oral tolerance. However, receptor-dependent 
uptake of orally administered soluble antigens can lead to the induction of an antigen-
specific immune response. Indeed, oral immunization of pigs with recombinant FaeG 
(rFaeG), the adhesin of the F4(K88) fimbriae of enterotoxigenic E. coli, induces an F-
specific humoral and cellular immune response. This response is accompagnied with a 
reduction in the excretion of F4+ enterotoxigenic Escherichia coli (ETEC) following 
challenge. In addition, rFaeG has the potential to function as a mucosal carrier since 
oral immunization of pigs with rFaeG induces antibodies against an N-terminally 
fused His- and S-tag. To improve the immune response against FaeG and the carried 
peptide, rFaeG was orally co-administered with the mucosal adjuvant cholera toxin 
(CT). Oral immunization of pigs with rFaeG and CT significantly enhanced the 
immune response against the peptide since significantly higher His-S-tag-specific 
antibodies were detected. In addition, the co-administration significantly improved the 
F4-specific humoral and cellular immune response and significantly reduced the fecal 
F4+ E. coli excretion following challenge infection as compared to rFaeG-immunized 
pigs. In conclusion, the results of the present study suggest that fimbrial adhesins can 
be used as a mucosal carrier for inducing an immune response against antigens, which 
normally are not immunogenic.  
 
10.1. Introduction 
 
The induction of an antigen-specific mucosal antibody response is needed to 
protect both humans and animals against an intestinal infection (Porter et al., 1974; 
Bloom and Boedeker, 1996). However, oral administration of most non-replicating 
antigens (e.g. food antigens) results in oral tolerance (Strobel and Mowat, 1998). One 
of the exceptions is the oral immunization of F4-receptor positive (F4R+) pigs with F4 
fimbriae, which induces a protective FaeG-specific intestinal antibody response (Van 
den Broeck et al., 1999b). In F4R- pigs, F4 fimbriae act as a normal food antigen (Van 
den Broeck et al., 2002). We recently demonstrated that this unique F4R-based uptake 
of antigen can be used to induce an antibody response against a heterologous peptide 
that is fused to the N-terminus of the F4 fimbrial adhesin FaeG (Chapter 9). On the 
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other hand, the FaeG-specific response was weaker following oral immunization with 
rFaeG than with purified F4, resulting in a decreased protection against an F4+ ETEC 
challenge. 
The interest of the present study was to improve the FaeG- and heterologous-
specific immune response following co-administration of rFaeG with the mucosal 
adjuvant cholera toxin (CT) (Ogra et al., 2001), since this rFaeG carrier system could 
open new perspectives to simultaneously induce a mucosal immune response against 
FaeG and against antigens of other enteropathogens. In mice, CT enhances co-
stimulation (Cong et al., 1997) and promotes Th2 cytokine responses with induction 
of antigen-specific serum IgG and mucosal IgA (Marinaro et al., 1995). In pigs, the 
oral administration of CT is non-toxic at an oral dose of 100 µg and is reported to 
enhance the induction of an antigen-specific immune response to co-administered 
antigens that are targeted to the gut-associated lymphoid tissue by coupling to CT-B 
(Foss and Murtaugh, 1999a). However, there is no information whether oral co-
administration of an antigen and CT, without conjugation of the antigen to CT or its 
B-subunit, improves the antigen-specific immune response in pigs. 
In the present study, it was determined if the use of CT could improve the 
induction of an immune response against the FaeG carrier as well as against the N-
terminal fused His-S-tag peptide following oral co-administration of newly weaned 
pigs with rFaeG.  
 
10.2. Material and methods 
10.2.1. Bacterial inoculum  
The ETEC strain GIS26 (serotype O149:K91, F4ac+, LT+STa+STb+) was 
cultured during 18 h in Tryptone Soya Broth (Oxoid, Basingstoke, Hampshire, 
England) at 37°C and 85 rpm. The bacteria were collected by centrifugation and 
washed with phosphate-buffered saline (PBS) (150mM, pH 7.4). The concentration of 
the bacteria was determined by measuring the optical density of 10-fold dilutions of 
the bacterial suspension at 660nm (OD660). An OD660 of 1 equals 109 viable 
bacteria/ml, as determined by counting colony-forming units. 
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10.2.2. Purification of F4 fimbriae 
F4 fimbriae were purified as described by Van den Broeck et al. (1999c). 
These fimbriae were used in the FaeG-specific antibody ELISA. Isolated F4 fimbriae 
were also further purified by anion exchange chromatography (AEC) using a Bio-
Scale Q5 column (BIORAD, Eke, Belgium) (indicated as AEC purified F4), 
subsequently sterilised by filtration through an 0.2 µm filter and used to induce F4-
specific proliferation. The percent purity of the isolated F4 and the AEC purified F4 
fimbriae was assessed using a Coomassie stained 15% SDS-PAGE and the 
ImageMaster 1D prime software (Amersham Pharmacia Biotech, Belgium). The F4 
fimbrial protein concentration was calculated from the total protein concentration as 
determined using the bicinchoninic acid (BCA) reaction with bovine serum albumin 
(BSA) as standard (ICN Biomedicals, Belgium) and taking into account the 
percentage of F4 fimbriae on the total protein concentration. 
 
10.2.3. rFaeG expression and refolding 
Recombinant FaeG (rFaeG) containing an N-terminal fused His- and S-tag 
was expressed and refolded as described in chapter 9. Briefly, 
BL21(DE3)[pETFaeG/7] E. coli were grown overnight in Luria broth (LB; Life 
Technologies, Paisley, Scotland) with 30 µg/ml kanamycin at 28°C. Afterwards, the 
bacteria were diluted 100 times in fresh LB supplemented with kanamycin and 
incubated at 28°C, 200 rpm to an OD660 of 0.2 – 0.3. rFaeG expression was 
subsequently induced by adding 1mM isopropyl-β-D-thiogalactoside (IPTG, Sigma) 
to the cultures, which were further incubated during 4 hours at 37°C and 200 rpm. 
Subsequently, the insoluble cytoplasmatic fraction was isolated and resuspended in 
PBS + 0.5 % SDS. Following overnight dialysis against PBS at 4°C, the concentration 
of rFaeG was determined using the BCA-reaction and used to immunize animals.  
 
10.2.4. Experimental procedure 
Twenty-one, F4R+ and FaeG-seronegative, conventionally bred pigs (Belgian 
Landrace x Piétrain) were weaned at the age of 4 weeks, transported to the 
experimental facilities at the faculty and subsequently housed in isolation units were 
they obtained water and food ad libitum. These pigs were treated orally with colistine 
(Promycine pulvis, VMD, Berendonk, Belgium, 150,000 U/kg of body weight/day) 
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from 2 days before till 3 days after weaning to prevent E. coli infections due to 
transport and handling. 
One week post weaning, all pigs were orally given 20 mg rabeprazolum 
(Pariet, Janssen-Cilag, Berchem, Belgium) on 3 subsequent days to block the gastric 
HCl production. They also received rabeprazolum 15 days post primary immunization 
(dppi). Twenty-four hours following each rabeprazolum ingestion (0, 1, 2 and 16 
dppi), the pigs were orally immunized with 50 µg CT (CT group, n=7), 4 mg rFaeG 
(rFaeG group, n=7) or 4 mg rFaeG + 50 µg CT (rFaeG+CT group, n=7) in 10 ml PBS. 
Each animal was deprived of food and water from three hours before till 2 h after 
gastric pH neutralization or immunization. One week following the booster 
immunization (23 dppi), the F4-specific proliferation of peripheral blood 
monomorphonuclear cells (PBMC) was determined. 
At 24 dppi, the animals were orally challenged with the virulent F4+ ETEC 
strain GIS26 as previously described (Cox et al., 1991) with minor modifications. 
Briefly, pigs were orally pre-treated at 21 and 22 dppi with 300 mg florfenicol 
(Nuflor, Schering-Plough, Brussels, Belgium) to decrease colonization resistance. 
Pigs were sedated with Stressnil (40 mg/ml ; Janssen-Cilag, Berchem, Belgium), after 
which the gastric pH was neutralized by intragastrical administration of 62 ml 
NaHCO3 (1.4% (w/v) in destilled water). Fifteen to thirty minutes later, 1010 F4+ 
ETEC (GIS26) in 10 ml PBS was given intragastrically. Faecal samples were taken 
daily to determine the excretion of F4+ E. coli from challenge till 8 days post 
challenge (dpc, 31 dppi). Furthermore, FaeG-specific IgA, IgG and IgM and CT-
specific  (total) antibodies were determined in serum at 0, 7, 16, 24, 28, 31, 38 and 49 
dppi, whereas FaeG-specific IgA was analysed in saliva at 0, 16 and 24 dppi. His-S-
tag specific (total) serum antibodies were determined in serum at 0 and 24 dppi. Three 
weeks following challenge (49 dppi), the remaining pigs were euthanatised and 
jejunal villi were isolated to confirm the presence of the F4R.  
All pigs were weighed at 0, 3, 7, 15, 24, 31 and 49 dppi. The daily weight gain 
of each pig was calculated at 3, 7, 15, 24, 31 and 49 dppi by substracting the weight of 
two subsequent measurements, and dividing the difference by the number of days 
between both measurements. Subsequently, the average daily weight gain (ADWG) 
per group was calculated ± standard error of the mean (SEM). 
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10.2.5. Samples 
To determine antigen-specific serum and mucosal antibodies, serum and saliva 
were sampled as described by Van den Broeck et al. (1999a) and Van der Stede et al. 
(2002a), respectively. 
F4+ E. coli were enumerated in faecal samples by dot blotting using the FaeG-
specific MAb IMM01 as previously described (Van den Broeck et al., 1999b). The 
resulting brown-red dots were counted and the average within each group was 
calculated. Results are presented as the mean number ± SEM of excreted F4+ E. coli 
per gram faeces.  
At the end of the experiment, jejunal villi were isolated of all euthanatised pigs 
to confirm the presence of the F4R as described by Van den Broeck et al. (1999c). 
Adhesion of more than five F4+ E. coli per 250 µm villous length was noted as 
positive (Cox and Houvenaghel, 1993). 
 
10.2.6. ELISA for FaeG-, CT- and His-S-tag-specific antibodies 
For detection of FaeG-specific antibodies, the indirect ELISA described by 
Van den Broeck et al. (1999a) was used. An identical ELISA which only differed in 
the coating step and conjugate was used to determine CT-specific antibodies : the 
wells of microtiter plates (NUNC, Polysorp Immuno Plates, Roskilde, Denmark) were 
coated with 5 µg/ml CT (Sigma) in PBS and an optimal dilution of horseradish 
peroxidase conjugated rabbit polyclonal antibodies (Dako, Denmark) was used as 
conjugate. The FaeG- and CT-specific cut-off values were calculated as the mean 
OD405-value of all sera (dilution 1/10) or saliva (dilution 1/2) samples at day 0, 
increased with 3 times the standard deviation (cut-off values of the FaeG-specific 
serum IgM, IgA, IgG and mucosal IgA and CT-specific ELISA were 0.32, 0.17, 0.31, 
0.28 and 0.21 respectively). The antibody titer was the inverse of the highest dilution 
that still had an OD405 higher than the calculated cut-off value. 
To analyse the capacity of rFaeG to function as mucosal carrier molecule, the 
presence of His-S-tag-specific antibodies was determined in serum at 24 dppi using 
the His-S-SctW fusion protein (Geens et al., unpublished data) that was kindly 
provided by Tom Geens et al. The His-S-SctW protein is encoded by pET-HTSctW 
that is obtained from ligation of the Chlamydia psittaci type III secretion protein SctW 
in the pET-30 Ek/LIC vector. His-S-SctW was purified with Ni-NTA agarose beads 
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according to the manufacturers instructions (Qiagen, Madison, US) and shown to be 
91 % pure following SDS-PAGE and Coomassie staining. The purified His-S-SctW 
protein was dialysed overnight at 4°C against PBS and used to coat the wells of 
microtiter plates (NUNC, Polysorp Immuno Plates) at a concentration of 20 µg/ml in 
PBS. Incubation times, blocking condition and washing procedures of this ELISA 
were identical as described by Van den Broeck et al. (1999a). The serum samples 
were added in series of twofold dilutions in ELISA dilution buffer (PBS + 0.2% 
Tween®20 + 3% BSA), starting from the dilution 1/4. Then, an optimal dilution of 
horseradish peroxidase conjugated rabbit polyclonal antibodies (Dako) was used as 
conjugate. Finally, ABTS and H2O2 were used as chromogen and substrate and the 
OD405 was spectrophotometrically determined. The His-S-tag-specific cut-off value 
(0.42) was calculated as the mean OD405-value of all sera (dilution 1/4) at day 0, 
increased with 3 times the standard deviation. 
 
10.2.7. F4-specific proliferation 
Blood was collected from the jugular vein and PBMC were isolated as 
described by Van den Broeck et al. (1999a). The PBMC were diluted to a 
concentration of 5.106 cells/ml in leukocyte medium (RPMI-1640 supplemented with 
penicillin (100 IU/ml), streptomycin (100 µg/ml), kanamycin (100 µg/ml), L-glutamin 
(200 mM), sodiumpyruvate (100 mM), non-essential amino acids (100 mM), β-
mercaptoethanol (5.10-5 M) and 5% (vol/vol) FaeG-seronegative serum. 
Subsequently, the isolated PBMC were incubated in medium (negative control) or 
medium with purified F4 (final concentration of 10 µg/ml), or concanavalin A (final 
concentration of 10 µg/ml, positive control) to determine their F4-specific 
proliferation as described by Van der Stede et al. (2003). The results are presented 
using the F4-specific stimulation index (SI), obtained by dividing the mean counts per 
minute (cpm) of the F4-stimulated cultures by the mean cpm of the non-stimulated 
cultures. Mean background levels of about 700 cpm were obtained in medium 
samples, whereas positive controls of concanavalin A reached 170,000 cpm. 
 
10.2.8. Statistical analysis 
Statistical analysis (SPSS 10.0 for Windows) of antibody titers and F4+ E. coli 
excretion (log-values) was done using General Linear Model (Repeated Measures 
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Analysis of Variance). Differences between groups in F4-specific cell proliferation 
and ADWG were analysed for statistical significance using the One-way Anova. P < 
0.05 was considered as statistically significant. 
 
10.3. Results 
10.3.1. FaeG-specific serum antibody response following oral 
immunization 
Oral immunizations of newly weaned pigs with rFaeG (rFaeG group) induced 
FaeG-specific serum IgM in all animals, resulting in a significantly higher titer 7 dppi 
as compared to the background value in animals immunized with CT (CT group; 
P=0.002) (Fig. 1). However, oral immunization of pigs with rFaeG in the presence of 
CT (rFaeG+CT group) resulted in significantly higher FaeG-specific IgM serum titers 
than in the rFaeG (16 dppi; P=0.004) groups. The oral booster immunization 16 dppi 
induced low FaeG-specific serum IgA and IgG titers in the rFaeG group, whereas the 
FaeG-specific IgM titer was significantly higher (P=0.011) 24 dppi as compared to 
the background value in the animals immunized with CT alone. The highest FaeG-
specific serum antibody titers following booster immunization were obtained in the 
rFaeG+CT group, with significantly higher titers than in the rFaeG group (IgG; 
P=0.038) and the CT group (IgM, IgA, IgG; P≤0.024) 24 dppi.  
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 Figure 1: Mean FaeG-specific IgM, IgA and IgG serum antibody titers (± SEM) at 0, 7, 16, 24, 28, 31, 38 and 49 
days post primary immunization (dppi) of pigs orally immunized with cholera toxin (CT, n=7), rFaeG (n=7) or 
rFaeG and cholera toxin (rFaeG+CT, n=7). Significant difference (P < 0.05) between CT and rFaeG (a), between 
CT and rFaeG+CT (b), between rFaeG and rFaeG+CT (c). Black arrow : immunization; white arrow : challenge.
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10.3.2. His-S-tag-specific serum antibody response following 
oral immunization 
 Besides inducing FaeG-specific serum antibodies following oral rFaeG 
immunization, rFaeG functioned as a mucosal carrier for the N-terminal fused His-S-
tag. Indeed, one week following oral booster immunization (24 dppi), His-S-tag-
specific antibodies were detected in the rFaeG group but not in the CT group (Fig. 2). 
However, oral co-administration of rFaeG and CT resulted in significantly higher His-
S-tag-specific serum titers than in the CT and the rFaeG groups (P=0.003 and 
P=0.047 respectively). 
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Figure 2 : Mean His-S-specific serum antibody titers (± SEM) at 24 days 
post primary immunization (dppi) of pigs orally immunized with cholera 
toxin (CT, n=7), rFaeG (n=7) or rFaeG and cholera toxin (rFaeG+CT, n=7). 
Significant difference (P < 0.05) between CT and rFaeG (a), between CT 
and rFaeG+CT (b), between rFaeG and rFaeG+CT (c).  
 
10.3.3. CT-specific serum antibody response following oral 
immunization 
The use of CT in the oral immunizations induced a CT-specific systemic 
immune response, whereas no CT-specific serum antibodies were detected in the non-
CT immunized rFaeG group (Fig. 3). One week following booster immunization (24 
dppi), the CT-specific antibody titer of both CT immunized groups was significantly 
higher as compared to the rFaeG group (P≤0.016). On the other hand, the dose of CT 
used, did not result in diarrhoea (data not shown) or growth retardation (Fig. 4) of the 
pigs. 
b 
 c 
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Figure 3 : Mean CT-specific serum antibody titers (± SEM) at 0, 7, 16, 24, 28, 31, 38 and 49 
days post primary immunization (dppi) of pigs orally immunized with cholera toxin (CT, 
n=7), rFaeG (n=7) or rFaeG and cholera toxin (rFaeG+CT, n=7). Significant difference (P < 
0.05) between CT and rFaeG (a), between CT and rFaeG+CT (b), between rFaeG and 
rFaeG+CT (c). Black arrow : immunization; white arrow : challenge. 
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Figure 4 : Mean weight at 0, 3, 7, 15, 24, 31 and 49 days post primary immunization (dppi) 
and average daily weight gain (ADWG) at 3, 7, 15, 24, 31 and 49 dppi of pigs orally 
immunized with cholera toxin (CT, n=7), rFaeG (n=7) or rFaeG and cholera toxin (rFaeG+CT, 
n=7). 
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10.3.4. F4-specific cell proliferation following oral 
immunization 
The observed adjuvanticity of CT on the F4-specific immune response to co-
administered rFaeG is not restricted to the antibody response, as also a significantly 
higher F4-specific cell proliferation was observed in the rFaeG+CT group as 
compared to both other groups 23 dppi (Fig. 5; P≤0.036). Oral immunization of pigs 
with rFaeG alone induced an F4-specific cell proliferation that was significantly 
higher as compared to the CT immunized pigs (P=0.021).  
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Figure 5 : Mean F4-specific stimulation index (SI) (± SEM) at 23 days post 
primary immunization of pigs orally immunized with cholera toxin (CT, n=7), 
rFaeG (n=7) or rFaeG and cholera toxin (rFaeG+CT, n=7). Significant difference 
(P < 0.05) between CT and rFaeG (a), between CT and rFaeG+CT (b), between 
rFaeG and rFaeG+CT (c). 
 
 
10.3.5. FaeG-specific mucosal antibody response following 
oral immunization 
Oral rFaeG immunization of newly weaned pigs resulted in the secretion of 
very low amounts of FaeG-specific antibodies in saliva. In the rFaeG group, an 
insignificant increase of FaeG-specific IgA was seen from 16 to 24 dppi (log2 titer 
1.08 and 1.25, respectively). In the rFaeG+CT group, significantly higher FaeG-
specific IgA was found as compared to both other groups both 16 and 24 dppi (log2 
titer 1.33 and 1.74 respectively, P≤0.047).  
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10.3.6. F4+ E. coli excretion following challenge
To determine if the induced FaeG-specific immune response was able to
protect against an F4+ ETEC infection, the pigs were challenge infected 24 dppi. Daily
enumeration of the faecal F4+ E. coli excretion (Fig. 6) revealed >107 bacteria per g
faeces in the CT group till 4 dpc, whereafter the excretion gradually decreased till 8
dpc. The excretion of the rFaeG-immunized animals was similar to that of the CT
group until 2 dpc, after which it decreased faster to become significantly lower from 4
till 7 dpc (P≤0.016). However, animals immunized with rFaeG in the presence of CT
already showed a significantly reduced F4+ E. coli excretion in comparison with the
CT group but also the rFaeG group from day 1 post challenge onwards until 7 and 6
dpc, respectively (P≤0.004). Despite these differences in F4+ E. coli excretion, no
significant differences were observed in faecal consistency (data not shown) and
ADWG (Fig. 4) between the groups.
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Figure 6 : Mean faecal F4+ E. coli excretion (log 10) per gram faeces (±
SEM) of pigs orally immunized with cholera toxin (CT, n=7), rFaeG
(n=7) or rFaeG and cholera toxin (rFaeG+CT, n=7). Significant
difference (P < 0.05) between CT and rFaeG (a), between CT and
rFaeG+CT (b), between rFaeG and rFaeG+CT (c).
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10.3.7. FaeG-specific serum antibody response following 
challenge 
In agreement with the high F4+ E. coli excretion in the CT group, the 
challenge infection induced a primary FaeG-specific immune response in the CT 
immunized group (Fig. 1). Indeed, an FaeG-specific IgM serum antibody response 
appeared 28 dppi (4 dpc) and was significantly higher than for both rFaeG immunized 
groups on 38 and 49 dppi (P≤0.019), whereas the FaeG-specific IgA and IgG serum 
antibodies were only detected from 38 dppi onwards. On the other hand, FaeG-
specific IgG of both rFaeG immunized groups showed a secondary response upon 
challenge with titers significantly higher as compared to the CT group 31 dppi 
(P≤0.043). Thereafter, IgG titers decreased again in the rFaeG group, but not in the 
rFaeG+CT group where they remained significantly higher than in the CT group (38 
and 49 dppi; P≤0.037).  
 
 10.3.8. CT-specific serum antibody response following 
challenge 
 Following challenge infection of CT-immunized animals with the LT-
producing F4+ ETEC strain GIS26, CT-specific antibodies remained increasing until 4 
or 7 dpc (rFaeG+CT and CT groups, respectively; Fig. 3) and then reached a plateau. 
The increase of the CT-specific antibody titer following ETEC infection could suggest 
a booster of the CT-response. On the other hand, challenge infection could not induce 
CT-specific serum antibodies in animals immunized with rFaeG alone, so that the 
observed increase in both other groups could still have been due to the CT 
immunization 16 dppi.   
 
10.4. Discussion 
The results of the present study show that oral immunization of newly weaned 
pigs with rFaeG results in an FaeG-specific mucosal and systemic immune response, 
in agreement with previous experiments (Chapter 9). However, the results of the 
present study indicate that oral co-administration of rFaeG with CT improves the 
induction of an FaeG-specific immune response in pigs. Indeed, the addition of the 
mucosal adjuvant CT induces faster and higher FaeG-specific antibody titers in serum 
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as well as F4-specific cell proliferation in the rFaeG+CT group, as compared to the 
animals immunized with rFaeG alone. The mechanisms underlying the observed 
mucosal adjuvanticity of CT are not clear, but there is growing evidence that the 
establishment of an environment leading to an enhanced antigen presentation is 
important (Porgador et al., 1998; Gagliardi and De Magistris, 2003). In pigs, CT 
increases CD80-CD86 expression and induces IL-1 expression by macrophages (Foss 
et al., 1999c). In addition, several studies in mice also report a CT-mediated optimised 
antigen presentation, influencing the induction or regulation of an antigen-specific 
immune response (Cong et al., 1997; Yamamoto et al., 1999; Jang et al., 2003).  
The high FaeG-specific serum IgG titers and the detection of FaeG-specific 
IgA in saliva samples in the rFaeG+CT group, are in agreement with the induction of 
antigen-specific IgG (mainly IgG1) and IgA in the serum and mucosal secretions 
respectively, following oral co-administration of different heterologous antigens with 
CT in mice (Xu-Amano et al., 1994; Marinaro et al., 1995; Cong et al., 1997; Kim et 
al., 1998). The low levels of FaeG-specific IgA in saliva samples suggest diffusion of 
FaeG-specific IgA from serum to saliva, instead of a local production of FaeG-
specific IgA (Vaerman et al., 1997). On the other hand, oral immunization of pigs 
with rFaeG has been shown to induce FaeG-specific antibody secreting cells in the gut 
associated lymphoid tissue (Chapter 9). Secretion of higher FaeG-specific IgA levels 
in the small intestinal lumen following rFaeG+CT immunization could occur since 
CT induces a predominant Th2-response (Xu-Amano et al., 1994; Marinaro et al., 
1995) and stimulates IgA isotype switching (Kim et al., 1998) in mice. This could 
explain the better inhibition of F4+ ETEC colonization following challenge of the 
rFaeG+CT immunized animals as compared to rFaeG immunized animals. Indeed, a 
correlation between the presence of FaeG-specific IgA in the small intestinal lumen 
and a reduction of the F4+ ETEC colonization has been reported (Porter et al., 1974). 
Other influences of CT on leukocytes or intestinal epithelial cells that could mediate 
the induction of high FaeG-specific cellular and humoral immune response in the 
rFaeG+CT group (Holmgren et al., 2003) cannot be confirmed nor excluded with the 
results of the present study. 
 Despite the improved FaeG-specific immune response, pigs orally immunized 
with rFaeG and CT are not fully protected against a subsequent F4+ ETEC challenge. 
Therefore, further improvement of the rFaeG immunization protocol is necessary. 
Perhaps, a higher rFaeG dose is necessary and/or the refolding of rFaeG must be 
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further optimised. Refolded rFaeG is reported to bind the F4R and to have the 
conformational epitopes a6, a7 and c in common with purified F4 fimbriae (Chapter 
9). However, if the rFaeG folding is not totally identical to that of purified F4, rFaeG 
could induce less neutralizing antibodies or antibodies with a lower affinity to the 
native structure. Indeed, conformational changes in antigens are reported to influence 
its immunogenicity in terms of both affinity and titer (Subramanian et al., 2001; 
Titball and Williamson, 2001; Joyce et al., 2002). On the other hand, the effect of the 
challenge infection in the present study was more severe as compared to a previous 
experiment (Chapter 9). Therefore, pigs need a higher FaeG-specific immune 
response to inhibit the F4+ ETEC colonization in this study. 
Results of the present study show that oral administration of CT to pigs results 
in the significant induction of CT-specific serum antibodies. In addition, Foss and 
Murtaugh (1999a) observe CT-B specific IgA and IgG in jejunal mucus and saliva of 
pigs that are orally immunized with CT. As could be expected, the CT-specific 
immune response did not reduce F4+ ETEC colonization since F4+ E. coli excretion 
resembled that of identically infected non-immunized pigs (Chapter 9). However, 
cross-reactivity is reported between antibodies against the related enterotoxins CT and 
LT (Svennerholm et al., 1983; Clements et al., 1988). In humans, the presence of high 
anti-LT antibody titers is also shown not to be protective against ETEC infections 
(Levine et al., 1979; Cravioto et al., 1990). Therefore, the induced CT-specific 
antibodies are likely to reduce or even inhibit the toxic effect of F4+ ETEC produced 
LT during challenge infection. Indeed, oral vaccines successful in protecting humans 
against ETEC-induced diarrhoea contain the cholera toxin B-subunit to induce anti-
toxin antibodies (Peltola et al., 1991; Savarino et al., 1999; Hall et al., 2001).  
 Foss and Murtaugh (1999a) suggest that the mucosal adjuvanticity of CT in 
pigs needs mucosal targeting of the added heterologue antigen, as an antigen-specific 
immune response is only observed when the co-administered heterologue antigen is 
coupled to CT-B. The significantly higher His-S-tag-specific antibody titer in the 
rFaeG+CT pigs as compared to the rFaeG immunized pigs, shows that CT can act in 
pigs as a mucosal adjuvant of a heterologous antigen that is targeted to the mucosae 
by other systems than binding to the CT receptor GM1. There are advantages that may 
promote the use of the F4 fimbrial adhesin FaeG as mucosal carrier of heterologous 
antigens in combination with the mucosal adjuvant CT in pigs. Indeed, CT improves 
not only the antibody response against the adhesin but also against the coupled 
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heterologous antigen. Furthermore, the absence of competition between adjuvant and 
carrier for receptor binding could be an advantage to enhance the immune response, 
since they bind to different receptors. Further experiments are needed to confirm the 
potential of this system to obtain a simultaneously protective mucosal immune 
response against the widely spread pathogenic ETEC strains and other 
enteropathogens in pigs such as rotavirus or verotoxigenic E. coli. However, F4 
fimbrial adhesins will not be able to function as universal mucosal carriers in pigs 
since F4 behaves as a normal food antigen in F4R- pigs (Van den Broeck et al., 2002). 
In conclusion, the results of the present study show that the potential of rFaeG 
as mucosal carrier antigen to induce an antibody response against a coupled 
heterologous antigen, is improved following co-administration of rFaeG with CT in 
pigs. These results open new perspectives in the development of mucosal vaccines 
against enteric infectious diseases in pigs.  
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11.1. Characterization of F4 and its adhesin FaeG 
Previous studies of our group have shown that oral immunization of pigs with 
purified F4 fimbriae results in a protective F4-specific immune response in F4R+ pigs 
(Van den Broeck et al., 1999b). In F4R- pigs, F4 fimbriae seem to act as a normal 
food antigen (Van den Broeck et al., 2002). Therefore, the mucosal immunogenicity 
of F4 relies on its binding to the F4R on porcine small intestinal enterocytes. In 
agreement, soluble antigens like cholera toxin, heat-labile enterotoxin and some plant 
lectins that bind to enterocytes can induce an antigen-specific immune response 
following oral immunization, but most soluble non-replicating antigens lead to the 
induction of oral tolerance (Strobel and Mowat, 1998). The aim of the present work 
was to determine if F4 fimbriae of the F4+ ETEC reference strain GIS26 or its adhesin 
FaeG could be used as a mucosal carrier molecule following oral immunization, 
inducing an immune response against a coupled/fused heterologous antigen in 
addition to a FaeG-specific immune response. 
F4 fimbriae are composed of the minor subunits FaeC, FaeF, FaeH and FaeI 
and the major subunit FaeG that also constitutes the adhesin (Bakker et al., 1992a and 
1992b). Fimbriae on the surface of bacteria can contain up to 1000 subunits, with a 10 
times higher molar amount of the major subunit than of the minor subunits (Klemm, 
1985). Probably, the fimbriae will break down in fragments due to the purification 
process, resulting in FaeG-containing multimers of different length (Chapters 4, 7 and 
8). The hydrodynamic radii of most fimbriae in a sample of purified GIS26 F4 
fimbriae is between 60 to 70 nm (Chapter 7), suggesting that the majority of purified 
F4 fimbriae contain at least 15 subunits since the hydrodynamic radii of monomeric 
rFaeG (without tags) is 3.8 nm (Bouckaert J., unpublished data). However, we were 
unable to determine the exact number of subunits in the purified fimbriae based upon 
these data since the multimeric F4 fimbrial structure can appear in linear or more 
winded forms depending on the medium conditions (Simons et al., 1994). This 
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multimeric character of purified F4 fimbriae is not unique to the GIS26 strain as it is 
also observed in 20 out of the 21-studied F4ac+ E. coli field isolates (Chapter 4). 
Purification of other fimbriae like type 1 pili, P pili and F18 fimbriae also show 
polymeric structures (Abraham et al., 1988; Bullitt et al., 1996), but their adhesin is a 
minor subunit (Lund et al., 1985; Jones et al., 1995; Imberechts et al., 1996).  
The multimeric character of the adhesin and major subunit FaeG distinguishes 
F4 fimbriae from other fimbriae like F18 where the adhesin is a minor subunit. This 
difference could at least partly explain the faster and more severe colonization and 
subsequent induction of a protective fimbriae-specific immune response following 
infection of pigs with the F4+ ETEC strain GIS26 as compared to infection with the 
F18+ VTEC strain F107/86 (Chapter 5). Furthermore, in contrast to F4 fimbriae (Van 
den Broeck et al., 1999b), oral immunizations with F18 fimbriae (Felder et al., 2000; 
Verdonck et al., unpublished data) do not lead to induction of a protective fimbriae-
specific immune response. Parenteral immunization studies using type 1 fimbriae 
indicate that the predominant immune response against fimbriae with the adhesin as 
minor subunit, is directed against the non-adhesive major subunit that composes more 
than 99% of the total protein mass of the pilus structure (Lund et al., 1988; 
Langermann et al., 1997). These major-subunit-specific antibodies often cannot 
provide protection against infection such as is the case for the major subunits of type 1 
pili since they are not conserved (Vandemaele et al., 2003a). On the other hand, the 
type 1 adhesin FimH is conserved (Sokurenko et al., 1994; Vandemaele et al., 2003a), 
but the low level of antibodies against this adhesive minor subunit cannot protect 
against a subsequent challenge infection (Lund et al., 1988; Langermann et al., 1997; 
Kariyawasam et al., 2002).  
Since the adhesin FaeG is also the major subunit of F4 fimbriae, it was 
necessary to examine if FaeG is conserved or not. There are three different faeG allels 
encoding the adhesin of F4ab, F4ac or F4ad fimbriae (Guinee and Jansen, 1979), but 
F4ac+ ETEC strains are most prevalent at different places all over the world 
(Westerman et al., 1988; Choi and Chae, 1999). Therefore, the FaeG amino acid 
sequence of the GIS26 reference strain and of 21 F4ac+ E. coli field isolates was 
determined and subsequently compared with the FaeG amino acid sequence of F4 
strains (F4ab+, F4ac+ or F4ad+) reported in the literature.  The percentage identity 
between FaeG of F4ac+ strains was 96%, whereas the percentage identity between 
FaeG of F4ac+ and this of F4ab+ or F4ad+ strains was 92 and 88% respectively  
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(Chapter 4). These degrees of sequence identity are in the range of percentages 
reported for other fimbrial adhesins such as F18 (Smeds et al., 2003; Tiels, 
unpublished results) and F17 (Buts et al., 2003a) and indicate that FaeG is as 
conserved as other fimbrial adhesins. The high percentage of identity among the 
adhesin of F4ac+ strains gave a reason to believe that the F4ac fimbriae of one F4ac+ 
E. coli strain could induce F4-specific antibodies that could inhibit adhesion of other 
F4ac+ E. coli strains to the F4R. In chapter 4, this was confirmed for the GIS26 strain. 
Indeed, F4ac fimbriae purified from GIS26 induced F4-specific antibodies that 
blocked adhesion of the 20 tested F4ac+ E. coli field isolates. Similarly, the degree of 
sequence identity between the adhesins of F4ac+ strains and this of F4ab+ or of F4ad+ 
strains could also suggest blocking of F4ab+ and F4ad+ strains by F4ac-specific 
antibodies. Bijlsma et al. (1987) reported that oral administration of a particular F4+ 
E. coli variant to pigs resulted in FaeG-specific antibody titers that were similar for 
the homologous as for the heterologous F4 variants. On the other hand, the three 
variants of FaeG have a different receptor specificity (reviewed in Van den Broeck et 
al., 2000) mediated at least in part by the variant-specific epitopes b, c and d (Bakker 
et al., 1992a; Sun et al., 2000b). Furthermore, of the 7 epitopes identified as the ‘a’ 
part of FaeG, only three ‘a’ epitopes are present in all three F4 variants, whereas the 
four other ‘a’ epitopes are only present in one or two F4 variants. This suggests that 
blocking of F4ab and F4ad strains by F4ac-specific antibodies will be incomplete if 
present at all. Nevertheless, Parry and Porter (1978) reported that antisera raised to 
F4ab and F4ac were cross-reactive with the heterologous fimbrial type and blocked 
binding of the heterologous and homologous fimbrial variants to porcine enterocytes. 
However Wilson and Hohmann (1974) could not demonstrate this cross-blocking. 
Further experiments are needed to elucidate these seemingly contradictory 
observations.  
The high immunogenicity of F4 fimbriae is mediated by its multimeric 
character, but probably also by its high stability, certainly in the case of an oral 
immunization. Passage of immunogenic proteins through the gastro-intestinal tract 
mostly renders them non-immunogenic through the extreme low pH of the 
environment and the degradation by proteolytic enzymes in stomach (pepsin, 
gastricsin and chymosin) and small bowel (trypsin, chymotrypsin and some other 
pancreatic proteases) (Mayer, 2003). F4 fimbriae were shown to be very stable and to 
retain their immunogenicity in conditions reflecting those of the gastro-intestinal tract. 
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Indeed, incubation of F4 fimbriae at pH 4 or pH2 for 30 minutes results in a 
conformational change that can be restored by neutralizing the pH (Chapter 8). A 
significant reduction in the multimeric FaeG composition and slow digestion is only 
observed following incubation of F4 fimbriae for 2 h or longer in a simulated gastric 
fluid at pH 1.5 and 2 (Snoeck et al., 2004a). Oral immunization of pigs with purified 
F4 will not result in total destruction of the fimbriae since there is a fast transport of 
ingested material in the gastro-intestinal tract. Snoeck et al. (2003) orally administered 
pellets to piglets and found already 40% of the pellets in the small intestine 1.5 h 
following oral administration and a solution can leave the stomach even faster 
(Gregory et al., 1990). Furthermore, F4 fimbriae are very stable proteins since they 
retain their receptor-binding capacity and multimeric FaeG composition following 
heating up to 70°C, incubation in the presence of 0.5% SDS, 4M urea, 4M GuHCl or 
5% non-ionic detergents (Chapter 8; Knörle and Hubner, 1995).  
Purified F4 fimbriae of strain GIS26 are contaminated with flagellin (Chapter 
4). Flagellin could induce a proinflammatory response during an infection when it 
would be able to interact with Toll-like receptor 5 (TLR-5), resulting in IL-8 
expression (Gewirtz et al., 2001a and 2001b; Yu et al., 2003). In the human enterocyte 
cell lines T84, HT-29cI19A and Caco-2BBE and the Madin-Darby canine kidney 
cells, expression of TLR-5 is restricted to the basolateral membranes (Gewirtz et al., 
2001a; Reed et al., 2002; Yu et al., 2003) so that if present on porcine enterocytes a 
similar location can be expected. Oral immunization with F4 most likely does not 
open the tight junction between enterocytes of the epithelial barrier since F4+ ETEC 
infection of newly weaned pigs even did not increase the permeability of the porcine 
jejunal epithelium (Egberts et al., 1993). Therefore the presence of flagellin is not 
supposed to be of any importance for the immunogenicity of F4. Furthermore, the 
great immunogenicity of F4 is not due to an adjuvant effect of LT as this molecule 
was not detected in 5 different samples of GIS26 purified F4 fimbriae using an 
agglutination assay with a detection limit of 2 ng/ml (Verdonck, unpublished data). In 
addition, lipopolysaccharides (LPS) in the purified fimbrial preparation will not 
influence the FaeG-specific response following oral F4 immunization. Indeed, even 
though LPS are known immunostimulating agents when used systemically (Johnson, 
1994), there are no studies reporting a significant immunostimulating effect of LPS 
when used orally with an antigen (Childers et al., 2000). This is most likely because 
LPS is already widely present in the gut. All these data confirm that the F4 fimbriae of 
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strain GIS26 are stable, immunogenic and are composed of multimers of a conserved 
FaeG adhesin, indicating that these fimbriae can be used in a mucosal vaccine against 
F4+ ETEC infections.  
 
11.2. Oral immunization with recombinant FaeG 
Immunization with the recombinant type 1 adhesin FimH reduced in vivo 
colonization of the bladder mucosa by more than 99% in a murine cystitis model 
(Langermann et al., 1997). To determine the potential of the F4 fimbrial adhesin FaeG 
to induce a FaeG-specific immune response following oral immunization, 
recombinant FaeG was produced in the cytoplasm of E. coli. A cytoplasmatic 
expression was chosen since high yields can be obtained in the cytoplasm (Makrides, 
1996) and periplasmic expression would require co-expression of the F4 fimbrial 
chaperone FaeE in the presence of the periplasmic protease DegP (Bakker et al., 
1992a). The produced rFaeG was only present in cytoplasmic inclusion bodies 
(Chapter 9). Fimbrial adhesins of P pili, type 1 pili and F18 fimbriae expressed in an 
E. coli expression system, were also found in inclusion bodies (Vetsch et al., 2002; 
Karyawasam et al., 2002; Tiels, unpublished data). Fimbrial subunits have an 
immunoglobulin-like fold, missing the seventh β-strand (Sauer et al., 1999; 
Choudhury et al., 1999). This missing strand is complemented by the fimbrial 
chaperone during fimbrial biogenesis or by the N-terminal strand of a subsequent 
subunit in the fimbrial structure (Thanassi and Hultgren, 2000a). In the absence of this 
complementing strand, the subunit contains a hydrophobic groove on its surface 
(Barnhart et al., 2000), what could lead to the observed aggregation of monomeric 
FaeG subunits (Chapters 4, 8 and 9). The structure of FaeG is not elucidated at the 
moment, but we believe that a similar mechanism of subunit interaction is present as 
that found in other fimbriae. This is discussed in the chapters 2 and 4.  
The refolding of rFaeG was screened with an ELISA using the FaeG-specific 
MAb IMM01 (Chapter 9), since the interaction of this MAb with F4 fimbriae 
correlated with the bio-activity of the fimbriae (Chapter 8). Refolding of rFaeG with 
SDS resulted in a conformation that contains conformational epitopes and binds the 
F4R in a specific and concentration-dependent manner, in contrast to refolding with 
for instance urea (Chapter 9). The potential of SDS to refold rFaeG was somewhat 
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surprising but is probably due to SDS-mediated shielding of the hydrophobic core of 
the FaeG subunits, reducing their non-specific aggregation. Heat treatment of F4 
fimbriae resulted in aggregation and loss of the F4R-binding capacity (Chapter 8), but 
FaeG that was heat denaturated and subsequently eluted out of an SDS-PAGE could 
bind the F4R (Van den Broeck et al., 1999c). Tewari et al. (1993) also observed 
receptor binding capacity of the type 1 fimbrial adhesin FimH, following heat 
denaturation and subsequent elution out of an SDS-PAGE. The influence of SDS on 
protein conformation is concentration and protein dependent (Otzen and Oliveberg, 
2002). Indeed, the protocol that was developed to refold rFaeG with SDS was not 
successful to refold the recombinant F18 fimbrial adhesin FedF (unpublished data, 
Tiels et al.).  
The conformation of refolded rFaeG influences its binding to the receptor and 
subsequently also the induction of an FaeG-specific immune response since FaeG-
specific ASCs were found in intestinal lymphoid tissues of pigs orally immunized 
with SDS-refolded rFaeG, but not with urea-refolded rFaeG (Chapter 9). This result 
confirms the need for receptor-binding to induce a FaeG-specific immune response 
following oral immunization (Van den Broeck et al., 1999b). Interestingly, Joensuu et 
al. (2004) reported the production of rFaeG subunits in tobacco, which bind the F4R 
without a refolding procedure. These plant-produced rFaeG subunits could be an 
alternative to the SDS-refolded rFaeG when further experiments are able to show that 
they can induce an FaeG-specific immune response following oral immunization.  
Snoeck et al. (2004c) showed that uptake of F4 at the follicle associated 
epithelium via enterocytes and M cells could result in the induction of a FaeG-specific 
immune response in the (jejunal) Peyer’s patches. In addition, F4 that binds F4R+ 
enterocytes, enters the lamina propria (LP) and is at least partly taken up by local 
antigen-presenting cells (Snoeck et al., 2004b). Probably, these antigen-presenting 
cells migrate to the MLN where they could induce an FaeG-specific immune response 
since high numbers of FaeG-specific IgM ASCs were detected in MLN four to seven 
days following an F4+ ETEC infection (Chapter 5). Then, FaeG-specific ASCs likely 
home to the intestinal effector sites meanwhile switching to the IgA isotype (McGhee 
et al., 1992), thereby explaining the high numbers of FaeG-specific IgA ASCs in the 
LP 7 to 11 days post F4+ ETEC infection (Chapter 5). Oral rFaeG and F4 
immunizations induce an FaeG-specific immune response that resembles the response 
induced following F4+ ETEC infection (Chapters 9 and 10). Indeed, following F4+ 
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ETEC infection as well as following oral immunization with rFaeG or F4, higher 
amounts of IgM than IgA ASCs were found (Chapters 5 and 9). IgM is a more 
important immunoglobulin in the mucosal secretions of pigs than of other animals 
(Porter et al., 1974; Bianchi et al., 1999).  It was only following oral rFaeG or F4 
booster immunization that a clear antibody class switch from IgM to IgA was seen, 
resulting in a change in the IgM-IgA ASCs ratio (Chapters 9 and 10). As expected, 
mucosal FaeG-specific IgG responses are low but not absent (Bianchi et al., 1999; 
Yuan et al., 2001). This could suggest a role for the FcRn receptor, recently 
discovered in pigs (Claypool et al., 2004). This receptor can transport IgG bi-
directionally through epithelial cells. 
Although oral immunization of pigs with rFaeG or F4 are both able to induce 
an FaeG-specific antibody response, F4 immunization is more effective than rFaeG 
immunization since a higher FaeG-specific immune response and a better protection 
against a subsequent challenge is observed (Chapters 9 and 10). This difference in 
FaeG-specific response is probably due to a combination of factors. First, rFaeG are 
monomers, whereas purified F4 fimbriae are polymeric FaeG structures (Chapters 4 
and 9). This difference may have consequences for the immunogenicity of the protein 
as discussed before. In addition, the different multimerization status could influence 
avidity for binding to the enterocytes. It is for instance well known that the binding 
strength of one binding site of an IgG towards a multimeric antigen is much lower 
than the avidity of a whole IgG antibody interacting with its two antigen-binding sites 
to this antigen (Lee et al., 2004). On the other hand, binding of SDS-refolded rFaeG to 
the F4R may be reduced due to repulsion of some negatively charged SDS molecules 
still present on the rFaeG by the negatively charged sialic acid and sulphate groups 
that are present in mucus oligosaccharides (Cone, 1999). Furthermore, it is possible 
that refolding of rFaeG results in a native-like structure that is not totally identical to 
native FaeG. Finally, the presence of the N-terminal His-S-tag does not inhibit F4R 
binding but may influence its binding. The reduced immunogenicity of rFaeG as 
compared to F4 is likely not a result of a difference in proteolytic degradation since 
the gastric HCl production was blocked at immunization. Furthermore, Joensuu et al. 
(2004) reported that their plant-produced rFaeG was as stable in simulated gastric 
fluid as compared to F4 fimbriae.  
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10.3. F4 and rFaeG as mucosal antigen carriers 
Binding of F4 or rFaeG to the F4R on small intestinal enterocytes and their 
ability to induce an FaeG-specific immune response led to the question if F4 and/or 
rFaeG could be used as a mucosal carrier, inducing an antibody response against a 
coupled or fused heterologous antigen following oral administration. Lectins that bind 
enterocytes in mice were already reported as functional mucosal carriers, inducing an 
antibody response against a carried heterologous antigen when orally administered 
(Lavelle et al., 2000). However, the advantage of using FaeG as a mucosal carrier in 
pigs would be the simultaneous induction of FaeG- and heterologous-specific 
antibodies. This could open perspectives for simultaneously vaccinating pigs against 
the widely spread F4+ ETEC and against another enteropathogen.  
Insertion of epitopes in variable regions of FaeG has been reported to induce 
epitope-specific antibodies following parenteral immunization (Thiry et al., 1989; 
Bakker et al., 1990). However, these constructs are not able to bind the F4R since the 
variable regions are involved in the F4R binding (Bakker et al., 1992a). In addition, 
even though small epitopes can be inserted without disturbing the folding of the 
subunit, vaccination with one epitope of an antigen does not always result in 
protection against a pathogen (Fayolle et al., 2001; Jeon et al., 2002; Rodriguez et al., 
2003).  
The potential of F4 fimbriae to function as a mucosal carrier molecule was 
investigated by chemically coupling the model antigen HSA to the fimbriae. HSA has 
no receptor on enterocytes. The chemical conjugation of antigen and carrier was 
performed with glutaraldehyde since several studies reported the effective production 
of immunogenic antigen-carrier complexes, using this technique (McKenzie and 
Halsey, 1984; Hamajima et al., 1995; Fujiwara et al., 1999).  Indeed, conjugation of 
F4 to HSA (F4/HSA) in a 1:1 molar ratio resulted in F4 fimbriae that were covalently 
bound to HSA and also retained their ability to bind to the F4R (Chapter 7). Oral 
immunization of pigs followed by two oral booster immunizations with F4/HSA 
conjugates primed the immune system against HSA as a secondary HSA-specific 
antibody response was observed when these animals were boosted intramuscularly 
with HSA. In contrast, a primary HSA-specific immune response was observed after 
the intramuscular immunization in pigs which orally received HSA/HSA following 
the same protocol as for F4/HSA (Chapter 7). These results indicate that F4 fimbriae 
Chapter 11 : General discussion 
193 
allow transport of conjugated HSA through the intestinal epithelial barrier. The 
presence of HSA-specific IgA antibodies in the F4/HSA group, but not in the 
HSA/HSA group following the intramuscular HSA boost immunization, suggest that 
translocated HSA reached the gut associated lymphoid tissue. Indeed, the induction of 
an antigen-specific immune response in mucosae-associated lymphoid tissue leads to 
the production of antigen-specific IgA (Murray et al., 1987). Russell-Jones (2001) 
reported the potential of F5 and F6 to function in mice as mucosal carrier for 
chemically conjugated DNP and BSA, but specific binding of the complexes to 
murine enterocytes was not proven and binding of F5+ or F6+ E. coli to murine 
enterocytes has not yet been demonstrated. 
Although F4 fimbriae were shown to have the capacity to function as a 
mucosal carrier, this system was not very effective since the oral immunization 
induced only low FaeG-specific antibody titers and even no HSA-specific antibodies 
(Chapter 7). The F4-specific serum antibody response was significantly lower than 
following oral F4 immunization (Chapters 7 and 9). F4/HSA is a large molecule and 
its subunits cannot fall apart due to covalent linking by glutaraldehyde (Chapter 7). 
This could reduce the diffusion through the intestinal mucus layer as compared to 
purified F4 fimbriae. In vitro studies have suggested that the rate of diffusion of 
molecules through mucus progressively decreases with increasing molecular size 
(Desai et al., 1992). However, intestinal mucus is not totally impermeable for large 
proteins provided that their luminal concentration is sufficiently high (Flemström et 
al., 1999). An additional reason for the low immunogenicity of F4/HSA could be a 
reduction in the F4R-binding capacity by the conjugated HSA molecules as well as a 
mimicking of F4 epitopes. Furthermore, the chemical linker molecule used to bind 
HSA to F4 can have an effect on the immunogenicity of carrier and HSA antigen as 
demonstrated by Kirkley et al. (2001). Also the molar ratio of carrier and antigen in 
the conjugates can influence the immunogenicity (Russell-Jones, 2001). In addition, 
the presence of free HSA molecules in the F4/HSA conjugate solution could 
negatively influence the induction of a HSA-specific immune response since it rather 
induces tolerance (Stok et al., 1994).  
A genetic fusion between FaeG and a heterologous peptide/antigen allows a 
strictly controlled coupling of both molecules and results in smaller molecules than 
antigen-F4 complexes. In addition, no free His-S-tag fragments are present in purified 
rFaeG. This could explain the higher immune response against the His-S-tag than 
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against HSA following oral rFaeG or F4/HSA immunization (Chapters 7, 9 and 10). 
However, this has to be confirmed for larger antigens and comparison can only be 
made correctly if the same antigen is conjugated to F4 as is conjugated to rFaeG.  
 
10.4. Complementary effect of F4 and rFaeG as 
mucosal carrier with the mucosal adjuvant CT 
  
To improve the immune response against the carried antigen, the F4/HSA or 
rFaeG complexes were orally co-administered with CT, one of the most potent 
mucosal adjuvants (Lycke, 2004). Supplementing CT induced a faster heterologous 
peptide/antigen-specific antibody response and significantly higher antibody titers 
than immunization without CT (Chapters 7 and 10). The improved heterologous-
specific antibody response is due to a complementary effect of the carrier system and 
the adjuvant (Chapter 7). Based on a study on the uptake of F4 in intestinal loops 
(Snoeck et al., 2004b), we believe that the F4 or FaeG carrier allows an F4R-
dependent uptake of a heterologous antigen or peptide by epithelial cells. 
Subsequently, this antigen could reach antigen-presenting cells (Snoeck et al., 2004b), 
resulting in an antibody response.  
Oral co-administration of CT and antigen leads mainly to an increase of 
antigen-specific IgG titers in serum and IgA titers in saliva (Chapters 7 and 10). It is 
likely that oral co-administration of CT with an F4- or FaeG-based carrier-antigen 
complex improves the induction of a local antigen-specific immune response since 
oral immunization with both rFaeG (Chapter 9) and F4 fimbriae (Van den Broeck et 
al., 1999a) results in the induction of FaeG-specific ASCs in intestinal lymphoid 
tissues and CT is a known mucosal adjuvant (Lycke, 2004). Furthermore, HSA-
specific IgA antibodies were detected 24 dppi in saliva of F4R+ pigs immunized with 
F4/HSA and CT, whereas no HSA-specific IgA antibodies could be detected in the 
serum at that moment. In addition, several other studies showed the ability of CT to 
enhance mucosal as well as systemic immune responses against a mucosal co-
administered antigen (Biet et al., 2003; Karlsen et al., 2003; Yasuda et al., 2003).  
In contrast to the high toxicity of CT in humans (Sack et al., 2004), the use of 
50 µg CT in pigs is not toxic and does not lead to growth retardation (Chapters 7 and 
10; Foss and Murtaugh, 1999a). Moreover, induction of CT-specific antibodies could 
Chapter 11 : General discussion 
195 
cross-react with LT and inhibit its toxic effect following ETEC infection (Holmgren, 
1973; Jacob et al., 1986). Indeed, no diarrhoea was observed in animals immunized 
with CT alone  (Chapter 10), whereas non-immunized animals that were identically 
challenged developed diarrhoea (Van der Stede et al., 2003). So, the presence of CT- 
and FaeG-specific antibodies most likely results in better protection against F4+ ETEC 
challenge than when only FaeG-specific antibodies are present, as has been reported 
by Francis and Willgohs (1991) for LT- and FaeG-specific antibodies. Therefore, it is 
worthwhile to determine if co-administration of the antigen-carrier system with LT 
has a similar or even better effect than with CT. 
 
11.5. Main conclusions and future perspectives 
 
The multimeric character, the stability and the conservation of the F4 fimbrial 
adhesin FaeG render the F4 structure very immunogenic and a good mucosal vaccine 
candidate against F4+ ETEC infections. The results of the present thesis suggest that 
polymeric FaeG structures are more immunogenic following oral immunization than 
monomeric FaeG. However, there is no information available whether this is due to a 
higher avidity of binding to the F4R or due to the polymeric character of the antigen. 
It could be worthwhile to study the binding kinetics of (r)FaeG mono-, di- and higher 
FaeG-multimers to the F4R in a biosensor, their uptake by M cells and enterocytes in 
intestinal loops and their mucosal immunogenicity by orally immunizing F4R+ pigs. 
The main conclusion of this work is that both purified F4 fimbriae and rFaeG 
have the potential to function as a mucosal carrier, inducing an antibody response 
against a coupled/fused heterologous antigen/peptide. A genetic fusion of an antigen 
and a carrier molecule is favourable since there is no free antigen or carrier present 
and the conjugation is more controlled and thus more reproducible than in the case of 
chemical coupling. However, the potential of rFaeG to function as a mucosal carrier 
to an antigen needs to be confirmed. Hereto, further research is necessary to elucidate 
the structure of FaeG. This information could probably enable the production of a 
stable FaeG lectin domain or alternatively fusion of the missing seventh β-strand to 
complete its immunoglobulin fold, thus making a stable immunogen. As a 
consequence, these new FaeG constructs would circumvent SDS-refolding that could 
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influence immunogenicity of a fused heterologous antigen. Perhaps, the plant-
produced rFaeG can be an alternative.  
Several methods of antigen targeting to M cells are described that induce a 
mucosal antigen-specific immune response against non-replicating soluble antigens, 
but the quantity of material taken up from the intestine is often low (Clark et al., 2000; 
Nicoletti, 2000). The low number of M cells and their location in restricted sites of the 
intestinal wall probably cause this problem. Therefore, targeting antigens to 
enterocytes and subsequently to the intestinal lymphoid tissues is probably an 
alternative, which can be studied using the F4- or rFaeG-based carrier systems. 
However, the F4 system will not be able to function as universal mucosal carrier in 
pigs since some animals lack the F4 receptor. The development of a universal 
mucosal carrier will require the identification of molecules that bind to and can 
translocate through enterocytes of all pigs. 
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Summary 
 
 
Intestinal infections are still an important cause of disease in both humans and 
animals. Fimbriae often play a prominent role in anchoring bacterial cells to host 
tissue and mediate the first step in pathogenesis. For instance, F4 fimbriae of F4+ 
enterotoxigenic Escherichia coli (ETEC) bind to F4-receptors on small intestinal 
enterocytes of pigs, resulting in colonization of the small intestine. Subsequently, F4+ 
ETEC secrete heat-labile (LT) and heat-stable (ST) enterotoxins that cause diarrhoea. 
As a consequence, there is a continuous development of new strategies to block the 
binding of fimbriae to their specific receptor on host cells. 
Chapter 1 gives an overview of the most prevalent fimbriae of pathogenic E. 
coli strains in humans and animals. The focus of the chapter concerns the differences 
in fimbrial structures, the use of fimbriae in systemic and mucosal immunizations 
against fimbriated pathogens and the use of fimbriae as carrier systems. F4 fimbriae 
differ from most fimbriae in that the F4 fimbrial adhesin FaeG also constitutes the 
major subunit of the fimbriae. In addition, oral immunization of pigs with F4 fimbriae 
has been reported to result in the induction of a FaeG-specific immune response that 
protects piglets against a F4+ ETEC infection. This is a remarkable finding since oral 
immunization with soluble non-replicating antigens often induces oral tolerance, 
which hampers the development of mucosal vaccines. Therefore, this finding opens 
the question if F4 fimbriae or its adhesin FaeG has the potential to function as a 
carrier molecule to induce immune response against a fused/coupled heterologous 
antigen/peptide. 
Chapter 2 reviews the present knowledge on the genetic configuration of the 
F4 fimbrial operon fae, the regulation of subunit expression and the biogenesis of the 
fimbrial structure. In addition, the similarities and differences with well studied other 
fimbrial systems are discussed. 
The enterotoxins are the second virulence factors of pathogenic (F4+) ETEC 
strains. In the first part of chapter 3, the structure, receptor binding and the mechanism 
of action of both LT and the closely related cholera toxin (CT) are described. In the 
second part of chapter 3, the immunomodulatory effect of both toxins is reviewed 
with the focus on their influence on the different leukocyte populations. 
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Chapters 4 to 10 present the experimental work of this thesis. The objective 
was to answer the following questions : 
 
• Are F4 fimbriae a good vaccine candidate to be used in a mucosal vaccine 
against an F4+ ETEC infection ? 
 
• Are F4 fimbriae or the F4 fimbrial adhesin FaeG able to induce an antibody 
response against a coupled/fused heterologous antigen/peptide following oral 
immunization of pigs ? 
 
• Can the oral co-administration of the carrier-antigen/peptide complex with CT 
improve the heterologous antigen/peptide-specific immune response ? 
 
In order to use F4 fimbriae or FaeG subunits in an oral vaccine against F4+ 
ETEC, it is necessary to determine the conservation of the adhesin subunit. Therefore, 
in chapter 4 the faeG sequence was determined of 21 F4ac+ E. coli field isolates from 
piglets with diarrhoea and subsequently compared with these of the reference strain 
GIS26 and previously reported faeG sequences from F4ab+, F4ac+ and F4ad+ strains. 
The FaeG amino acid sequence was 96-100% homologous within each F4 serotype, 
but only 92% and 88% when the F4ab and F4ad serotypes were compared with the 
F4ac serotype. In addition, antibodies induced by purified GIS26 F4ac fimbriae 
immunization were able to inhibit binding of all 21 F4ac+ E. coli field isolates. 
Further characterization of purified F4 fimbriae of GIS26 revealed the presence of 
flagellin and the multimeric character of the FaeG adhesin. This multimeric character 
was also found in 20 of the 21 F4ac+ E. coli field isolates. In conclusion, the results of 
the experiments reported in this chapter support the usefulness of GIS26 F4 fimbriae 
in an oral vaccine against F4+ E. coli infections. 
In chapter 5, the fimbriae-specific systemic and mucosal immune response 
following infection with F18+ VTEC (strain 107/86) was compared with the response 
following an infection with the F4+ ETEC strain GIS26. These strains differ in both 
their virulence factors : the F4+ ETEC strain has a major subunit as adhesin and 
secretes heat-labile enterotoxin (LT), whereas the F18+ VTEC strain has a minor 
subunit as adhesin and secretes the shiga-like toxin II variant (SLT-IIv).  Weaned 
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F18-seronegative F18-receptor positive piglets were infected with the F18ab positive 
strain and weaned F4-seronegative F4-receptor positive (F4R+) piglets with the F4+ 
strain. The peak excretion of bacteria was 2 days post primary infection (dpi) 
following the inoculation with the F4+ ETEC strain and between 3 and 5 dpi after the 
F18+ VTEC inoculation. ELISPOT assays enumerating the fimbriae specific IgM, IgA 
and IgG antibody secreting cells (ASCs) revealed high numbers of fimbriae-specific 
IgM ASCs in the spleen 4 dpi with both strains. F18-specific IgM ASCs were present 
4 dpi in the mesenteric lymph nodes and from 7 dpi onwards in the Peyer’s patches, 
whereas F4-specific IgM ASCs were detected in the mesenteric lymph nodes and the 
Peyer’s patches 4 dpi. Besides the faster induction of an immune response following 
F4+ ETEC infection compared with F18+ VTEC infection, the switch from IgM to 
IgA and IgG was also earlier following the F4+ ETEC infection. F4-specific IgA and 
IgG ASCs were detected from day 4 onwards, together with F4-specific IgA 
antibodies in serum and intestinal contents. F18-specific IgA and IgG ASCs and F18-
specific IgA in serum and intestinal contents were found 11 dpi. The results of this 
study suggest that the multimeric adhesin character of F4 fimbriae and/or the 
immunomodulatory effect of LT enterotoxin may accelerate the mucosal immune 
response in the F4+ ETEC infected piglets.  
Chapter 6 describes the usefulness of a real-time biomolecular interaction 
analysis system (BIAcore® 3000), based on the principles of surface plasmon 
resonance (SPR) for the study of the interaction of F4 fimbriae and porcine 
enterocytes. Using this system, F4 fimbriae were found to interact with F4R+ porcine 
enterocytes, whereas no interaction was observed with enterocytes that were typed 
F4R- or weakly F4R+ based on an in vitro adhesion assay. Since the flow rate in the 
biosensor resembles the in vivo intestinal flow better as compared to the in vitro 
adhesion assay, it is likely that the biosensor can better mimic the in vivo situation. 
Furthermore, this method offers new opportunities to analyse the receptor-binding 
capacity of an F4-antigen conjugate or to screen therapeutics for prevention of ETEC 
adhesion. 
 The potential of F4 fimbriae to act as a mucosal carrier molecule for the model 
antigen human serum albumin (HSA), was examined in chapter 7. Oral immunization 
of pigs with glutaraldehyde coupled HSA molecules (HSA/HSA complexes; 
HSA/HSA group) did not result in the induction of a HSA-specific immune response, 
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in contrast to oral co-administration of HSA/HSA with CT (HSA/HSA/CT group). 
These results showed that CT acts as a mucosal adjuvant in pigs, which is in 
accordance with the reported CT adjuvant effect in other animals. Glutaraldehyde-
conjugation of HSA to purified F4 fimbriae resulted in F4/HSA complexes that were 
able to bind the F4R. Oral immunization of F4-HSA in F4R+ pigs (F4/HSA group) 
induced a HSA-specific immune response, however this immunization did not result 
in the detection of HSA-specific antibodies. Indeed, intramuscular HSA immunization 
induced a secondary response in the F4/HSA immunized pigs (F4/HSA group), as 
compared to a primary response in HSA/HSA immunized animals (HSA/HSA group). 
These data indicated that F4 fimbriae could function as a mucosal carrier to a 
chemically coupled heterologous antigen. In addition, oral co-administration of F4-
HSA with CT (F4/HSA+CT group) to F4R+ pigs induced HSA-specific antibodies in 
serum and saliva that were significantly higher than these in the F4/HSA and the 
HSA/HSA+CT groups. The high HSA-specific response seems to be due to a 
complementary effect of F4-mediated binding of HSA to F4R+ enterocytes and the 
mucosal adjuvanticity by CT since a significantly lower HSA-specific antibody 
response is observed following oral immunization of F4R- pigs with F4/HSA and CT. 
This combined use of CT as mucosal adjuvant and F4 fimbriae as mucosal carrier 
system could open new perspectives in the development of vaccines against F4+ 
ETEC and other enteropathogens in pigs. 
In chapter 8, it was determined if altered interaction of F4 fimbriae with the 
FaeG-specific monoclonal antibody (MAb) IMM01 correlated with an altered 
bioactivity of F4 fimbriae. Hereto, purified F4 fimbriae were first treated in conditions 
that are known to alter protein folding. Indeed, the F4R-binding and FaeG 
multimerization of purified F4 fimbriae was observed to be reduced following 
incubation with SDS at concentrations of 1.5 % or higher and at temperatures of 85°C 
or higher. Incubation of purified F4 fimbriae at pH 4 or lower resulted in a reversible 
conformational change that became irreversible and stabilised in the presence of 0.05 
% SDS, a concentration that did not affect the F4 fimbrial bioactivity at neutral pH. 
The altered bioactivity of treated F4 fimbriae correlated with optical density 
determined in ELISA using the FaeG-specific MAb IMM01. This fast and sensitive 
assay opens new perspectives to analyse the FaeG conformation following refolding 
of recombinant protein, the release of bioactive FaeG from microcapsules and the 
production of appropriate oral F4 subunit vaccines. 
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In chapter 9, the gene of the F4-fimbrial adhesin FaeG of the pathogenic F4+ 
ETEC strain GIS26 was cloned in the pET30Ek-LIC vector and expressed with an N-
terminal His- and S-tag in the cytoplasm of BL21(DE3). Recombinant FaeG (rFaeG) 
subunits were isolated from insoluble cytoplasmic aggregates and refolded into a 
native-like F4R-binding conformation using SDS. The presence of conformational 
epitopes was confirmed by ELISA and the ability to bind the F4R was confirmed by 
inhibiting the adhesion of F4+ ETEC to F4R+ villi with increasing concentrations of 
native-like SDS-refolded rFaeG subunits, in contrast to urea-refolded rFaeG. The 
rFaeG subunits appear as monomers, whereas the purified F4 fimbriae are multimers. 
Oral immunization of newly weaned piglets with native-like rFaeG induced a mucosal 
and systemic FaeG-specific immune response, whereas oral immunization with ureum 
refolded rFaeG did not induce FaeG-specific ASCs. In agreement, SDS-refolded 
rFaeG immunized pigs showed a significantly reduced F4+ E. coli excretion from 2 
till 5 days following challenge infection. However, improvement of stability and 
immunogenicity of (SDS-refolded) rFaeG will be necessary since rFaeG 
immunization resulted in a lower F4-specific response compared to immunization 
with purified F4 fimbriae. Furthermore, the N-terminal fusion of a His- and S-tag was 
not detrimental for binding the F4R, supporting the use of FaeG as mucosal carrier. 
Indeed, oral immunization of pigs with SDS-refolded rFaeG resulted in the production 
of His-S-tag specific antibodies as determined in Western blot. In conclusion, oral 
immunization with a native-like refolded recombinant FaeG fimbrial adhesin subunit 
of Escherichia coli induces a mucosal and systemic FaeG-specific immune response 
and rFaeG functions as a mucosal carrier inducing antibodies against a fused His-S-
tag peptide. 
Chapter 10 describes the results of oral co-administration of rFaeG and CT, to 
improve the immune response against FaeG and the N-terminally fused His-S-tag. 
Oral immunization of pigs with rFaeG and CT significantly enhanced the immune 
response against the heterologous peptide since significantly higher His-S-tag-specific 
antibodies were detected. In addition, the co-administration improved the FaeG-
specific humoral and cellular immune response and significantly reduced the fecal F4+ 
E. coli excretion following challenge infection as compared to rFaeG-immunized 
pigs. In conclusion, the results of this study show that fimbrial adhesins can be used as 
mucosal carrier for inducing an immune response against peptides, which normally 
are not immunogenic following oral administration.  
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 The experiments in the current thesis demonstrated the multimeric character, 
the stability and the conservation of the F4 fimbrial adhesin FaeG, which make it very 
immunogenic and a good mucosal vaccine candidate against F4+ ETEC infections. 
The main statement of the present work is that both purified F4 fimbriae and rFaeG 
have the potential to function as a mucosal carrier, inducing an antibody response 
against a coupled or fused heterologous antigen or peptide following oral 
immunization. However, the potential of rFaeG to function as a mucosal carrier to an 
antigen needs to be confirmed in further experiments. These F4- and rFaeG-based 
mucosal carrier systems, although restricted to F4R+ pigs, enable to study the 
potential of enterocyte-targeting of antigens to induce a mucosal antigen-specific 
immune response, which perhaps could be an alternative to M-cell-targeting of 
antigens.  
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 Darminfecties vormen nog steeds een belangrijke oorzaak van ziekte bij mens 
en dier. Fimbriae zorgen voor de binding van bacteriën aan gastheerweefsel en zorgen 
zo de eerste stap in de pathogenese. Zo binden bijvoorbeeld F4 fimbriae van F4+ 
enterotoxigene Escherichia coli (ETEC) aan F4-receptoren op dunne darm 
enterocyten van varkens, wat resulteert in kolonisatie van de dunne darm. Vervolgens 
zullen F4+ ETEC hitte-labiele (LT) en hitte-stabiele (ST) enterotoxines secreteren die 
diarree veroorzaken. Het belang van fimbriae in de pathogenese leidt tot de 
voortdurende ontwikkeling van nieuwe methoden om binding van fimbriae aan hun 
specifieke receptor op gastheercellen te blokkeren. 
 
 Hoofdstuk 1 geeft een overzicht van de meest voorkomende fimbriae van 
pathogene E. coli stammen bij mens en dier. Dit overzicht richt zich voornamelijk tot 
de verschillen in fimbriële structuren, het gebruik van fimbriae in systemische en 
mucosale immunisaties tegen pathogenen met fimbriae als virulentiekenmerk en het 
gebruik van fimbriae als dragermoleculen. F4 fimbriae verschillen van de meeste 
andere fimbriae doordat het F4 fimbrieel adhesine FaeG tevens de meest 
voorkomende subeenheid is van de fimbriae. Daarenboven resulteert orale 
immunisatie van varkens met F4 fimbriae in inductie van een FaeG-specifieke 
immuunrespons die varkens beschermt tegen een F4+ ETEC infectie. Dit is een 
opmerkelijke bevinding aangezien orale immunisatie met oplosbare niet-
vermenigvuldigende antigenen meestal leidt tot de inductie van orale tolerantie, wat 
de ontwikkeling van mucosale vaccins belemmert. Deze unieke eigenschappen van F4 
fimbriae brengen dan ook de vraag naar voor of F4 fimbriae of het F4 fimbrieel 
adhesine FaeG in staat is te werken als een dragermolecule die een immuunrespons 
kan induceren tegen een chemisch of genetisch gekoppeld heteroloog antigeen of 
peptide. 
 
 Hoofdstuk 2 geeft een overzicht van de huidige kennis in verband met de 
genetische configuratie van het F4 fimbrieel operon fae, de regulatie van de expressie 
van de verschillende fimbriële subeenheden en de biogenese van de fimbriële 
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structuur. Bijkomend worden gelijkenissen en verschillen tussen F4 en andere goed 
bestudeerde fimbriële systemen bediscussieerd. 
 
 Naast fimbriae fungeren enterotoxines als tweede virulentiefactor van 
pathogene (F4+) ETEC stammen. In het eerste gedeelte van hoofdstuk 3 worden de 
structuur, de receptorbinding en het werkingsmechanisme van zowel LT als het sterk 
gelijkende cholera toxine (CT) beschreven. In het tweede gedeelte van hoofdstuk 3 
wordt een overzicht gegeven van de immunomodulerende effecten van beide 
bacteriële toxines, waarbij vooral aandacht besteed wordt aan hun invloed op 
verschillende populaties witte bloedcellen. 
 
 De hoofdstukken 4 tot 10 stellen het experimenteel gedeelte van deze thesis 
voor. Deze thesis had tot doelstelling volgende vragen te beantwoorden : 
• Zijn F4 fimbriae goede antigenen om te gebruiken in een mucosaal vaccin 
tegen een F4+ ETEC infectie ? 
• Zijn F4 fimbriae of het F4 fimbriële adhesine FaeG in staat te werken als 
mucosaal dragermolecule die na orale immunisatie van varkens een 
antistoffenrespons kan induceren tegen een chemisch of genetisch gekoppeld 
antigeen of peptide ? 
• Kan gelijktijdige toediening van het drager-antigeen/peptide complex met CT 
de heterologe antigeen/peptide-specifieke immuunrespons verbeteren ? 
 
Vooraleer F4 fimbriae of FaeG subeenheden in een oraal vaccin tegen F4+ 
ETEC te gebruiken, is het noodzakelijk te onderzoeken of het adhesine geconserveerd 
is. Hiervoor werd in hoofdstuk 4 de faeG sequentie van 21 F4ac+ E. coli veldisolaten 
van biggen met diarree bepaald en nadien vergeleken met deze van de referentiestam 
GIS26 en eerder gerapporteerde faeG sequenties van F4ab+, F4ac+ en F4ad+ E. coli 
stammen. De FaeG aminozuursequentie was 96-100% identiek binnen elke F4 
variant, maar enkel 92% en 88% wanneer de F4ab en de F4ad varianten werden 
vergeleken met F4ac. Tevens kunnen antistoffen die geïnduceerd werden met 
gezuiverde GIS26 F4ac fimbriae de binding van alle 21 F4ac+ E. coli veldisolaten 
verhinderen. Verdere karakterisatie van gezuiverde F4 fimbriae van GIS26 toonde de 
aanwezigheid van flagelline aan evenals het multimeer karakter van het FaeG 
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adhesine. Dit multimeer karakter werd ook gevonden in 20 van de 21 F4ac+ E. coli 
veldisolaten. De resultaten van de experimenten die in dit hoofdstuk worden 
beschreven suggereren het gebruik van GIS26 F4 fimbriae in een oraal vaccin tegen 
F4+ E. coli infecties. 
 
In hoofdstuk 5 werd de fimbriae-specifieke systemische en mucosale 
immuunrespons na een F18+ verotoxigene E. coli (VTEC) (stam F107/86) infectie 
vergeleken met de respons na een infectie met de F4+ ETEC stam GIS26. De F4+ 
ETEC en de F18+ VTEC stam verschillen in hun beide virulentiefactoren : de F4+ 
ETEC stam heeft een major subeenheid als adhesine en expresseert het hitte-labiel 
enterotoxine (LT), terwijl de F18+ VTEC stam een minor subeenheid als adhesine 
heeft en de shiga-achtige toxine II variant (SLT-IIv) secreteert. Gespeende F18-
seronegatieve F18-receptor positieve biggen werden geïnfecteerd met de F18ab 
positieve stam en gespeende F4-seronegatieve F4-receptor positieve (F4R+) biggen 
met de F4+ stam. Een maximale excretie van bacteriën werd waargenomen 2 dagen na 
infectie (dpi) bij de F4+ ETEC stam en tussen 3 en 5 dagen na F18+ VTEC inoculatie. 
ELISPOT testen om het aantal fimbriae-specifieke IgM, IgA en IgG antistoffen 
secreterende cellen (ASCs) na te gaan, tonen hoge aantallen fimbriae-specifieke IgM 
ASCs in de milt 4 dpi bij beide stammen. F18-specifieke IgM ASCs waren aanwezig 
4 dpi in de mesenteriale lymfeknopen (MLN) en vanaf 7 dpi in de Peyerse platen 
(PP), terwijl F4-specifieke IgM ASCs gedetecteerd werden in de MLN en de PP op 4 
dpi. Naast de snellere inductie van een immuunrespons na F4+ ETEC infectie in 
vergelijking met F18+ VTEC infectie was er ook een snellere omschakeling van IgM 
naar IgA en IgG na F4+ ETEC infectie. F4-specifieke IgA en IgG ASCs werden 
gedetecteerd vanaf 4 dpi, samen met F4-specifieke IgA antilichamen in sera en 
darminhouden. F18-specifiek IgA en IgG ASCs en F18-specifieke IgA werden 11 dpi 
gevonden in sera en darminhouden. De resultaten van deze studie suggereren dat het 
multimeer voorkomen van het adhesine in F4 fimbriae en/of het 
immunomodulatorisch effect van LT enterotoxine de mucosale immuunrespons 
mogelijks versnelt in de F4+ ETEC geïnfecteerde biggen. 
 
Hoofdstuk 6 beschrijft de mogelijkheid van een ‘real-time’ biomoleculair 
interactie analysesysteem (BIAcore® 3000), gebaseerd op de principes van 
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oppervlakte plasmaresonantie, voor de studie naar de interactie van F4 fimbriae en 
varkens enterocyten. Een binding van F4R+ enterocyten aan F4 fimbriae kon worden 
waargenomen met dit systeem, maar er werd geen interactie gevonden tussen F4 
fimbriae en enterocyten die als F4R- of zwak F4R+ werden bestempeld in een in vitro 
adhesie test. Aangezien de vloeistofstroom in de biosensor deze van de in vivo situatie 
meer benadert dan de in vitro test is het mogelijk dat de biosensor de in vivo situatie 
beter nabootst. Bovendien biedt deze methode nieuwe mogelijkheden om de receptor-
bindingscapaciteit van een F4 conjugaat te analyseren of om geneesmiddelen te 
zoeken voor de preventie van ETEC adhesie. 
 
De mogelijkheid van F4 fimbriae om te werken als mucosale dragermolecule 
voor het modelantigeen humaan serum albumine (HSA) werd onderzocht in 
hoofdstuk 7. Orale immunisatie van varkens met glutaraldehyde gekoppelde HSA-
moleculen (HSA/HSA complexen, HSA/HSA groep) resulteerde niet in de inductie 
van een HSA-specifieke immuunrespons, in tegenstelling tot een gelijktijdige orale 
toediening van HSA/HSA met CT (HSA/HSA+CT groep). Deze resultaten toonden 
dat CT werkt als mucosaal adjuvant in varkens, wat in overeenstemming is met het 
beschreven adjuvant effect in andere dieren. Glutaaraldehydeconjugatie van HSA aan 
gezuiverde F4 fimbriae resulteerde in F4/HSA complexen die in staat waren te binden 
aan de F4R. Orale immunisatie van F4R+ varkens met F4/HSA (F4/HSA groep) 
induceerde een HSA-specifieke immuunrespons, hoewel deze immunisatie niet 
resulteerde in de inductie van HSA-specifieke antistoffen. Inderdaad, intramusculaire 
HSA immunisatie induceerde een secundaire immuunrespons in de F4/HSA 
geïmmuniseerde varkens (F4/HSA groep), terwijl een primaire respons werd 
geobserveerd in de oraal HSA/HSA geïmmuniseerde dieren (HSA/HSA groep). Deze 
gegevens tonen aan dat F4 fimbriae zouden kunnen werken als een mucosaal 
dragermolecule voor chemisch gekoppelde heterologe antigenen. Bovendien leidde de 
gelijktijdige orale immunisatie van F4R+ varkens met F4/HSA en CT (F4/HSA+CT 
groep) tot de inductie van HSA-specifieke antistoffenresponsen in serum en speeksel 
die significant hoger waren dan deze in de F4/HSA en de HSA/HSA+CT groepen. De 
hoge HSA-specifieke respons lijkt een gevolg te zijn van een complementair effect 
van F4-afhankelijke binding van HSA aan F4R+ enterocyten en de mucosale adjuvant 
eigenschappen van CT aangezien een significant lagere HSA-specifieke antistoffen 
respons werd waargenomen na orale immunisatie van F4R- varkens met F4/HSA en 
Samenvatting 
207 
CT. Het gelijktijdige gebruik van CT als mucosaal adjuvant en F4 fimbriae als 
mucosale dragermolecule zou nieuwe mogelijkheden kunnen openen in de 
ontwikkeling van vaccins tegen F4+ ETEC en andere enteropathogenen in varkens. 
 
In hoofdstuk 8 werd onderzocht of een veranderde interactie van F4 fimbriae 
met het FaeG-specifieke monoklonaal antilichaam (MAb) IMM01 in verband staat 
met een veranderde bioactiviteit van F4 fimbriae. Hiervoor werden gezuiverde F4 
fimbriae eerst behandeld in condities die gekend zijn de opvouwing van eiwitten te 
veranderen. De F4R-binding en FaeG multimerizatie van gezuiverde F4 fimbriae was 
gereduceerd na incubatie met SDS aan een concentratie van 1.5% of hoger en een 
temperatuur van 85°C of hoger. Incubatie van gezuiverde F4 fimbriae bij pH 4 of 
lager resulteerde in een reversibele conformationele verandering die irreversibel werd 
in de aanwezigheid van 0.05% SDS, een concentratie die geen effect heeft op de F4 
fimbriële bioactiviteit bij neutrale pH. De veranderde bioactiviteit van behandelde F4 
fimbriae staat in verband met de optische densiteit bepaald in een ELISA die gebruik 
maakt van het FaeG-specifieke MAb IMM01. Deze snelle en gevoelige test opent dan 
ook mogelijkheden voor de analyse van FaeG-opvouwing na heropvouwing van 
recombinant eiwit, de vrijstelling van bioactief FaeG uit microcapsules en de 
productie van orale F4 subeenheid vaccins. 
 
In hoofdstuk 9 werd het gen van het F4 fimbrieel adhesine FaeG van de 
pathogene F4+  ETEC stam GIS26 gekloneerd in de pET30Ek-LIC vector en 
geëxpresseerd met een N-terminale His- en S-staart in het cytoplasma van 
BL21(DE3). Recombinant FaeG (rFaeG) subeenheden werden geïsoleerd uit 
onoplosbare cytoplasmatische aggregaten en heropgevouwen gebruik makend van 
SDS in een natief-achtige F4R-bindende conformatie. De aanwezigheid van 
conformationele epitopen in deze natief SDS-heropgevouwen rFaeG subeenheden 
werd bevestigd in ELISA en de mogelijkheid te binden aan de F4R werd bevestigd 
door inhibitie van adhesie van F4+ ETEC aan F4R+ villi met toenemende 
concentraties natief SDS-heropgevouwen rFaeG subeenheden. Anderzijds bleek 
ureum-heropgevouwen rFaeG niet aan de F4R te kunnen binden. De rFaeG 
subeenheden komen voor als monomeren, waar de gezuiverde F4 fimbriae 
multimeren zijn. Orale immunisatie van gespeende biggen met natief-achtig (SDS-
heropgevouwen) rFaeG induceerde een mucosale en systemische FaeG-specifieke 
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immuunrespons, terwijl orale immunisatie met ureum-heropgevouwen rFaeG geen 
FaeG-specifieke ASC induceerde. Tevens kon worden vastgesteld dat varkens die 
geïmmunizeerd werden met SDS-heropgevouwen rFaeG een significant verlaagde 
F4+ E. coli uitscheiding vertoonden van 2 tot 5 dagen na de challenge infectie. 
Verbetering van de stabiliteit en immunogeniciteit van (SDS-heropgevouwen) rFaeG 
is echter noodzakelijk aangezien deze na immunisatie aanleiding geven tot een lagere 
F4-specifieke antistoffenrespons in vergelijking met gezuiverde F4 fimbriae. 
Bovendien bleek de N-terminale fusie van een His- en S-staart niet schadelijk voor 
binding aan de F4R, wat het gebruik van rFaeG als mucosale dragermolecule 
suggereert. Inderdaad, orale immunisatie van varkens met SDS-heropgevouwen 
rFaeG resulteerde in de productie van His-S-staart-specifieke antistoffen zoals werd 
aangetoond in Western blot. Samenvattend stellen de resultaten van deze studie dat 
orale immunisatie van F4R+ biggen met natief-achtig heropgevouwen rFaeG een 
mucosale en systemische FaeG-specifieke immuunrespons induceert en dat rFaeG kan 
werken als mucosale dragermolecule die antistoffen induceert tegen een genetisch 
gekoppeld His-S-peptide. 
 
Hoofdstuk 10 beschrijft de resultaten van een gelijktijdige orale toediening 
van rFaeG en CT aan F4R+ biggen om de immuunrespons tegen FaeG en het N-
terminaal gekoppelde His-S-peptide te verbeteren. Orale immunisatie van varkens met 
rFaeG en CT verbeteren de immuunrespons tegen het heterologe peptide aangezien 
significant hogere His-S-staart-specifieke antistoffen werden gedetecteerd. Bijkomend 
werd er opgemerkt dat de gelijktijdige toediening van rFaeG en CT een verbeterde 
FaeG-specifieke humorale en cellulaire  immuunrespons tot gevolg had, alsook een 
significant verlaagde uitscheiding van F4+ E. coli na een challenge infectie in 
vergelijking met rFaeG geïmmunizeerde varkens. De resultaten van deze studie 
bevestigen dat fimbriële adhesines kunnen gebruikt worden als mucosale 
dragermolecule om een immuunrespons op te wekken tegen peptiden die normaal niet 
immunogeen zijn na orale toediening. 
 
Het laatste hoofdstuk van dit proefschrift (Hoofdstuk 11) omvat de algemene 
discussie van de resultaten. De experimenten tonen het multimeer karakter, de 
stabiliteit en de conservatie van het F4 fimbrieel adhesine FaeG, waardoor het zeer 
immunogeen is en mogelijkheden biedt voor vaccins tegen F4+ ETEC infecties. Het 
Samenvatting 
209 
belangrijkste besluit van het voorgestelde werk is dat zowel gezuiverde F4 fimbriae 
als rFaeG de capaciteit hebben te werken als een mucosale dragermolecule die in staat 
is na orale immunisatie een antistoffenrespons te induceren tegen een chemisch of 
genetisch gekoppeld heteroloog antigeen of peptide. Verder experimenteel onderzoek 
is echter nodig om de capaciteit van rFaeG als een mucosale dragermolecule voor 
antigenen aan te tonen. Deze mucosale dragersystemen gebaseerd op F4 en rFaeG, die 
weliswaar beperkt zijn tot varkens die tot het F4R+ fenotype behoren, geven de 
mogelijkheid om de toepasbaarheid te onderzoeken van het richten van antigeen naar 
enterocyten en vervolgens een mucosale antigeen-specifieke immuunrespons op te 
wekken. Dit zou mogelijks een alternatief kunnen zijn voor het richten van antigenen 
naar M-cellen.  
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